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Abstract  
Assessment of human health and environmental risk is based on multiple sources of 
information, requiring the integration of the lines of evidence in order to reach a conclusion. 
There is an increasing need for data to fill the gaps and new methods for the data integration. 
From a regulatory point of view, risk assessors take advantage of all the available data by means 
of weight of evidence (WOE) and expert judgement approaches to develop conclusions about 
the risk posed by chemicals and also nanoparticles. The integration of the physico-chemical 
properties and toxicological effects shed light on relationships between the molecular properties 
and biological effects, leading us to non-testing methods. (Quantitative) structure-activity 
relationship ((Q)SAR) and read-across are examples of non-testing methods. In this dissertation, 
(i) two new structure-based carcinogenicity models, (ii) ToxDelta, a new read-across model for 
mutagenicity endpoint and (iii) a genotoxicity model for the metal oxide nanoparticles are 
introduced. Within the latter section, best professional judgement method is employed for the 
selection of reliable data from scientific publications to develop a data base of nanomaterials 
with their genotoxicity effect. We developed a decision tree model for the classification of these 
nanomaterials. 
The (Q)SAR models used in qualitative WOE approaches mainly lack transparency resulting in 
risk estimates needing quantified uncertainties. Our two structure-based carcinogenicity models, 
provide transparent reasoning in their predictions. Additionally, ToxDelta provides better 
supported techniques in read-across terms based on the analysis of the differences of the 
molecules structures. We propose a basic qualitative WOE framework that couples the in silico 
models predictions with the inspections of the similar compounds. We demonstrate the 
application of this framework to two realistic case studies, and discuss how to deal with 
different and sometimes conflicting data obtained from various in silico models in qualitative 
WOE terms to facilitate structured and transparent development of answers to scientific 
questions. 
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CHAPTER 1 
Introduction 
1.1 Genotoxicity, Carcinogenicity and Mutagenicity 
“The term carcinogen denotes a chemical substance or a mixture of chemical substances which 
induce cancer or increase its incidence” 1. 
Carcinogenicity is a crucial endpoint for the chemical safety. Carcinogenic compounds may 
promote carcinogenicity in one of the three phases of causing cancer: initiation, promotion and 
progression 2 (Figure 1-page 7). Carcinogenesis begins with a mutation, a change of a genetic 
material for which no DNA repair mechanism during cell proliferation has happened. This 
happens in the initiation phase. During the second phase (promotion) which is reversible, the 
initiated cells are affected by endogenous or exogenous chemicals and because of the clonal 
growth, the tumour starts to form. For this reason these endogenous or exogenous chemicals are 
called promoters. These chemicals are not intrinsically mutagenic but cause changes in gene 
expression or other mechanisms that will be passed to the daughter cells. At this point, cell 
proliferation rate increases and apoptotic cell death decreases. In the last stage (progression) 
additional genotoxic events such as chromosomal aberrations and translocations take place. 
Progression is irreversible and it leads to the formation of neoplasms, benign and malignant 
alike 3–5. 
 
Figure 1. Multistage carcinogenesis 
Genotoxicity describes a damaging action on a cell's genetic material affecting its integrity. 
Genotoxicity is similar to mutagenicity except that genotoxic effects that cause DNA damage 
are not themselves necessarily transmissible to the next generation of cells, while mutagenicity 
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refers to the production of transmissible genetic alterations. Genotoxic substances which are 
capable of causing genetic mutation (pre-mutagenic) and contributing to the development of 
tumours (carcinogenic) are known to be potentially mutagenic or carcinogenic. Certain chemical 
compounds and some radiations can induce genotoxicity.  
Even low exposure levels of genotoxic substances may actuate serious health effects in somatic 
and germ cells. Somatic cell genotoxicity plays a role in a variety of genetic diseases. Also 
degenerative conditions such as accelerated aging, immune dysfunction, cardiovascular and 
neurodegenerative diseases and cancer are the outcome of accumulation of DNA damage in 
somatic cells. Mutations in germ cells can lead to spontaneous abortions, infertility or heritable 
damage to the offspring and possibly to the subsequent generations. 
There is a strong correlation between mutagenicity and carcinogenicity. Studies show that 
approximately 90 percent of the known carcinogens are also mutagens. The somatic mutation 
theory of cancer states that the mutation of the somatic cells cause cancer. 
According to the mode of action, carcinogens can be classified into genotoxic or nongenotoxic 
carcinogens. Genotoxic carcinogens interact directly with DNA, resulting DNA damage or 
chromosomal aberrations that can be detected by genotoxicity tests 6. Adversely, nongenotoxic 
carcinogens have no direct reactivity with DNA and use other mechanisms in the process of 
tumour development such as affecting gene expression, signal transduction, and/or cell 
proliferation.  
Mutation may occur in two modes: “spontaneously” or “inducted mutagenicity”. DNA 
molecules are not stable in the cellular environment and each base pair in a DNA double helix is 
mutable with a certain probability. Mutations may affect entire chromosomes or large pieces of 
chromosomes. Gene alterations are the simplest form of mutation. This gene alteration is 
swapping of one base pair for another. Another cause of mutation can be the insertion of a 
transposable element from outside the genome. Most of the time the DNA damages are 
identified and corrected by cells. Figure 2 (page 9) shows the parallels between crossing-over 
and two kinds of mutational repair (excision and double-strand break repair). 
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Figure 2. Parallels between recombination and certain types of mutational repair.7 
1.1.1 Gene Mutation 
The gene mutation can be divided into two classes:  
- Mutations affecting single base pairs; 
- Mutations altering the number of copies of a small repeated sequence within a gene. 
1.1.2 Mutation in Cancer Cells 
Tumours occur from a sequence of mutational incidences that lead to uncontrolled proliferation 
and cellular immortality. The transformation of cells from the benign into the carcinogenic state 
has genetic origins. 
1. Most of the induced carcinogens (chemical substances and radiations) are also 
mutagenic and they cause cancer by originating mutations into cells. 
2. A large number of mutagens affiliated with cancer have been identified. Experimental 
models (in vivo and in vitro) help to find these associations between mutagenicity and 
carcinogenicity. 
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1.1.3 Base Alteration 
Sometimes the mutagenic agent alters a base in a DNA causing specific mispairing. Figure 3 
(page 10) shows the pairing between the normal forms of the bases. Certain alkylating agents 
such as ethylmethanesulfonate and nitrosoguanidine, are some of the examples of these 
mutagens that operate by this pathway. These mutagens add alkyl groups to many positions on 
all four bases. Figure 4 (page 10) shows the alkylation that leads to direct mispairing and results 
in G.C -> A.T transitions in the next round of replication. Another important class of DNA 
modifiers are intercalating agents. Compounds such as proflavin, acridine orange and ICR 
compounds are some examples of this group (Figure 5-page 11). These agents are able to 
intercalate between the stacked nitrogen bases at the core of the DNA and cause single-
nucleotide-pair or deletions. 
 
Figure 3. Pairing between the normal form of the bases 7 
 
Figure 4. Alkylation-induced specific mispairings 7 
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Figure 5. (a) Structures of common intercalating agents and (b) their interaction with DNA 8  
1.2 Genotoxic and Carcinogenic Chemicals 
Absorption ways of chemical carcinogens following exposure are oral, inhalator, cutaneous and 
injection. Afterwards, different issues will be involved 9. All the substances absorbed orally are 
distributed in the body through the liver, whereas those absorbed by the lung will enter the 
blood and after that will reach the liver 10. Genotoxic chemical carcinogens directly damage 
DNA, non genotoxic carcinogens or procarcarcinogens require enzymatic conversion before 
affecting DNA 11.  
Non genotoxic chemical carcinogens require bioactivation to electrophiles in order to bind 
covalently to DNA and often act by producing mutations. Different enzymes are involved in 
bioactivation reactions, such as oxidation, reduction, thiol conjugation, acetyl transfer, sulfur 
transfer, methyl transfer, glucuronosyl transfer, and epoxide hydrolysis. These enzymes are 
classified as oxidoreductases 12. Human body controls metabolic activation by phase I reactions. 
Phase II reactions protect the body by transformation of activated compounds into inert products 
that will be eliminated from the body 13. Phase II enzymes have role in the conjugation and 
inactivation of carcinogens and include transferases. Originally, these enzymes were considered 
to be involved only in the detoxification of biotransformation, but they can also trigger 
activation of certain epigenetic carcinogens 11. 
Peroxidations occur together with metabolic reactions and cause production of ROS 14,15. 
Several chronic diseases are related to these radicals including chemical carcinogenesis 14. 
Chemical reactions such as oxidation, nitration/nitrosation and halogenation, which are 
associated with ROS trigger damage to DNA, RNA, and proteins. Consequently, mutations and 
alterations in the functions of important enzymes and proteins occur as a result 13. It is 
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demonstrated that excess amount of ROS created by chemical compounds stimulates initiation, 
promotion and progression of tomour through genotoxicity 16,17.  
Although the above-mentioned metabolic methods are important for both humans and animals, 
differences are important to be considered. Incorrect interpretations may occur in animal models 
used in the assays and analysis of chemicals carcinogenicity 18,19. 
1.3 The Animal Test(s) 
Carcinogenicity studies cannot be limited exclusively to the epidemiological data about 
carcinogens. For over 40 years, long-term rodent carcinogenicity bioassay using the maximum 
tolerated dose in 2 species over 2 yr. has been the standard procedure for detecting potential 
human carcinogens20.  
Data obtained from the initial 2-year carcinogenicity studies is often subjected to critiques of the 
screening procedures since it is inadequate for risk assessment regulatory decisions. 
In laboratory experiments on animals, it is shown that most potent mutagenic chemicals are also 
carcinogenic21. Thus, all the chemicals that are mutagenic in animals are considered also 
mutagenic or suspected mutagenic and consequently human carcinogens, until there is found 
some reliable evidence which shows the contrary 22. 
1.3.1 Rodent Carcinogenicity Bioassay 
There is increasing understanding that carcinogenesis is a multistep process 23–25. Chemicals 
with positive carcinogenicity results are subjected to more accurate and detailed evaluations 
about their unsafe effects for humans. Verifying whether or not the “carcinogen” chemical with 
positive results in long-term rodent assays is also hazardous for humans needs more chemical 
evaluations. These evaluations are necessary to understand the dose-response relationships, the 
potential hazard for humans 26. It may be unrealistic to expect a basic 2 year study to provide all 
the complex data needed for risk management decisions. 
Even though the quality of the studies used in toxicity assessments is high, these toxicity 
conclusions are not sufficient for the regulatory agencies. Some results in the NCI/NTP data 
base and other data sources clearly show that some chemicals that cause cancer in rodent 
models are not carcinogenic for humans 23,27. The procedure which states that a chemical with 
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positive effect in at least one of the 4 sex/species combinations is “carcinogen”, is more 
adequate for selecting compounds to undergo further study than regulatory purposes. Dose 
extrapolation, different organ responses are among the essential factors that influence the 
applicability of the rodent bioassays directly to risk assessment.  
1.3.2 Some Notes about Rodent Carcinogenicity Bioassay 
Mechanistic considerations are essential in carcinogenicity studies especially for nongenotoxic 
chemicals. Use of cell culture methods will fill the gap of information about the differential 
metabolism between animal models and humans. According to the legislations for risk 
assessment, data obtained from different sources, included experiments and mechanistic studies 
need to be used for the decision-making process. Many nongenotoxic chemicals are sex- or 
species specific, for this reason the mechanism of tumour formation has to be studied in both 
species and sex 28. 
The reasonable solution is considering and using the whole available data rather than relying 
only on the most sensitive test results 29. Information about the chemical concentration used for 
each animal species or sex combination is crucial and explains the sex/species specificity of the 
chemical effects 29. This additional information plays an important role in extrapolation of the 
results to humans. Studying specific chemicals by rodent tests, produces useful mechanistic 
information. The methodologies for predicting carcinogenicity can be explored by conducting 
high quality rodent studies. These studies will lead us to developing better dose-response 
relationships and increasing our knowledge about interspecies extrapolation. Despite all the 
progressions in the animal tests, there is still lack of adequate rodent studies for identifying 
carcinogens 30.  
The 2-year rodent studies are the most expensive tests that usually take place as the first step of 
the carcinogenicity assessment of a chemical. The following assessments, in case the rodent test 
result is positive, are more mechanistic, quicker and less expensive. The use of predictive 
models prior to the animal studies should be more reliable in the chemical evaluation process. 
This approach makes more resources available for the mechanistic studies and will accelerate 
the risk assessment deliberations for humans 31. 
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1.4 Ames Test 
Tests for carcinogenicity are generally time consuming and are performed on small mammalian 
animals. Alternative tests use microbes (e.g. fungi and bacteria) and test for mutagenicity 
instead of carcinogenicity. Any living organism can be used for testing the mutagenicity of a 
chemical, this is because DNA is chemically equal in all organisms. Bacteria can be used as an 
alternative to mammalian models, as its life cycle is much shorter and the results can be 
obtained easier and faster. The most famous mutagenicity test was developed by Bruce Ames in 
the 1970s, which is done using Salmonella typhimurium. Properties of the bacteria were 
genetically engineered into these strains to make them suitable for mutagen detection. The 
genotype of the mutant strains in this assay is given as his-. In addition, they carry a mutation 
that eliminates the protective lipopolysaccharide coating of wild-type Salmonella to facilitate 
the entry of many different chemicals into the cell.  
In a media lacking histidine this mutant bacteria will die. The “revertant” mutants revert the his 
– to his + genotype and phenotype and this will help the bacteria to grow in a media without 
histidine. In the Ames test the Salmonella bacteria is placed on plates with a very small amount 
of histidine and the chemical to be tested is added to the plate. The grown colonies on the plate 
indicate the number of revertants. To generate a dose-response curve, different concentrations of 
the chemical under study is tested. 
A positive result of the mutagenicity Salmonella typhimurium test is an indication of the high 
probability that the tested chemical will be carcinogenic in laboratory animals and in 
consequence is more likely to be a carcinogen. Not all chemicals that cause cancer in laboratory 
animals are mutagenic in the Ames test, but still three quarters of the chemicals with positive 
result in Salmonella test are carcinogenic in also animal studies. The rapidity (3-4 weeks) and 
low cost of the Ames test makes it an important tool for the mutagenicity screening.  
1.5 Nongenotoxic Carcinogens 
A great number of human carcinogens are “genotoxic” chemicals, which means their 
carcinogenicity effect is caused by inducing DNA damage. The rest of the carcinogens are 
named “nongenotoxic” chemicals, and they induce cancer in other modes of action. 
Nongenotoxic mechanisms are not as extensive as for genotoxic carcinogens, but evidence 
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shows that alteration in multiple pathways is responsible for their carcinogenic behaviour. Some 
other processes in which the nongenotoxic carcinogens act are: tumor promotion, endocrine 
modification, immune suppression, and tissue-specific toxicity and inflammatory responses 32,33. 
Nongenotoxic carcinogens unlike genotoxic carcinogens are tissue and species specific. In the 
past, the unique method of identifying nongenotoxic chemicals was the 2-year carcinogenicity 
bioassay, but the REACH legislation recommends fewer bioassays to be used in the process of 
carcinogenicity assessment. The main assessment strategy of REACH for the carcinogenicity 
endpoint is based on Ames mutagenicity test, genotoxicity in mammalian cells (in vitro and in 
vivo), and germ cell mutagenicity tests. These kind of tests are unable to identify the 
nongenotoxic carcinogens, the result of these tests are negative for such substances 34. Thus, it is 
important to understand the mechanisms of action of these nongenotoxic carcinogens in order to 
help the decision makers in detecting these substances. 
1.5.1 Modes of Action of Human Nongenotoxic Carcinogens  
Nongenotoxic carcinogens induce cancer without altering DNA, by indirect stimulation of 
hyperplastic responses, or chromosome number or structure. The modes of action of these 
chemicals include receptor and non-receptor - mediated endocrine modulation, tumour 
promoting, inducers of tissue-specific toxicity and inflammatory responses, 
immunosuppressants, or gap junction intercellular communication inhibitors. The identification 
of these substances is very challenging. Also the kinetics of human risk assessment is different 
from genotoxic chemicals, and a non-linear approach (threshold) is applied for nongenotoxic 
carcinogens. Because of the variety of the mechanisms of action of nongenotoxic carcinogens, 
the assessment is done on gathered data with a WOE approach. The assessment is done 
individually from 90-day toxicity studies, toxicokinetic and disposition studies. If any data 
about 2-year chronic bioassays in rodents and human epidemiological data is available they are 
also used in the WOE process. 
1.6 Genotoxic Carcinogens 
Genotoxic carcinogens involve direct damage to DNA, to which the cell responds by repair of 
the damages, arrest of the cell cycle or induction of apoptosis. 
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1.6.1 Modes of Action of Human Genotoxic Carcinogens  
1.6.1.1 Electrophilic Chemical Reaction Mechanisms Forming Adducts with DNA 
Conjunction, substitution and addition are three classical chemical reactions through which the 
electrophiles react with biological nucleophiles. During these mechanisms of action electron-
rich component interacts with the electron-deficient one 35. Among all the known mechanisms 
of covalent binding, only the following mechanisms can lead to cancer: SN1, SN2, acylation, 
Schiff base formation, Michael addition, and SNAr. These mechanisms are used for the 
classification of the electrophiles into appropriate mechanistic domain (Table 1-page 17) 36. 
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Table 1. Structural alerts belonging to certain mechanistic domains 36–38 
Mechanistic domains Structural alerts 
SN2 Akyl esters of either phosphonic or sulphonic acids 
Monohaloalkenes 
S- or N-mustards 
Propiolactones and propiolsultones 
Epoxides and aziridines 
Aliphatic halogens 
Alkyl nitrite 
SN1 Aromatic nitro groups 
Alkyl hydrazines 
Alkyl and aryl N-nitroso groups 
Aliphatic N-nitro group  
Aromatic nitroso group 
Aromatic amines and hydroxylamine 
Halogenated polycyclic aromatic hydrocarbon (PAH) 
Halogenated dibenzodioxins 
Acylation Aromatic diazo groups 
Acyl halides 
Schiff Base Formation Simple aldehydes 
N-methylol derivates 
Michael addition Quinones 
SNAr Aromatic N-oxides, 
Aromatic mono- and dialkylamino groups 
Halogenated benzene 
1.6.1.2 Epigenetic Mechanisms of Carcinogenic Molecules 
Epigenetic chemicals cause cancer without changes in the nucleotide sequences. Epigenetic 
factors can be found in cells under stress. The nongenotoxic (or epigenetic) carcinogens do not 
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make changes in DNA and do not form DNA adducts, but they changes the expression of 
certain genes 39. Epigenetic factors mainly cause cancer in two ways: by methylation or post-
translational modifications of histones (acetylation). DNA methylation happens in the promoter 
region 40 and results in the conversion of cytosin to 5-methylcytosine, with a high mutagenic 
potential. Acetylation of histones is controlled by histone acetyl transferases, which are 
important in chromatin transformation and the regulation of gene transcription 41.  
1.6.1.3 Other Factors Determining the Carcinogenic Potential of Chemical Compounds 
Carcinogenicity and mutagenicity are not caused only by SAs. The presence of a SA does not 
imply the mutagenic or carcinogenic property in a molecule. In fact, some SAs are not 
metabolically active in some chemicals. Molecular weight and the size of chemicals are 
important factors which may make the molecule lose its toxic property. Molecules with higher 
weights have less chance to be absorbed by cells. State of matter may make it difficult for the 
compound to reach the critical point. Solubility is another factor that affects the carcinogenic or 
mutagenic properties of the chemicals. High hydrophilicity leads to less absorption by the cells. 
Geometry of chemical and chemical reactivity are other important factors 35. There are also 
other factors that cause the increase of decrease of carcinogenicity and mutagenicity of the 
chemical compounds, such as stability and transport through the membrane and half-life 2,42.  
1.7 Carcinogenic Categories of the Substances 
The substances classified in the Category 1A are known or presumed human carcinogens for 
which their mutagenicity has been proved in epidemiological and/or animal studies. 
First category is known or presumed human carcinogens. A substance is classified in category 1 
for carcinogenicity on the basis of epidemiological and/or animal data.  
Category 1A  
Substances known to have carcinogenic potential for humans. The classification in this category 
is largely based on human evidence, human studies that establish a causal relationship between 
human exposure to a substance and the development of cancer.  
Category 1B  
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Substances presumed to have carcinogenic potential for humans. The classification in this 
category is largely based on animal evidence, animal experiments for which there is sufficient 
evidence to demonstrate animal carcinogenicity.  
Second category: category 2  
Suspected human carcinogens. The placing of a substance in category 2 is done on the basis of 
evidence obtained from human and/or animal studies, but is not sufficiently convincing to place 
the substance in category 1A or 1B.34 
1.8 Structural Alert Lists for Carcinogenicity and Mutagenicity 
John Ashley introduced SAs for the first time in 1985. The SAs are molecular substructures 
which are associated with carcinogenicity or mutagenicity properties of the molecules. These 
moieties represent potential mutagenicity or carcinogenicity and are the results of a long series 
of studies on the mechanisms of action of the mutagenic and carcinogenic chemical compounds 
43. The SAs are useful in the prediction of toxicity and the classification of potential 
carcinogens, as well as, in understanding the mechanism of genotoxicity 39,43–46. The 
electrophilic theory of carcinogenic chemicals introduced by James and Elizabeth Miller 11,47 
was the first step in rationalization of the mode of action of animal carcinogens known by the 
1970s. The Miller’s hypothesis also helped to justify mutagenicity of chemicals towards 
Salmonella 48. The electrophilic hypothesis has become a general theory of the carcinogens. The 
epigenetic carcinogens do not bind covalently to DNA and cause carcinogenicity through a 
large variety of mechanisms, while the genotoxic carcinogens are either electrophiles or can be 
activated to electrophilic reactive intermediates. During the last decade, several chemical 
functional groups or SAs have been identified for genotoxic carcinogens, based on Miller’s 
theory. The identification of nongenotoxic carcinogens is much more challenging because there 
is no unifying theory for the explanation of their mechanisms of action.  
John Ashby in 1985 introduced a list of SAs for carcinogenicity. This list contained eighteen 
SAs. The revised list of these SA can be found in Ashby and Tennant 48. Each SA in the Ashby 
list has its specific mechanism of action. It is noticeable that there are some physico-chemical 
factors that may override the effect of these SAs in a molecule. The biological activity of a 
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molecule depends on different factors such as molecular weight, physical state, solubility and 
chemical reactivity. The Ashby and Tennant preliminary lists of carcinogenic SA was one of the 
most useful schemes to assess carcinogenic potential of substances with unknown carcinogenic 
properties. In 1996 Munro et al. created a functional groups list for genotoxicity based on the 
SAs of Ashby 49. Cheeseman et al. 50 identified SAs useful to support higher threshold levels by 
using (Q)SAR, genotoxicity and short-term toxicity data. The identified SA were similar to the 
Ashby and Tennant list and were correlated with the TD50. The new list contained eight new 
more complex SAs. The list of SAs proposed by Ashby and Tennant and Cheeseman was 
revised by Kroes et al. 51.  
Kazius et al. 46 expanded and refined Ashby’s SAs by applying modern data mining techniques 
on chemical data of mutagenicity in Salmonella. Kazius et al. introduced a final set of 29 
toxicophores which was able to classify the chemicals in the evaluation data set with 18% of 
classification error.  
One of the most recent rule sets defined by human expert for mutagenic carcinogenicity has 
been developed by Benigni and Bossa 39,43. The updated version of this rule set 39 is 
implemented in Toxtree version 2.6.13 52. 
1.9 Current Hazard Identification Procedures and Related Considerations 
Since the carcinogenicity is a complex process, the rodent bioassay results are insufficient for 
accurate human health risk assessments 53. Currently, genotoxic properties of the new chemicals 
are evaluated mostly by short-term studies. The chemicals that show genotoxic effects do not 
undergo long-term studies. Extrapolation of the results to humans from the rodent data is 
possible by considering the similarities and dissimilarities of the species. 
Most of the identified carcinogens in humans are genotoxic or interact directly with DNA. 
Genotoxic chemicals are essentially different from nongenotoxic chemicals 16,54. The 
classification of a carcinogen into genotoxic or nongenotoxic category has an important effect in 
the choice of the further studies and the indication of the chemical for risk assessment. 
Genotoxicity screening of a chemical by its metabolic information is more standardized 
compared to the chemical evaluation approach for defining nongenotoxic chemicals. While for 
evaluation of genotoxic chemicals a standard decision approach is approved 55, more effort is 
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needed for defining nongenotoxic chemicals 54. Following the scheme of genotoxicity 
assessment reduces the number of animals used in carcinogenicity tests early in the evaluation 
process.  
1.10 (Q)SAR and REACH 
(Q)SARs are mathematical models that correlate the physico-chemical properties of chemicals 
to their biological activity such as toxicological and environmental fate properties. The (Q)SAR 
models are mainly statistical correlations, which describe a relationship between one or more 
quantitative characteristics of a chemical (descriptor) which is calculated from the chemical 
structure to a quantitative measure of property or activity of that chemical. These biological 
activities or properties for which the (Q)SAR models seek to estimate a predicted value are 
usually toxicological endpoints for human or environment. These prediction models can yield 
either continuous or categorical endpoint 56.  
In other words, the information on the chemical structure of chemicals is connected to a specific 
property such as toxicity by means of mathematical and statistical methodologies and this 
relationship can be used as a predictive model for a new substance. Chemical applicability 
domain of each model should be defined by effective validation to make the model reliable for 
the new predictions. Considering the established applicability domain of each model, the 
reliability of the prediction of a substance by the model is decided. The chemically induced 
adverse effect of chemicals can be predicted by (Q)SAR models, as these models are becoming 
more and more robust and reliable. In addition, these models are fast and cost-effective and can 
replace a significant number of tests on animals and cells. The legislation on Registration, 
Evaluation, Authorisation and restriction of Chemicals, REACH, promotes the use of (Q)SAR 
models provided that, their scientific validity has been established, the substance falls within the 
applicability domain, the results are adequate for classification and labelling and/or risk 
assessment, and adequate and reliable documentation of the method is given. The REACH 
guidance has not determined any fixed criteria for the acceptance of the (Q)SAR models. In case 
a chemical is registered by an industrial registrant using a (Q)SAR model, the (Q)SAR model 
must be explained by them 56. The application of (Q)SAR predictions can be useful in numerous 
fields, for example, in the initial phase of selecting chemicals for testing, experimental design of 
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experimental tests, evaluate and improve the data obtained from experiments, classification and 
labelling, and persistent, bioaccumulative and toxic assessment 56. 
Another important field in which (Q)SAR predictions play role is in classification, clustering 
and read-across. Meaningful groups of chemicals can be created by the help of (Q)SARs. 
(Q)SARs are mathematical models that reveal the physico-chemical properties of the chemicals 
associated with their biological properties or activities. Presumably, these relationships 
modulate the activity giving rise to a trend development over a congeneric series of chemicals. 
The (Q)SAR predictions for molecular and toxicokinetic endpoints provide information for 
grouping and read-across process. Although, some (Q)SAR models may not provide adequate 
information for REACH or EU regulation CLP about the classification or the risk assessment of 
a compound or mixture, they can be used in a WOE approach together with other sources of 
data for designing a testing strategy and filling data gaps about the chemical properties 57. 
According to REACH all other alternative testing options, such as (Q)SARs, should be 
considered before performing or requiring vertebrate testing 58. All existing information on 
physico-chemical properties, toxicological and ecotoxicological data from in vivo and in vitro 
experiments and other non-testing methods must be gathered and put together for this end. 
Adding (Q)SAR and other non-testing methods, makes the information sufficient for the 
REACH requirements for the low tonnage substances. The REACH endpoint guidance claims 
that currently not all the mechanisms associated with reproductive toxicity can be identified by 
(Q)SAR models 59. Although REACH demands and encourages the use of non-testing and in 
vitro methods to avoid vertebrate animal testing, unaccompanied (Q)SAR models do not 
produce reliable results that can replace whole-animal reproductive toxicity testing 59. 
Supporting results from other experiments is needed to complete the negative result of the 
(Q)SAR and non-testing predictions for reproductive hazard assessment of a chemical. 
However, results of predictions of (Q)SAR models are useful in a WOE approach for grouping 
and read-across models and they contribute to reduction of animal tests 60. 
According to the REACH Annexes VII-X for known genotoxic carcinogens or germ cell 
mutagens for which sufficient risk management measures are accomplished, no testing is 
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needed for reproductive effects 58. Thus, according to the REACH guideline for chemical safety 
assessment 59, (Q)SAR results may contribute to reducing testing for reproductive toxicity. 
Among these points non-testing information which involves Quantitative Structure Property 
Relationships (QSPRs) and read-across can be used in accordance with the limitations explained 
for each individual endpoint. Each QSPR model has been built using a training set of substances 
and is more applicable to the chemicals which most closely match the samples used in the 
models. Therefore, the estimation of the QSPR models requires expert judgment. The 
predictions of such models need to be reasonable. 
1.11 REACH Guidelines 
Endpoint specific guidance of the REACH regulation 59 describes in what manner the WOE 
approach could be used for each endpoint. This section describes how the information collected 
from different sources could be integrated and used so that the conclusion on this information is 
sufficient for regulatory purposes (i.e. risk assessment). In other words, before proposing 
additional animal testing, use of alternative methods and adequacy of methods for generating 
additional information must be considered. It is precisely emphasized that experiments on 
vertebrate animals should be limited to the cases that all other data sources have been exhausted 
61.  
There are a number of issues determined by REACH to be considered before taking decision to 
perform the testing. These issues help to design fit for purpose in vivo tests, also provide 
evidence for not performing in vivo testing under certain circumstances. 
 Testing requirements; 
 Exposure/use pattern (emissions, yes or no, consumer use, etc.);  
 Occurrence (monitoring data); 
 Indications of the effect/ property based on animal or human data, in vitro data and non-
testing information; 
 Any concern e.g. based on toxicokinetics, read-across and (Q)SAR considerations, 
 WOE; 
 Seriousness of the effect; 
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 Other effects of relevance for the endpoint.62 
1.12 Genotoxicity Assessments in the EU Regulations 
The EURL ECVAM defines 3 endpoints that need to be assessed in the process of genotoxicity 
for the safety assessment of chemicals and the protection of human health and environment 63. 
These 3 endpoints are: gene mutation, structural chromosome aberrations, and numerical 
chromosome aberrations (Table 2-page 25). Classification and labelling (C&L) of chemical 
substances is based on the results of the genotoxicity tests of the scientific tests for toxicity 
assessment in the EU 34 and in the world (UN GHS).  
According to the EU legislations and directives there are two different approaches for the 
assessment of genotoxicity to humans. According to the first approach, a chemical that is 
nongenotoxic in the in vitro analysis is not considered for the further in vivo assessments (e.g. 
REACH, CLP and Cosmetics Directive). The second approach, foresees in vitro tests of 
chemicals followed up by in vivo assessments (e.g. ICH for pharmaceuticals and VICH for 
veterinary drugs). This decision is made because the alternative methods to in vivo test for 
carcinogenicity cannot thoroughly replace the animal tests 64. Analyzing the regulatory 
requirements, EURL ECVAM suggests an efficient approach to improve the traditional 
genotoxicity assessment. The new approach has the objective of reducing the animal use in 
genotoxicity testing, and EURL ECVAM suggests that efforts should be directed towards the 
improvement of the current assessments while reducing the use of animals and at the same time 
satisfies regulatory information approach. The identified solutions for improving the 
genotoxicity assessment have the following aims: 
 Increasing the performance of in vitro tests in order to avoid the additional follow-up in 
vivo tests; 
 Improving the accuracy and quality of the in vivo follow-up testing to reduce 
unnecessary use of animals.  
According to the chemical authorities the positive results of the in vitro genotoxic predictions 
need to be verified by in vivo tests, and this fact highlights the importance of finding solutions 
for reduction and refinement of genotoxicity tests. A strategy to reduce animal tests for 
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decision-making about carcinogenic or toxic compounds, can be collecting relevant data and 
drawing a conclusion on the basis of a data obtained from different sources. Pfuhler et al. 65 
published some solutions to reduce animal tests in an ECVAM workshop report. 
Table 2. Test methods most commonly used for genotoxicity/mutagenicity testing 63 
 Test Method 
COUNCIL 
REGULATION 
(EC) No 440/2008 
Test Method 
OECD Test 
Guideline 
endpoint 
In vitro/ 
in vivo 
Bacterial reverse mutation test 
(Ames test) 
B.13-14 TG 471 Gene mutations vitro 
In vitro mammalian chromosome 
aberration test 
B.10 Updated TG 473 Structural aberrations vitro 
Mammalian cell gene mutation 
test 
B.17 
TG 476 (under 
revision) 
Gene mutations vitro 
In vitro mammalian cell 
micronucleus test 
 Updated TG 487 
Structural and 
numerical aberrations 
vitro 
Mammalian erythrocyte 
micronucleus test 
B.12 Updated TG 474 
Structural and 
numerical aberrations 
vivo 
Mammalian bone marrow 
chromosome aberration test 
B.11 Updated TG 475 Structural aberrations vivo 
Transgenic rodent somatic and 
germ cell gene mutation assays 
 TG 488 Gene mutations vivo 
In vivo mammalian alkaline 
comet assay 
 TG DNA damage vivo 
 
1.13 Read-across 
A read-across approach finds out the relevance or relationship between the properties of the 
chemical structures and then make assessment on the applicability of this information to another 
substance. It is crucial to detail the reasoning behind the inference on the substance for which 
the property is unknown.  
A read-across process which is based on the concept of similarity can be applied in different 
forms: one-to-one (a similar substance can be used to make an estimation for a target substance) 
b) many-to-one (two or more analogues used to make a prediction for a single substance c) one-
to many (one analogue used to make estimations for two or more substances) d) many-to-many 
(two or more similar compounds used to make estimations for two or more substances). 
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There are some important issues to be considered when using a read-across model. These 
characteristics are as follows:  
 The source substances must have the same structural features and the functional groups 
of the target substance; 
 the physico-chemical profile of the similar compounds must be comparable to those 
present in the target substance; 
 the relevant molecular descriptors must have comparable values;  
 the analogue substances must have approximately the same molecular weight.66 
The results of a read-across should be interpreted using expert judgement and for the support of 
the conclusion detailed documentation is required. The read-across approach is more suitable 
for the physical hazard related to physico-chemical properties of the substances, as reliable test 
data should be available according to the CLP regulation. Therefore, if read-across is used as a 
unique method to generate a value to meet the endpoint data requirements, the criteria given in 
section 1.5 of Annex XI to REACH must be met.66 
1.14 Classification and Labelling and Chemical Safety Assessment 
Knowledge about physico-chemical properties of the chemicals and chemical safety assessment 
is important for the environment and human health. All the stages of the substances’ lifecycle 
must be assessed and controlled in the process of chemical safety assessment, these stages 
include manufacture, transfer, use and disposal of the chemical substances. Further, physico-
chemical data are essential for the correct planning of (eco)toxicological studies and for the 
optimization of the test conditions. 
The standard test and most confident assay for carcinogenicity is the 2-year rodent 
carcinogenicity bioassay determined and described by OECD. The purpose of this assay is “to 
observe test animals for a major portion of their life span for the development of neoplastic 
lesions during or after exposure to various doses of a test substance by an appropriate route of 
administration.” Usually two species (mice and rats) and both sexes are used in this test. The 
chemical exposure is dosed and executed by oral, dermal or inhalation modes based on the 
expected human exposure. Dosing is done during two years and animal health is screened 
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throughout the test. The most important results of the test is obtained by the thorough 
examination of the animal tissues and organs at the termination of the assay. 
The combination of carcinogenicity and chronic toxicity animal bioassays endpoints may reduce 
the animal use 67. A number of transgenic rodent models have been suggested as alternatives to 
the standard bioassay carcinogenicity test by the ILSI HESI, but none of them was as efficient 
as the traditional 2-year assay for identification of carcinogens 68. Most of these models were 
capable of detecting genotoxicity that can be already detected by other in vitro genotoxicity 
assays. Alternative models are not still suitable for the detection of nongenotoxic carcinogens 69.  
1.15 Development and Optimisation of Alternative Methods 
1.15.1 Importance of Mode of Action and Weight of Evidence Approach  
The most appropriate key events are needed to understand the mechanisms of action of 
nongenotoxic carcinogens. Since there exist numerous modes of action for these substances, a 
WOE approach seems to be essential to deduce a reasonable conclusion out of the gathered data 
for a chemical.  
There are nongenotoxic carcinogens in IARC group 3 (i.e. not classifiable as to its 
carcinogenicity to humans) which are not carcinogenic in humans. To evaluate these group of 
carcinogens, the WOE approach is a useful tool. This approach helps the scientists to 
understand the differences of modes of action in rodents and humans. 
1.15.2 Alternative Methods for Detecting Nongenotoxic Carcinogens  
In the process of the detection of the nongenotoxic carcinogens and exploring alternative 
methods for their assessment, it is important to consider the vast range of modes of action of 
these chemicals. These modes of action include: mitogenic induction, inhibition of gap-
junctional intercellular communications, endocrine modifiers, oxidative stress, 
immunosuppressants, regenerative proliferation and/or DNA methylation. Some of the 
examples of alternative methods for the nongenotoxicity detection are: (Q)SARs, measuring 
replicative DNA synthesis as an indication of cell proliferation, the in vitro cell transformation 
assays, measurements of inhibition of gap junction intercellular communication 70 and the use of 
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gene expression profiles with mechanistic networks for the identification of potential markers of 
nongenotoxic carcinogens. 
1.16 Quantitative Structure–Activity Relationship (QSAR) 
The main results of in vitro cell toxicity used by (Q)SAR models for nongenotoxic 
carcinogenicity are: several markers of in vitro cell toxicity including inhibition of gap-
junctional intercellular communications, modulation of apoptosis and induction of cellular 
proliferation 71. In this study, the structural features of the nongenotoxic carcinogen associated 
with toxicity or ligand binding, as in the case of estrogen, peroxisome proliferators and tubulin 
protein receptors, have been analyzed 71. 
The (Q)SAR models for detection of carcinogenicity use information and correlate biological 
activity or chemical reactivity to chemical structure. These models are practically based on the 
assumption that similar chemicals have similar activities. The OECD has defined a number of 
principles for the validation of the (Q)SAR models for regulatory analysis 72,73. These principles 
for (Q)SAR models are: having a defined endpoint, an unambiguous algorithm, and measures of 
goodness-of-fit, robustness, predictivity, and applicability domain.  
A great number of nongenotoxic carcinogens are mutagenic inducers which cause cancer by 
increasing cellular proliferation. Hepatocyte rodent in vivo studies indicate that most of the 
hepatocarcinogens cause cancer by accelerating hepatocyte division 74–77. 
As a result of putting into practice the REACH legislation, the number of 2-year rodent 
carcinogenicity bioassay is reduced and this fact can lead to the lack of detection of a large 
number of nongenotoxicity carcinogens. Because of the high risk of hazard associated with this 
group of carcinogens, there is an increasing need of alternative methods for their detection. 
Possible alternative methods for this purpose include: SARs and (Q)SARs, replicative DNA 
synthesis assay, the in vitro cell transformation assay and/or inhibition of GJICs. None of these 
alternative methods provide any information on the mode of action, thus further studies are 
needed to fill this gap of data. Using toxicogenomics to analyse multiple pathway-specific gene 
expression profiling is an efficient method to identify putative alerts. Additionally, statistical 
validation studies to examine the sensitivity, specificity and accuracy of these models play an 
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important role in improving these alternative models. It is important to discover as much as 
possible different modes of action of nongenotoxic carcinogens and not to depend only on the 
traditional nongenotoxic carcinogens identification methods (tetrachlorodibenzo-p-dioxin, 
carbon tetrachloride, and cyclosporine). 
1.17 Software Packages for Mutagenicity and Carcinogenicity Predictions 
Two major alternatives to in vivo testing are in vitro and in silico techniques. In the last decade, 
numerous computer software have been developed in order to replace, reduce and refine the 
animal tests. These software packages include also mutagenicity and carcinogenicity predicting 
models of the chemical compounds. 
1.17.1 VEGA Platform 
The VEGA platform contains a number of (Q)SAR models for predicting mutagenicity and 
carcinogenicity such as CAESAR. Two new carcinogenicity models have been added to the 
VEGA platform by the author 78. CAESAR ((Q)SAR mutagenicity models) was specifically 
developed for the REACH regulation in collaboration with the United States Environmental 
Protection Agency (http://www.caesar-project.eu/). The mutagenicity models in the VEGA 
platform are based on data obtained from the Ames bacterial test. Models on carcinogenicity, 
developmental toxicity and etc. are freely available from the VEGA platform.  
1.17.2 DEREK Nexus  
The DEREK Nexus 79 is a knowledge-based expert system, developed by LHASA Limited that 
predicts the genotoxicity, mutagenicity and carcinogenicity of a chemical by highlighting the 
SAs present in its molecular structure. Derek Nexus toxicity predictions are a result of two 
processes: evaluating SAs and estimating the likelihood of toxicity.  
The knowledge-based SAs for in vitro mutagenicity have been implemented by experts who 
have assessed relevant Ames data and supporting mechanistic data (e.g. DNA adduct formation 
experiments). If a query compound matches a SA, the alert will fire with an associated 
reasoning level (e.g. plausible, probable or certain). The reasoning levels associated with the in 
vitro bacterial mutagenicity alerts in Derek Nexus gives an indication of the likelihood for 
compounds in that class to be active in the Ames test 80. 
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Each bacterial, in vitro mutagenicity alert in the knowledge base was examined by a scientist 
with expertise in mutagenicity alert development. The patterns encoding the SAR for each alert 
were modified using the Derek Knowledge Editor if they contained features that were 
implemented to prevent the pattern being activated by nonmutagenic compounds (so-called 
exclusion patterns). Such features were removed and the resultant ‘predictive space’ was stored 
within a modified knowledge base. Thus, each bacterial, in vitro mutagenicity alert in Derek had 
a corresponding region of predictive space 81. 
1.17.3 TOPKAT 
TOPKAT 82 is a (Q)SAR-based system, developed by Accelrys Inc. (http://accelrys.co m/). 
Some of the TOPKAT toxicological endpoints are mutagenicity, developmental toxicity, rodent 
carcinogenicity, rat chronic LOAEL, rat MTD and rat oral LD50. TOPKAT models are 
developed using two-dimensional molecular, electronic and spatial descriptors. The toxicity 
prediction is obtained from a chemical’s molecular structure. TOPKAT defines an applicability 
domain value which estimates the confidence in the prediction by applying the patented Optimal 
Predictive Space validation method. Any prediction generated for a query structure outside of 
the OPS space is considered unreliable. 
1.17.4 MultiCASE  
MultiCASE 83 (MultiCASE Inc., Cleveland, OH, USA) is a prediction model for genotoxicity 
and carcinogenicity endpoints based on US FDA and US EPA. MultiCASE identifies SAs with 
a potential to initiate high biological activity, in addition, some statistical parameters are 
analysed to complete the predictions. The mutagenicity and genotoxicity models are based on 
the data obtained from Ames test, direct mutagenicity, base-pair mutagenicity, frameshift 
mutagenicity, chromosomal aberrations, and sister chromatid exchange data. The 
carcinogenicity model includes different rodent assays (rate, mouse, male, female, and TD50 
rats) and human epigenetic studies. All models use the statistical approach with the exception of 
the rule-based model for the Ames mutagenicity. 
1.17.5 QSAR Toolbox 
QSAR Toolbox 84 in cooperation with the ECHA is a read-across tool for grouping the 
chemicals and examining their toxicity effects according to the OECD principles 
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(http://www.qsartoolbox.org/). QSAR Toolbox systematically groups chemicals into classes 
according to their molecular structure, physico-chemical and biological properties. This 
software extracts structural characteristics and modes of action based on experimental 
information for the target molecule. The common mechanisms of action and common 
toxicological behaviour or consistent trends among results related to regulatory endpoints are 
results for an evaluation in this prediction software. 
1.17.6 Toxtree 
Toxtree 52 is a free tool for the assessment of mutagenicity and carcinogenicity of the chemicals 
using decision trees. Toxtree mutagenicity and carcinogenicity model is based on the SAs of the 
Benigni-Bossa rule set, SAs for identification of Michael acceptors, and SAs confirmed by 
positive in vivo micronucleus tests. The program identifies any SA present in the target 
molecule structure and concludes about the mutagenic or carcinogenic property of the chemical 
compound under investigation. The result of the prediction can be class I (inactive), class II 
(weak activity), or class III (active). 
1.17.7 LAZAR 
LAZAR 85 is an open source tool for the prediction of carcinogenicity and Salmonella 
mutagenicity. LAZAR creates local endpoint (Q)SAR models based on a training set (only 
nearest neighbours) for each chemical separately. It first calculated the descriptors and 
determines the molecular similarity and then it builds a local (Q)SAR model based on a 
database of experimental toxicity data. This program meets all five OECD principles.  
1.17.8 ACD/Tox Suite 
The ACD/Tox Suite 86 package contains predicting models for genotoxicity and carcinogenicity. 
The assessments are made based on validated (Q)SAR models in combination with expert 
knowledge. The software highlights and identifies the SAs which are responsible for toxic 
properties and extracts some similar molecules from the training set. The training set is 
composed of compounds that are genotoxic in Ames test. 
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1.17.9 Leadscope Model Applier  
The Model Applier developed by Leadscope 87 (Leadscope Inc., Colombia, OH, USA), uses 
(Q)SAR models for Salmonella mutagenicity, E. coli mutagenicity, mouse lymphoma, in vitro 
chromosome aberrations, and in vivo micronuclei. 
1.17.10 SARpy 
SARpy 88 is a data mining tool which works in a SAR approach. This tool is able to identify a 
list of active and inactive molecular fragments that act as SAs for biological activity from a 
learning set of chemical compounds with known binary classification toxicity property (e.g. 
carcinogenicity, mutagenicity, etc.). The entire process is designed to fit with human reasoning. 
In fact, SARpy is a computerized tool which helps the expert to extract significant molecular 
substructures with potential effect in toxicity or in nontoxicity in an automatic way with 
customized requirements to be set by the user. The extracted list of active and/or inactive SAs 
identified by SARpy are considered new prediction models with satisfactory prediction ability 
on an external test set, in particular in the case of mutagenicity 89. 
1.18 Weight of Evidence 
Human health and environmental decision-making is often based on multiple lines of evidence. 
WOE is a process for integrating different and sometimes conflicting sources of information 
(lines of evidence) to determine a relative support for possible answers to a scientific question 
or assessment. A line of evidence is a group of evidence of similar type which pertain to an 
important aspect of the environmental or human health assessment. The distinct elements of 
information forming a line of evidence are called “studies” or “pieces of evidence”. The 
multiple sets of information of lines of evidence can be divided into three types: the biological 
field line, the toxicity line and the chemistry line 90. Combining information from multiple 
sources to be used in decision-making is not a simple procedure. From a regulatory point of 
view, risk assessors make use of WOE approaches to perform integration and reach conclusions 
91 in a qualitative or quantitative manner. Also the industry employs different sorts of WOE 
approaches in the toxicity assessment of the chemicals 92. The guidance on WOE provided by 
EFSA introduces a general framework of approaches used to weigh the lines of evidence in 
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order to find an answer for any scientific question which needs to consider different sources of 
information and integrate various data in its assessment process. This document explains types 
of qualitative and quantitative approaches in the WOE field and lists the relative methodologies. 
According to the EFSA document, the WOE assessment consists of three steps: 
1. Assembling the evidence 
2. Weighing the evidence 
3. Integrating the evidence 
The first step compromises searching and selecting relevant evidence for answering the 
question, and also grouping the evidences found into lines of evidence. The second step 
involves the evaluation and assigning weight to the evidence. In the third step, the collected 
lines of evidence are integrated to reach conclusions, by weighing the relative support for 
possible answers to the question at hand. 
During the process of a scientific assessment the three above mentioned steps may be required 
at one or more points, whenever integration of evidence is necessary to reach a conclusion. 
Problem formulation is the first stage of scientific assessment in which the question to be 
addressed by each WOE assessment is defined. The three steps of the WOE framework is the 
preceding step in the scientific assessment. The outcome of the process of WOE influences 
directly or indirectly the overall conclusion of the scientific assessment. The existing 
uncertainties that may affect the overall assessment are evaluated during the steps of the WOE 
and in addition, a separate step is considered for the analysis of these uncertainties as the last 
stage of the scientific assessment before any conclusion is reached. In some assessments an 
additional sensitivity and influence analysis is performed to examine the influence of evidence 
and uncertainties that may influence the conclusion. This process is iterating, and permits the 
assessor to return to an earlier step in order to refine the scientific assessment. 
Reliability, relevance and consistency are mentioned as three key considerations for weighing 
evidence in many scientific publications. The quality of the evidence considered for supporting 
an answer to a scientific question (reliability), how applicable the evidence is to that question 
(relevance) and how consistent the line of evidence (or the piece of evidence) is with other 
existing evidence to answer the same question (consistency). Relevance needs to be considered 
34 
 
when identifying evidence, and relevance and reliability are the key considerations when 
selecting which evidence to be concluded in the assessment. Relevance and reliability may be 
different in the selected evidence and this will be analyzed in the phase of weighing the 
evidence. 
Reliability measures the correctness of a piece of evidence, and whether this piece of evidence 
represents correctly the quantity, property or event it refers to. Reliability consists of accuracy 
and precision. 
Relevance defines to what extent a piece of evidence is relevant to answer a specified question, 
provided that the information it consists is reliable. 
Consistency explains the compatibility of the information obtained from different pieces of 
evidence, after analysis of reliability and relevance. 
The important role of multi-criteria decision analysis and WOE methodologies in environmental 
decision-making 93,94, as well as, hazard ranking of NMs 85,95–97 has been assessed by numerous 
scientists.  
1.18.1 Weight of Evidence Method Classification 
Linkov et al. 98 provided a brief review of qualitative and quantitative WOE approaches in 
human and environmental risk assessment. Linkov et al. introduced a classification system for 
characterizing WOE methods, based on Weed 99 and Chapman et al.’s 100 (Table 3-page 35) The 
methods implied in this table are ordered from the most qualitative methods (e.g. listing 
evidence and BPJ or narrative review) to the most quantitative methods (e.g. indexing and 
quantification) which incorporate methods involving decision analysis tools and defining the 
problem as statistical hypothesis testing.  
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Table 3. Weight of evidence methods 98 
Method Method description 
Listing Evidence Presentation of individual lines of evidence without attempt at 
integration 
Best Professional Judgment Qualitative integration of multiple lines of evidence 
Casual Criteria A criteria-based methodology for determining cause and effect 
relationships 
Logic Standardized evaluation of individual lines of evidence based on 
qualitative logic models 
Scoring Quantitative integration of multiple lines of evidence using simple 
weighting or ranking 
Indexing Integration of lines of evidence into a single measure based on 
empirical models 
Quantification Integrated assessment using formal decision analysis and statistical 
methods 
 
Listing evidence as the simplest form of WOE, collects lines of evidence together. Lines of 
evidence are presented without any integration phase. The assessors may reach a conclusion 
considering the list of evidence. All the other methods presented in Table 3 (page 35) include a 
form of integration. BPJ is similar to listing evidence, but it attempts to integrate the evidence 
by invoking a professional opinion. Casual criteria methods consist of methods evaluating cause 
and effect relationships. Casual criteria and logic provide a consistent structure for the analysis 
and transferability of the methods are improved by these methods. Casual criteria methods by 
means of outlined criteria, establish a cause and effect criteria, by illustrating that the specific 
criteria is met. While logic methods make use of previously outlined methods for integrating 
lines of evidence, such as US EPA carcinogenicity guidelines 101. Casual criteria and logic leads 
to a more transparent integration, but the methods are qualitative and may be biased by 
experience. Casual criteria and logic depend on BPJ to synthesize lines of evidence. Scoring is 
the simplest quantitative method of WOE which assigns weights to lines of evidence. A 
numerical WOE score is a combination of weights calculated by different methods such as BPJ 
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based on consistency, specificity and strength of the association. Indexing determines a single 
value as the outcome of the analysis by integrating all the weights assigned to each line of 
evidence. Scoring and indexing do not quantify judgments using formal decision analysis or 
probabilistic techniques. Formalized mathematical methods involving quantitative methods are 
used by quantification category to weigh the evidence. Non linearity and correlations can be 
integrated in the methodologies of quantification category. Also in this category scientific 
results with individual expert or decision maker judgment and comparison across multiple 
experts can be integrated in a transparent and reproducible manner. Multiple-criteria decision 
analysis is a quantification method which uses likelihoods to weigh the evidence.  
1.18.2 Weight of Evidence Application 
Linkov et al.98 reported a summary of methods and application areas of WOE. The WOE 
applications are divided into two main categories: human health and ecological. Under category 
of human health that we focus on, WOE can be applied to i) method development, which 
develops methodologies for human health risk assessment, ii) toxicity analysis, which assesses 
the adverse effects of a substance, iii) mode of action determination, the modes in which a 
substance may cause harm to human health, iv) benchmark development, defines the allowed 
exposure levels of various substances, and other fields. This literature review yielded a 
comparable number of human health and ecological uses. Human health methodologies are 
performed mostly by best judgment methods, and a minor number of studies are conducted by 
quantitative methodologies. The qualitative methods are based on BPJ as recommended by the 
US EPA guidelines. Casual criteria and logic are mainly used by ecological methodologies. 
Overall, this review indicates that qualitative methods of WOE are used more than quantitative 
ones in the applications of WOE and BPJ is the most widely used method. 
1.18.3 Weight of Evidence Approach in Nanomaterials Risk Assessment 
Hazard identification is an important step in the process of NMs risk assessment and is required 
under regulatory frameworks of the US, Europe and worldwide. The current risk assessment 
methods used for chemical and biological materials may not be adoptable for NMs because of 
the existing uncertainties in identifying the relevant physico-chemical and biological properties 
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that are able to adequately describe the NMs. Understanding and managing the impact of NMs 
on human health and environment need new approaches. Currently, our knowledge about the 
toxicity of NMs is barely comprehensive 102,103. The potential toxicity as well as potential for 
exposure and risk of NMs may be highly impacted by their physico-chemical characteristics. In 
the absence of definitive data, NM research and regulations can make use of a systematic 
characterization of factors to identify toxicity and risk of NMs 104. On the other hand, given the 
complexity of NMs and high uncertainties associated with them, multiple studies on the 
characteristics and potential hazard effects result in varying data points. WOE approaches are 
recommended for NMs risk assessment for prioritizing research studies and identifying NMs 
with hazard effects. Expert opinion is frequently used to fill the knowledge gaps during 
decision-making. Influence diagrams by using expert judgment approach are designed to assess 
the risk of NMs on human health 105. Linkov et al. 96,97 proposed a WOE approach for NMs 
regulation and management. For the evaluation of the adverse effects of NMs, different aspects 
such as life cycle and characteristics of NMs must be addressed. To follow the European 
Commission PEC/PNEC (the ratio of predicted environmental concentration (PEC) and 
predicted no effect level (PNEC)) approach of the TGD 106, there is lack of information about 
toxicity and characteristics of NMs in order to estimate exposure concentration and no effect 
concentration and thus the risks. Available information about the life cycle phases of NMs 
concerning different issues such as environmental behavior relevant for exposure and effect are 
gathered in lines of evidence. Finally, the information gathered in these lines of evidence are 
integrated to reach a conclusion about the adverse effects of NMs. The results are usually 
qualitative, assigning the assessed NM to a specific class. This ranking system helps the 
assessors to prioritize the most potential NMs which may pose risk to human health or 
environment.  
Zuin et al. 95 reports the application of a WOE procedure to the assessment of NMs that may 
cause harm to human health. The procedure is divided into three steps. 
The starting point in the assessment of NMs is physico-chemical characterization and properties 
and toxicological information. Physico-chemical properties of NMs are the first line of 
evidence, which is mainly related to the capacity to evaluate the potential exposure according to 
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their physico-chemical properties, such as adsorption tendency and bioaccumulation potential. 
The second line of evidence addresses the evidence that a NM may enter the body and cause 
adverse biological harms. For the estimation of the hazard effects, within each line of evidence 
other indicators, such measurement endpoints are identified. These indicators should include a 
wide range of information, like physico-chemical properties, toxicological endpoints, and data 
obtained from literature. 
The second step is defining rating classes for each indicator. The assignment of each NM to a 
specific rating class may be performed on the basis of (i) characterization activity and toxicity 
test, (ii) expert judgment, (iii) literature data. The defined classes can be high, moderate, low 
and negligible. The qualitative and quantitative values associated with the indicators permits the 
NM to be assigned to a class, on the basis of its properties-related exposure level and toxicity.  
Ranking procedure is the last step of the process of the WOE approach-based method. In the 
suggested procedure the calculation of frequency of hazard occurrence is performed on the basis 
of the rating class assigned to different indicators.  
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1.19 Abstracts of the Main Parts 
1.19.1 Part 1- New Clues on Carcinogenicity-Related Substructures Derived From Mining Two 
Large Datasets of Chemical Compounds 
The first section of my thesis is about development of two SA-based (Q)SAR models for 
carcinogenicity. Two (Q)SAR models were developed by extracting data from well known 
carcinogenicity databases with genotoxic and nongenotoxic carcinogenicity reliable data 
gathered from rodent in vivo tests, Ames test and in vitro tests and epidemiological data. 
(ANATARES 107 carcinogenicity database and the combination of Kirkland et al. 108 and 
ISSCAN 109 database). 
1.19.2 Part 2 - Toxdelta: A New Program to Assess How Dissimilarity Affects the Effect of 
Chemical Substances. 
The second part explains a new read-across tool embedded in the ToxRead software: ToxDelta. 
Two structurally similar molecules share an MCS. In order to evaluate if two similar molecules 
have different effects, we focused our attention on the molecular fragments which are not in the 
MCS. These parts may increase or decrease the value of the property. We considered a variation 
of the MCS concept of efficient relevance in toxicity assessment where the rings of molecules 
must not be broken. To assess the toxicity of the target chemical, ToxDelta extracts the MCS 
and delineates the remaining fragments. Each of these fragments moiety represents a difference 
between two molecules and its relevance in the toxicity assessment are evaluated against a 
knowledge based list of active and inactive fragments. ToxDelta considers the dissimilarities of 
the molecules in a read-across approach. 
1.19.3 Part 3 – Genotoxicity Induced by Metal Oxide Nanoparticles: a Weight of Evidence 
Study and Effect of Particle Surface and Electronic Properties  
Genotoxicity of metal oxide NMs is an endpoint with intensive testing resources mainly 
resulting from in vitro comet assay. Current contributions to the genotoxicity data assessed by 
the comet assay provide a case-by-case evaluation of different types of metal oxides that ranged 
from 15 to 90 nanometres and had different crystal structures. We have assessed the quality of a 
multi-source data set of in vitro comet assay data retrieved from genotoxicity profiles for 16 
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bare nano-sized metal oxides with different chemical core compositions. There is an 
inconsistency in the literature as to the genotoxicity testing data that requires intelligent 
strategies, such as WOE evaluation. An evaluation criterion was applied to establish which of 
these meta data were of sufficient quality and what weight could have been given to them in 
inferring genotoxic results. We surveyed the collected data on 1) minimum necessary 
characterization of NPs, and 2) principals of correct comet assay testing for NMs. We quantum-
chemically calculated a set of structural descriptors for the 16 metal oxides. A classification 
model based on a decision tree has been developed for the prepared dataset. Three descriptors 
have been identified as the most relevant variables to genotoxicity prediction in our 
classification model: heat of formation, molecular weight and area of the oxide cluster based on 
conductor like screening model. The proposed genotoxicity assessment strategy that is based on 
quantum-chemical descriptors is useful to prioritise the study of the NMs, which may lead to 
high risk for human health.  
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CHAPTER 2 
2. Aim of the Study 
Human health and environmental risk assessment draw upon multiple sources of information. 
Combination and integration of multiple lines of evidence is required to draw conclusions about 
the risks posed by chemical compounds and NPs. To this end, scientists and assessors take 
advantage of WOE approaches. The increasing need for new non-testing methods for the 
estimation of toxicity of chemicals coincides with the emergent necessity of more adequate 
WOE approaches to facilitate the process of decision-making. The proposed non-testing 
methods such as (Q)SAR and read-across are promising methodologies that help the assessors 
to fill the gaps of information, which in their turn provide means that can be used in risk 
assessment in a WOE approach. The regulatory bodies (such as EFSA) and industry already 
make use of WOE approaches in the process of decision-making. 
The main aim of the present study is to introduce a new WOE framework for the results of in 
silico models, which explores the structural properties of the target and the similar compounds 
(used in read-across terms) and combines the estimations of the (Q)SAR models with the 
toxicity information associated with the molecular structures in an interpretable manner. 
In this dissertation, for the improvement of the in silico ((Q)SAR and read-across) methods in 
genotoxicity assessment of chemicals (i) two new structure-based carcinogenicity models, (ii) a 
new read-across model based on maximum common substructure for mutagenicity endpoint, are 
developed. Additionally, (iii) a genotoxicity model for the metal oxide NPs is introduced.  
We addressed two WOE methods in the present study. BPJ method as a qualitative approach is 
used in the study of genotoxicity of metal oxide NPs. Given the very high uncertainties with 
NMs and their hazard effect on environment and human health, research resources should be 
conducted in the direction of integrating the available data to help the manufactures, regulators, 
consumers and other stakeholders in the process of decision-making. A genotoxicity data base 
of metal oxide NPs is developed using a BPJ framework for selecting the most reliable data 
from peer reviews. A decision tree model is built for classification of these data base using three 
quantum-chemical descriptors, by the machine learning means. 
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Multiple studies for hazard identification of chemical substances often result in varying data 
pointing in different directions, and this causes conflict in the process of decision-making when 
data interpretation is attempted. The majority of WOE frameworks for the analysis of the results 
of in silico models are qualitative and do not satisfy the growing need of objectivity and 
transparency that are essential for regulatory purposes. Most often, the prediction results of 
(Q)SAR or read-across models lack the reasoning part, by which the assessor can interpret and 
clarify the objectivity of the hazard predictions for a chemical under investigation. The 
structure-based models such as the two models introduced in the first part of the present 
document, are adequate means to resolve the shortcomings of the in silico models with no 
interpretation for their estimations. These structure-based models are also useful for the analysis 
of the similar compounds to address the structural similarities and dissimilarities and the 
presence or absence of the known SAs in individual chemical during the process of comparison 
and inference. ToxDelta as a new read-across tool is developed for the comparison between the 
target and the source chemicals, and to analyse the different fragments and their role in 
amplifying or reducing the toxicity. 
In addition, we discussed how to deal with different and sometimes conflicting data obtained 
from various in silico models ((Q)SAR and read-across) in qualitative WOE terms based on 
identification of SAs in a read-across approach to facilitate structured and transparent 
development of answers to scientific questions. The results of different (Q)SAR models are 
explored together with the analysis of the similarities and differences of the similar compounds 
in read-across terms. The study of the structural similarities and dissimilarities between the 
target and the source compound helps the expert to validate or revoke the assumption that the 
properties of the similar compounds can be assigned to the target compound. To show the utility 
of the use of multiple tools ((Q)SAR, ToxRead and ToxDelta) within an integrated WOE 
prospective to obtain a toxicity conclusion, the application of the framework is illustrated using 
two drugs as case studies: Valproic acid and Diclofenac. 
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2.1 Part 1 – Carcinogenicity Models 
The identification of the SAs is a compelling factor in understanding mechanisms, and assessing 
the hazard risk of chemicals. The already known lists of carcinogenicity SAs, including 
genotoxic and nongenotoxic moieties can still be refined and enhanced by further studies on 
carcinogenic substances.  
Within the ANTARES project (LIFE08 ENV/IT/000435), a carcinogenicity data set is 
developed for testing the performance of seven software packages. This dataset comprises 1543 
chemicals together with their carcinogenicity values apparently of good quality. The 
carcinogenicity properties of the chemicals are related to rat toxicity (presence of carcinogenic 
effects in male or female rats). This dataset is a combination of the CAESAR data set and “FDA 
2009 SAR Carcinogenicity - SAR Structures” database. The CAESAR data set encloses 805 
chemicals taken from DSSTox Public Database Network 
(http://www.epa.gov/ncct/dsstox/sdf_cpdbas.html) which was developed from the Lois Gold’s 
CPDB. All the chemicals have been cleaned and cross checked in this data set. ID number, 
chemical name, CASRN, experimental carcinogenic potency (TD50) values for rat and 
corresponding binary carcinogenicity classes are supplied for each chemical in this data set. In 
addition, 739 compounds not present in the CAESAR dataset were taken from the “FDA 2009 
SAR Carcinogenicity - SAR Structures” database using the Leadscope software 
(http://www.leadscope.com/). A categorical label for carcinogenicity was already provided in 
the original database. A compound was labeled as carcinogenic if a positive outcome was 
detected in male or female rats. 
The ANTARES rodent carcinogenicity data set is a promising source for developing models for 
classification of carcinogenic potency. Accurate preprocessing of data and selection of data with 
rats carcinogenicity provide consistent data suitable for QSAR modeling with carcinogenic 
response closer to human. Additionally, a wide diversity of molecular structures, thus a diverse 
number of chemical classes and biological mechanisms improves the carcinogenicity prediction 
ability of QSAR models.  
Taking advantage of SARpy 88, as a statistical fragment extraction tool -without any a priori 
information- on a large data set of chemicals, is a promising strategy to inspect carcinogenicity 
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potential SAs. The SAs extracted by SARpy are subsequently revised and checked by human 
expert and a list of more significant SAs has been created out of the initial rulesets. The first 
carcinogenicity model is the collection of these SAs. 
The second model is based on a combination of the ISSCAN database 109 and the 
Carcinogenicity Genotoxicity eXperience (CGX) database created by Kirkland et al. 108. 
The ISSCAN database contains information on chemical compounds tested with the long-term 
carcinogenicity bioassay on rodents (rat, mouse). For the chemicals in the ISSCAN database 
this information is provided: carcinogenic potency in rat and mouse, mutagenicity in Salmonella 
typhimurium (Ames test), carcinogenicity results in the four experimental groups most 
commonly used for the cancer bioassay, carcinogenicity results from the NTP experimentation 
(when available), overall carcinogenicity, and the source of carcinogenicity data. 
Kirkland et al. 108 used a battery of three commonly used in vitro genotoxicity tests—Ames + 
mouse lymphoma assay + in vitro micronucleus or chromosomal aberrations test— to classify 
rodent carcinogens and non-carcinogens, inside a large database of over 700 chemicals 
compiled from the CPDB, NTP, IARC and other publications. A WOE approach has been 
applied to integrate the results obtained for these chemicals from the literature. 940 chemicals 
present in the Kirkland et al.’s dataset were merged to the ISSCAN data set. The duplicates and 
the conflicting values have been eliminated. The resulting dataset is conventionally named 
ISSCAN-CGX data set which contains 986 chemicals together with their carcinogenicity calls. 
The ISSCAN-CGX data set contains human-based assessment data on carcinogenicity. The 
second carcinogenicity model is developed by extracting the active SAs from the ISSCAN-
CGX data set by means of SARpy.  
The advantage of developing QSAR models using such large datasets is that changes in “calls” 
for a small number of chemicals containing a potential SA will not significantly influence the 
overall findings. In addition, there is more chance to extract the potential carcinogenicity 
fragments from a data base which contains chemicals with more functional groups. A model 
that considers more molecular functional groups has a wider applicability domain. All the 
extracted rules or SAs are examined by an expert and their significance in carcinogenicity is 
verified based on his expertise. 
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It is to be noted that rodents are considered more sensitive than humans to carcinogen 
chemicals. The ANTARES model being developed on pure rodent data is supposed to be more 
conservative rather than the ISSCAN-CGX model which is developed using integrated data 
obtained from more carcinogenicity assays in a WOE approach by human expert. 
The aim of the first part of my study was expanding and upgrading the knowledge on the SAs 
by the help of artificial intelligence and data mining approaches. The new carcinogenicity 
models have been implemented in the VEGA platform with notable prediction results. In both 
rule sets some new SA have been identified.  
2.2 Part 2 – ToxDelta 
The read-across approach is based on the similarity property principle. The similarity property 
principle states that structurally similar molecules are more likely to have resembling properties. 
Contrarily, studies show that structural similarity does not always imply similarity in activity 110 
nor in descriptors 111. Minor modifications can make active molecules to lose their activities 
completely. Structurally similar compounds can have very different properties. We 
contemplated the effects that the dissimilarities may trigger on the properties of the structurally 
similar compounds. To this end, we developed a new read-across tool, ToxDelta, to accomplish 
the effects of the dissimilarities in a read-across approach. This new tool is considered as a 
complementary tool to be implemented in the ToxRead software.  
ToxRead, is a new read-across tool developed by our group. ToxRead is an ad hoc visualization 
and data search method which use similarity measures and SA search to organize in a chart a 
picture of all the relevant information. ToxRead, with its original representation of the read-
across results makes it easy for the user to move in different directions of toxicity or nontoxicity 
properties of the target and source molecules which share the same SAs. ToxRead does not 
provide exclusively toxic SAs, it extracts and depicts also the nontoxic SAs present in the target 
molecule. ToxRead is currently applied to mutagenicity and bioconcentration. 
At the present moment, the ToxDelta tool is a stand-alone software for the read-across 
mutagenicity assessment. ToxDelta focuses on the dissimilar substructures between two similar 
molecules, and analyses whether these dissimilarities reduce or amplify the toxicity in the target 
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chemical compound. The MCS between two structurally similar molecules has been already 
analysed by ToxRead, and all the possible SAs present in the sharing structure has been already 
examined. As a further assessment, ToxDelta takes a closer look at these fragments and exploits 
the role of these differences in the hazard risk of the chemicals. The characteristics of the 
extracted molecular fragments is assisted in an a priori list of mutagenicity SAs. 
2.3 Part 3 – Metal Oxide NMs Genotoxicity Model 
NMs are utilised in many fields of industry, medicine and military applications. The NMs’ 
potential hazardous effects can cause a wide range of damage to human health and environment. 
While the acute toxicity of NMs has been addressed in many studies, genetic toxicity, in 
particular genotoxicity of the NMs still needs to be explored by more scientific works.  
In order to examine the toxic effect of a single NM, given the diversity within each group of 
NM a large number of property combination need to be considered (different shapes, size, 
crystallography, etc.). The risk assessment in a case-by-case manner makes the task challenging. 
In addition, increasing the number of in vivo tests is opposing to the Russel and Burch’s 3R 
principle to replace, reduce and refine animal testing of the EU Directive 2010/63/EU. The 
REACH regulation promote exploiting all existing data and focusing on new approaches e.g. 
non-testing methods and data integration using WOE strategies as effective tools to achieve this 
goal. 
In this study, we assessed the genotoxicity properties of sixteen metal oxide NPs in a WOE 
approach using the results obtained by in vitro Comet assays. Different peer review studies from 
1994 to 2014 about genotoxicity of metal oxide NMs using in vitro Comet assay have been 
collected. The reliability and the relevance of these scientific articles have been assessed taking 
advantage of the WOE technique. The overall assessment of a series of queries for this 
assessment led us to assign a genotoxic property to each of the metal oxide NM under study as a 
conclusion. In addition to the preparation of a list of metal oxide NMs with their genotoxic 
overall effect, we decided to study the relationships between quantum-chemical / physico-
chemical descriptors of these NMs and the overall assessment of their genotoxicity effects. We 
quantum-chemically calculated a series of quantum-mechanical descriptors for the set of metal 
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oxide NMs in our dataset and then opted for an understandable classification method, 
considering the binary classification nature of the endpoint. In order to exploit any significance 
relationship between the quantum-chemical descriptors and genotoxicity of the prepared dataset, 
a tree decision model is applied to the dataset. Three descriptors have been identified as the 
most relating variables to genotoxicity property in our classification model: heat of formation, 
molecular weight and area of the oxide cluster based on conductor like screening model. 
Although the number of samples in our dataset, from a modelling prospective is small, the 
simplicity and the interpretability of the developed model are the positive aspects of the new 
model.  
This part of the thesis provides a relatively comprehensive review upon WOE as inferred from 
the present large data and potentiality of metal oxide NMs chemical descriptors for assessment 
of DNA damage. It can be used as an informative platform in genotoxicity studies of metal 
oxide NMs. Such a combined approach can assist in providing useful insight about parameters 
that affect genotoxicity and thus provide guidance for the selection and/or design of safe NMs. 
In addition the identified quantum-mechanical descriptors in the classification model can be 
useful to prioritise the study of the NMs, which may lead to high risk for human health, 
especially in regulatory purposes.  
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CHAPTER 3 
3. Materials and Methods 
3.1 Part 1 – Carcinogenicity Models 
3.1.1 Carcinogenesis Data Sources 
3.1.1.1 ANTARES Carcinogenicity Dataset: Rat Carcinogenesis Learning Set 
The first carcinogenicity model is developed on the basis of carcinogenicity database of EU-
funded project ANTARES 107. This data base contains rat carcinogenesis data (presence of 
carcinogenic effects in male or female rats). The ANTARES carcinogenesis data base is a 
collection of the EU-funded project CAESAR data set and the “FDA 2009 SAR 
Carcinogenicity—SAR Structures” data base. The 
CAESAR toxicity values were originated from the Distributed Structure-Searchable 
Toxicity DSSTox database, which was built from the Lois Gold’s Carcinogenic Potency 
Database 112. The compounds with a definite TD50 (which is the dose that produces an 
incidence of 50% of the tumors in animals) value for rat in this dataset were labeled as 
carcinogenic, while the remaining were labeled as noncarcinogenic. 805 chemicals with 
carcinogenicity data were obtained from the CAESAR data set and 738 compounds are added 
from the “FDA 2009 SAR Carcinogenicity—SAR Structures” database using the Leadscope 
database 87. A total number of 1543 compounds constituted the ANTARES dataset. 
3.1.1.2 ISS Carcinogenicity Database and Carcinogenicity Genotoxicity Experience Dataset: 
Different Species Carcinogenesis Learning Set 
For the learning set of the second prediction model we combined two carcinogenesis data sets. 
The ISS Carcinogenicity (ISSCAN) 109 database provided by the Istituto Superiore di Sanità is 
designed for the carcinogenicity predictive models. Most of the chemicals in the ISSCAN 
database are labelled as carcinogens by various regulatory agencies and scientific bodies. The 
database has been specifically designed as an expert decision support tool and contains 
information on chemicals tested with the long-term carcinogenicity bioassay on rodents 
(presence of carcinogenic effects in male or female rats and mice). 
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This carcinogenicity dataset contains 622 carcinogens, 210 noncarcinogens and 58 equivocals. 
We eliminated the chemicals with equivocal data, as we needed a definite carcinogenic effect 
for each data point. We merged the positive and the negative compounds with the ISSCAN 
database and the Carcinogenicity Genotoxicity eXperience (CGX) database. The CGX database 
was created by Kirkland et al. 108 and did not contain any equivocal result. 
All compounds in the combined dataset have been checked for their consistency between the 
two sources. We found 651 compounds in common, 15 of them with inconsistent 
carcinogenicity values. These compounds have been removed from the combined dataset. In the 
present study, this combined dataset is conventionally called ISSCAN-CGX. 
3.1.2 Comparison between the ANTARES Dataset and the ISSCAN/CGX Dataset 
We compared the ISSCAN-CGX dataset with the ANTARES carcinogenicity dataset prepared 
for the development of the first model. The result of the check was 105 compounds with 
conflicting values. In order to develop a more conservative model, we decided to remove only 
15 compounds with positive result in the ANTARES dataset and negative results in the second 
dataset, and left as carcinogenic those that had carcinogenicity result the opposite way. 
Consequently, there are 90 positive compounds in the ISSCAN-CGX database which are 
negative in the ANTARES dataset. Afterward, we checked and cleaned the structures manually, 
and by the help of the istMolBase 113 and InstantJChem 114 software formed the final dataset. In 
addition, we kept only the compounds with connected molecular structure; those which had 
unconnected structures have been removed from the dataset. The final dataset contained 986 
compounds with 734 carcinogens and 252 noncarcinogens. For compound in the list these 
information are available: a chemical name, a CAS number, a SMILES 115, and its categorical 
designation (i.e., carcinogen or noncarcinogen).  
3.1.3 Data for Model Validation 
3.1.3.1 ECHA Database 
In order to evaluate the two new carcinogenicity models developed, we prepared an external test 
set from carcinogenicity data in the eChemPortal inventory 116.  
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The constraints of the first query were: Study result type: experimental result; Reliability: 1 and 
2 (1 = reliable without restrictions. 2 = reliable with restriction); Species: mouse and rat; 
Maximum number of studies: 4.  
The second query consisted of: Study result type: experimental result; Reliability: 1 and 2; 
Species: mouse and rat; Sources: any guideline and exposure route. 
The result of the first query was 308 compounds, whereas the second query returned 166 
compounds, which were mostly in common with the chemical compounds of the first query. We 
manually examined the studies conducted for the first list of compounds, then we looked into 
the CLP inventory 117 for the positive chemicals collected by the previous queries. Inside the 
CLP inventory we found 68 compounds, which were already present in our data collection. This 
search confirmed the carcinogenic property of these compounds. The dataset consisted of 64 
positive compounds, 169 negative compounds, and 90 equivocal compounds. The equivocal 
results are due to the presence of conflicting information in different sources or different studies 
in the same source. It should be noticed that for already classified compounds (no conflicting 
information), the level of uncertainty in the assignment is not homogeneous, because some of 
the compounds were classified on the basis of a single study (i.e., data present in one single 
source). 
From the reliability point of view, in the data collected in our dataset, 49 positive compounds 
have positive carcinogenic effect in at least two sources. Fifty-seven negative compounds are 
noncarcinogenic in both lists, and they are not present in the list of compounds retrieved from 
the CLP inventory. Sixty four compounds are considered as noncarcinogens because of the 
presence of only one single study in the two lists. 
3.1.4 Active Molecular Fragments Identification by SARpy 
The SAR in Python (SARpy) program is a Python script based on the OpenBabel chemical 
library. SARpy creates classification models by identifying active and inactive molecular 
fragments by mining the chemical structures in a learning set. These extracted molecular 
substructures in the form of SMARTS 118 may be exactly similar to the already known SAs or 
newly developed SMARTS that are associated with a particular biological, pharmaceutical, or 
toxicological activity. 
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The generated molecular fragments are of arbitrary complexity, and the fragments candidate to 
become SAs are automatically selected on the basis of their prediction performance in a learning 
set. 
SARpy takes a learning set of chemicals, where the molecule structures are represented as 
SMILES 115 notations, along with their experimental activity binary labels (e.g. toxic/nontoxic, 
mutagenic/nonmutagenic). This data mining tool generates every possible substructure in the set 
and finds correlations between a particular molecular substructure and the activity of the 
molecules that contain it. This is achieved in three phases:  
(1) Fragmentation: this novel, recursive algorithm considers every combination of bond 
breakages working directly on the SMILES string. During this procedure the rings are not 
fragmented, they remain entire. 
(2) Evaluation: the predictive ability of each extracted potential SA is examined on the training 
set.  
(3) Rule set extraction: a reduced set of rules is extracted in the form:  
‘IF contains <SA> THEN <apply activity label>’; 
Where the SA is expressed as a SMARTS string, for use by human experts or chemical 
software. SMARTS notations are text representations of substructures that allow specification of 
wild card atoms and bonds, which can be identified to formulate substructure queries for a 
chemical database. Those rules can be used as a predictive model simply by calling a SMARTS 
matching program. For the matching phase, 
SMILES and the SMARTS strings are translated into graphs and the two graphs are compared 
to each other 119.  
This approach has been tested on the mutagenicity endpoint, showing marked prediction skills 
and, more interestingly, bringing to the surface much of the knowledge already collected in the 
literature as well as new evidence.  
To each SA extracted from the learning set a statistical value is associated: training likelihood 
ratio. The molecular fragments identified by SARpy as active or inactive rules are compared to 
the molecules in the training set. Considering the experimental label of each molecule, there are 
two possibilities for each SA: i) the active SA is found in a positive compound, called “true 
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positive”, or in the case of inactive SA, it is found in a negative compound, called “true 
negative”, ii) the active SA is found in a negative compound, it is called “false positive”, or the 
inactive SA is found in a positive compound, called “false negative”. These indicators are used 
to calculate the accuracy of each SA in predicting the target activity label. In the case of active 
SAs, the likelihood ratio, which is a measure of precision intrinsic to the test (not depending on 
the prevalence of activity labels in the training set), is used as in the Formula 1:  
𝐿𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑟𝑎𝑡𝑖𝑜 = (
𝑇𝑃
𝐹𝑃
) ∗ (
𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠
𝑝𝑜𝑠𝑡𝑖𝑣𝑒𝑠
)    (Formula 1) 
 
The training LR as a statistical measurement helps the user to evaluate the relevance of each SA 
in the training set used for building the model. 
SARpy can be also used as a prediction tool for structure-based classification models. A list of 
SAs presented as SMARTS can be loaded into SARpy and a list of molecules SMILES strings 
can be inserted as test set. SARpy calculates the confusion matrix on the basis of the prediction 
results and provides accuracy, sensitivity and specificity of the classification model as output of 
the model evaluation.  
3.1.5 Extracting Active Fragments 
3.1.5.1 R (Rat) Model 
To obtain a more comprehensive collection of potential carcinogenic fragments, five learning 
sets were randomly created from the ANTARES carcinogenicity dataset with 1543 compounds, 
preserving 80% for the learning set and 20% for the evaluation set. In other words, for each 
model a random set of 20% of chemicals in the learning set was removed, with the remaining 
80% of the compounds a model was developed and the activity of the compounds left out was 
predicted with the same model. We combined the five models and put together the lists of the 
potential active fragments, removed the duplicates and eliminated the SAs with likelihood ratio 
lower than two. We opted for the likelihood ratio threshold of two in order to retain the SAs that 
are statistically more significant. A measure of each fragment’s association with biological 
activity is determined by SARpy as “training likelihood ratio,” and it is given along with the list 
of the potential fragments or the rule set in the output. The likelihood ratio can be taken into 
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account to determine the goodness of a SA identified by SARpy. Even if a SA that is associated 
with activity (i.e., carcinogenicity) is present in a molecular structure, the molecule may contain 
other fragments that make it inactive (i.e., noncarcinogen), thus the specific SA might not be 
expected to be found only in active compounds. This evidence is the basis of the determination 
of the likelihood ratio. 
Using the SARpy software, each chemical in the learning set was fragmented in silico into all 
possible fragments meeting user-specified criteria. For this study we extracted only the 
“ACTIVE” fragments (or SAs) and the default values for the minimum and maximum number 
of atoms in a fragment were set for the fragment extractions of each model (minimum = 2; 
maximum = 18). Another configuration to establish by the user is the minimum number of 
compounds in the learning set in which an active (or inactive) fragment is found. In our 
analysis, the minimum number of compounds that contain a potential active fragment was set to 
three. 
Conventionally, in this study we call this model R. 
3.1.5.2 E (Expert) Model 
SARpy was used for model development and statistical analysis using the ISSCAN-CGX 
dataset. 
The extraction settings are as follows: the minimum number of atoms in a fragment is equal to 
four, whereas the maximum number of atoms is equal to 10, and the minimum number of 
compounds containing the active fragment is six. These configurations have been set in favor of 
a model with a more balanced sensitivity and specificity values. In order to assess the 
predicitivity of the model, statistical analysis have been conducted in terms of accuracy, 
sensitivity, and specificity using cross-validation routine as an internal evaluation, in addition to 
an external evaluation using an external test set. In this article, we name this model E. 
3.1.6 Internal Evaluation of the Models 
Accuracy, sensitivity, and specificity have been determined for the internal evaluation of each 
model using the SARpy program. For the internal validation, five-fold cross-validation routine 
was conducted for each model. In the five-fold cross-validation the learning set is randomly 
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partitioned into five equal sized subsets. For each iteration, a single subset of chemicals was 
retained as the validation data for testing the model, and the remaining subsets were used as 
training data. The cross-validation process was repeated five times (the folds). The evaluation 
results of five iterations were then averaged to produce a single estimation. Accuracy, 
sensitivity, and specificity of the internal evaluation are assessed in addition to the MCC. 
3.1.7 External Evaluation of the Models 
The predictability of the models has been evaluated on two external test sets: the first external 
set is the dataset used as the learning set of the opposite model (e.g., for the R model we used 
ISSCAN-CGX dataset and vice versa), and the second dataset is a collection of 258 compounds 
collected from the eChemPortal inventory. Accuracy, sensitivity, specificity, and the MCC for 
the external evaluation are determined using SARpy. Although the external evaluation is 
considered the best mean for the assessment of the predictive ability of a (Q)SAR model 120,121, 
the results of the external evaluation of any model are highly related to the relative similarity of 
the external evaluation set in relation to the learning set. 
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3.2 Part 2 – ToxDelta 
3.2.1 Database of Active and Inactive Structural Alerts 
Benfenati et al. 122 in a previous study have collected an expanded list of mutagenicity SA. This 
rule set is implemented in the ToxRead 123 software for the mutagenicity assessment within a 
read-across approach. The rules identified and collected in this collection are associated with 
Ames test bacterial mutagenicity and are based on more than 6000 chemicals from different 
chemical classes. These rules belong to both categories mutagenic and nonmutagenic and are 
sorted in a hierarchical way. ToxRead utilizes these rules in order to identify the active or 
inactive mutagenic substructures present in the target compounds. The hierarchical 
characteristic of the SAs in the list makes the process of rule search and identification more 
systematic. In other words, the exact SAs that match the target molecules are identifies and then 
more generic ones, which may match with the target molecule. In addition to the mutagenic 
active and inactive SAs, the rules present in this data set are accompanied with the exceptions 
and modulators of activity. From a toxicity prediction point of view, the identification of these 
SA in the compounds under assessment helps the expert to address the toxicity or nontoxicity of 
a molecule concerning the influence of each SA found in the molecular structure. Each SA is 
associated with its accuracy and p-value as statistical characterizations. The accuracy value 
indicates the precision of the SA as a potential agent in causing mutagenicity or decreasing the 
risk, considering the number of the molecules including this SA in the original training set. This 
set of SAs are implemented in the ToxRead program. There are more than 800 SAs present in 
this dataset with a high level of details such as accuracy and statistical significance.  
3.2.2 The MCS Algorithm 
While ToxRead analyses the similarities between a target molecule and the source molecules 
which are structurally similar, ToxDelta identifies the dissimilarities between these molecules. 
The identification of the dissimilar fragments is achievable after extraction of the MCS between 
two molecular structures. In our study, the degree of similarity between pairs of molecules is 
based on their molecular structure. Molecular structures can be encoded in several computer 
formats with topological information about the atoms and bonds of a molecule, as well as other 
56 
 
chemical information such as charges, aromaticity, etc. We opted for SMILES strings 115 as 
presentation of the input molecule in our program. The algorithm proposed by the fmcs_R 
package 124 extracts the MCS part between two molecule graphs using a novel backtracking 
algorithm by constructing a search tree of correspondences between nodes of the two graphs 
representing the two molecules. Each node in the tree presents a set of atoms correspondences 
of the respective molecule and the connected sub-graph we are looking for are in fact leaves, 
and the deepest leaves in the tree are the MCSs found. 
An important issue to be noticed about the algorithm of the fmcs_R package is that it consists of 
a further characteristic, with respect to the other MCS extraction algorithms, and that is its 
“flexibility”. In fact, this algorithm gives the possibility to the user to search not only all the 
exact MCSs, but also the flexible ones, in which the type of a limited number of atoms and 
bonds can be different in the two MCS extracted from two similar molecules. The result of 
searching a flexible MCS, probably, are pairs of different MCS, each belonging to one of the 
molecules under investigation. This option although makes the process of similarity finding 
more flexible and the number of the results is more elevated than the exact MCSs between two 
compounds, it is not in line with our objectives. Since our purpose of the MCS extraction is 
identifying the dissimilar fragments, for being more precise, we need to stay on the idea of the 
“exact” MCS extraction.  
From a toxicity point of view, it is important to pay attention to the aromatic and aliphatic rings 
of the compounds.  
The role of the aromatic and non-aromatic rings as structural properties of molecules have been 
highlighted in peer review resources. Among the important lists of mutagenic and carcinogenic 
SAs, aromatic and aliphatic rings play an important role. Different forms of rings are present in 
the mutagenicity and carcinogenicity rules 43. The fmcs_R package breaks the rings whenever it 
is necessary in order to find the greatest part in common between two graphs. This leads to a 
significant loss of structural information and consequently the implication of the extracted MCS 
which is meant to be equal for both molecules may differ for each compound. Considering this 
important issue, we decided to add a new restriction to the fmcs_R algorithm. This restriction is 
to keep all the rings present in the target and the source molecule entire and do not partially 
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select a number of atoms of a ring. The algorithm selects the whole ring and add it to the MCS 
whenever this is possible, otherwise it does not take the ring into consideration for the MCS.  
The restriction of not breaking the rings in the process of MCS findings is added during the 
process of atom selection in the algorithm. Before adding any atom to the string of the MCS the 
algorithm checks if the atom belongs to a ring in both molecules and gathers all the information 
about the corresponding ring in the target and the source molecule. Only if the rings in both 
molecules have the same properties, (e.g. the number of atoms, the type of atoms, the type of 
bonds), the whole ring is added to the MCS. At this point we can extract the structural 
differences between the two compounds under investigation: we overlap each graph with the 
MCS and highlight all the sub-branches not in the MCS (Figure 6-page 59). 
3.2.3 ToxDelta Implementation 
ToxDelta is implemented as a complementary section to the ToxRead program. ToxRead 
associates the most similar molecules present in its data base with the target molecule, pointing 
out the mutagenic (or nonmutagenic) fragment(s) as toxicity rules present in both the target and 
the similar chemical compounds. ToxRead is a read-across tool based on similarity and 
identifies the mutagenic or nonmutagenic SAs in common between the target and the source 
chemicals. These SAs belong by definition to the MCS of the pair of compounds under 
investigation. Both tools operate by taking advantage of the list of identified mutagenic and 
nonmutagenic potential SAs. The user who wants to assess the mutagenicity effect of a 
molecule can evaluate the results obtained from ToxRead and the evidences gained from 
ToxDelta and make a decision regarding the mutagenicity of the target molecule, in a WOE 
approach. Figure 7 (page 60) shows the two phases of implementation of ToxDelta: i) the SA 
list creation and improvement, and ii) the evaluation of the mutagenicity of the target molecule 
considering its similarities and dissimilarities comparing to other known molecules with a high 
structural similarity. The evaluation of the degree of similarity in ToxDelta relies on the 
ToxRead program, which uses an ad hoc similarity algorithm described elsewhere 125. A stand-
alone version of ToxDelta is accessible on the VEGA home page (https://www.vegahub.eu/).  
Examining the results of ToxRead and ToxDelta will allow a thorough investigation of a 
compound with unknown mutagenicity property. As a first step, ToxRead investigates all the 
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SAs present in the target molecule and represents the most similar molecules to the target 
molecule which share the same SA with the target molecule. After this assessment, in order to 
have a further look, the user can select each of the source molecules and check the 
dissimilarities of the target and the source compounds. These tools help the researchers to 
identify the similar and dissimilar moieties. ToxDelta provides the most similar SAs for each of 
them in the collection of the known SAs for each moiety found. To obtain a conceivable result, 
the structure of the target and the source molecules in the comparison need to be sufficiently 
similar. If the structures of the molecules compared by ToxDelta do not share a significant 
MCS, the dissimilarities may not be interpretable to an acceptable level. In other words, 
whenever the structures of two molecules are strongly dissimilar, the user may not expect a 
significant MCS. In this regard the VEGA chemical similarity index 125 is used as a screening 
before applying the MCS approach. 
In case the identified dissimilar fragment in the target of the source molecule is a SA, and it 
belongs to the list of SAs with an assigned accuracy and p-value information, there are three 
possible scenarios that can be associated with the dissimilar fragment: 
1. The SA is an active substructure with strong potential to increase toxicity; 
2. The SA is an inactive fragment with strong potential to decrease toxicity,  
3. The SA has no relevant impact on the effect. 
In case 1 and 2 there is more probability that the dissimilar fragment affect the whole molecule, 
while in case 3 the dissimilar substructure does not cause any toxicity or nontoxicity in the 
effect of the molecule. In all three cases the software will provide documentation about each SA 
found as a dissimilar fragment in the target molecule. From regulatory point of view, 
documentation is an important factor in toxicity assessment of the compounds and the 
acceptance of the read-across results. ToxDelta makes a thorough search in the list of identified 
SAs and provides not only the exact SA found as dissimilar fragment in the molecules but also 
the SAs which are so similar to the identified SA, in order to give more information to the 
expert for the assessment of the new molecule. This whole list of SAs is used by ToxDelta to 
assess whether the fragments resulting from the subtraction of the MCS from the molecule are 
associated with an increased or decreased or neutral effect. 
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The output of ToxDelta consists of all the possible MCSs extracted from two molecules of 
interest. The user can select one of these MCSs and evaluate the dissimilarities calculated based 
on the selected MCS. The different fragments present in both molecules, are the result of the 
subtraction of the MCS and the target or source molecules. 
 
 
Figure 6. The MCS between two molecules is shown with bold lines, and the other branches are 
the differences 
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Figure 7. The flow chart of ToxDelta: the molecular similarity/dissimilarity structure analysis 
software for the mutagenicity endpoint  
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3.3 Part 3 – Metal Oxide NMs Genotoxicity Model 
3.3.1 Data Collection and Assessment 
Metal Oxide Nanomaterials and Genotoxicity Data 
The list of metal oxide NMs considered in this study consists of: Al2O3, NiO, Co3O4, CuO, 
Fe2O3, Fe3O4, TiO2, ZnO, SnO2, V2O3, V2O5, MgO, ZrO2, CeO2, and Bi2O3. These metal 
oxide NMs with different chemical core compositions have been selected to study their 
genotoxicity effect towards humans. Although SiO2 is technically a metalloid 126 it is 
considered a metal oxide NM in different nanotoxicity peer review documents 127. Considering 
the similarities between silicon oxide and other metal oxides, we also considered SiO2 as a 
metal oxide. Previously, our group conducted a study in which a collection of metal oxides with 
their Comet assay results were published 128. These results are reported in the Appendices 
section. (Table S1.A and Table S1.B, Appendices) 
3.3.1.1 Assessment of the Experimental Protocol  
The different protocols and standards of the laboratories, result in heterogeneous results. 
Consistency and integrity are two challenging issues in this field. Consequently, the raw 
collected data is not suitable for building (Q)SAR models, since the data lines are now 
comparable 129. Therefore, the experimental collected data were evaluated in order to put 
together data from different laboratories with the compatible protocols. We assessed 103 studies 
obtained from 75 publications for the assessment of metal oxide NMs in the in vitro Comet 
assay. 
3.3.1.2 Prior Chemical Characterization 
The assessment of the peer review documentation has been done on the basis of the criteria 
stabilized within the NanoPUZZLES project 130.  
The same criteria in the NanoPUZZLES project has been applied to our data, and additional 
assessment criteria to NanoPUZZLES analysis were introduced in the current work.  
The physico-chemical characterization of the NMs is reported in Table 4 (page 68) and should 
meet at least points 1, 2 and 3 of the following list:  
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1. Chemical composition and purity 
2. Surface area 
3. Particle size/size distribution 
4. Crystal structure 
5. Surface charge/zeta potential 
6. Aggregation/Agglomeration status in the relevant medium. In principle, these are 
different phenomena (strong/weak binding between NMs), but are not always 
differentiated 131. 
3.3.1.3 Minimum Criteria for the In vitro Comet Assay  
We considered only the studies of the Comet assay or its variations as described by Singh et al. 
132. To each data point of 103 case study a list of queries have been applied. This list is reported 
below.  
1. Whether the Comet assay was performed according to the guidelines presented by 
Singh et al. 132 with or without minor modifications. 
2. Whether any of the following variations of the Comet assay were performed: with 
addition of 8-oxodguanine (8oxodG), formamidopyrimidine DNA glycosylase (FPG) 
and endonuclease III (endoIII). (It is to be noted that Comet assay can be performed by 
adding lesion specific bacterial glycosylase/endonuclease enzymes after analysis. These 
tests will detect a broader class of oxidative DNA damage bases. Whether the assays 
mentioned above were performed or not was verified).  
3. Whether the pH of the electrophoresis was alkaline 
4. Whether the concentrations of the tested NM were expressed in one of the three 
modalities as indicated in Table 4 (page 68). 
5. Whether a cytotoxicity test was performed 
6. Whether uptake into the cells was evaluated 
7. Whether a dose - response analysis was performed 
8. Whether positive and negative controls were used 
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9. Whether the Olive tail percentage was measured by analysis of at least two replicates of 
50 cells 
10. Whether there was an exposure of at least 3h 
3.3.1.4 Classification of the Data Based on the Assessed Quality 
We examined the experimental protocols of the Comet assays according to the questions listed 
in the “Minimum criteria for the in vitro Comet assay” section. The answers to these queries 
were “yes” or “no”. The results of this assessment is classification of the data into three classes 
of reliability: 
1st class data (high reliability): if at least questions 3 to 7 were answered “yes”, the data line 
in classified into this class. 
2nd class data (moderate reliability): Whenever cytotoxicity was not assessed (question 5), 
the corresponding meta data were classified into class 2 and less reliability value is assigned to 
the data of the second class in the final overall assessment of the genotoxicity of a specific metal 
oxide with the same core composition. 
3rd class data (low reliability): data without any dose-response studies performed (NMs of 
only two different concentrations were tested) or DNA unwinding performed in non-alkaline pH 
(question 7 and 3). 
3.3.2 Weight of Evidence Approach in the Evaluation of the Data Set  
To conclude and overall genotoxicity property for each metal oxide NM under investigation we 
employed a quantitative WOE approach. It is demonstrated that the quantitative WOE approach 
is the best strategy where individual lines of evidence are integrated by an authoritative expert 
to form a conclusion 133.  
3.3.2.1 Assessing Data for the Same Core Composition but Different Size Range or 
Crystallography Reported in One Single Publication 
In our study, we assigned an overall positive sign to a NM with the same core composition and 
size, were at least one positive result in a study was reported for the concerned metal oxide NM. 
Whereas, a negative sign was assigned to a NM, whenever all the studies reported a negative 
outcome for that specific metal oxide NM. 
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3.3.2.2 Assessing Data Derived from Different Publications for the nanomaterials of the Same 
Core Composition 
The data points with “highly reliable” property had more priority in the assessment of the data 
gathered from the publications for the NMs. Whenever the results were conflicting the 
judgement was added to by second and third class data. In addition, where the characterization 
and the reliability class of the Comet assay were equal, we considered the results of the majority 
of the data lines. We eliminated one of the data points from the final overall dataset, as 
minimum criteria for the assay performed could not be assigned to any of the classes of 
reliability (extracted from Sekar et al.134). The numbers of genotoxic and nongenotoxic results 
for each metal oxide of the same core composition are presented in Table 5 (page 69). Each 
single datum point reported here is considered as one genotoxic or nongenotoxic call. 
3.3.3 Case Studies for Illustrating the Weight of Evidence Evaluation 
We selected three case studies in order to illustrate the WOE approach applied in the present 
study. The final judgement for each metal oxide NMs, of the same core composition, is reported 
as the “overall assessment” in Table 5 (page 69). 
Case study 1  
The TiO2 NPs have been tested in the Comet assay more often than other metal oxides (37 
reports among which 31 reports were genotoxic and six were nongenotoxic). Hence, our overall 
assessment of the TiO2 NM, according to expert judgement, is that it is genotoxic. There were 
16 highly reliable data points according to the criteria defined in Section “Minimum criteria for 
the in vitro Comet assay”; genotoxicity was seen in 12 out of these 16 data points. 
Case study 2 
The Al2O3 NPs were designated as being genotoxic. However, there are two Comet assay 
studies with nongenotoxic results for aluminium oxide: Kim et al.135 and Demir et al.136. The 
extent of characterisation and minimum Comet protocol were not completely met by the study 
reported by Demir et al.136 (e.g. it lacked a dose-response relationship study); thus, greater 
reliance is placed on the highly reliable results presented by Kim et al.135. 
Case study 3 
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Overall six reports for Fe2O3 NMs were available. Among these publications the results 
published by Auffan et al.137 fulfilled all the criteria to be highly reliable data. This study was 
the only one to use the positive and negative controls as well as fulfilling the rest of the 
requirements as described in Section “Minimum criteria for the in vitro Comet assay”. Guichard 
et al.138 provided details of the assay performed that satisfy the criteria for highly reliable meta 
data and agree with the assessment of nongenotoxicity. Of all the six studies, only these two 
provided results of uptake studies. Furthermore, in support of our conclusion that Fe2O3 is 
nongenotoxic, the same result was found in most the reports of data with moderate reliability.  
The same reasoning approach was used for Fe3O4, ZnO, SiO2 (Table 5-page 69). Data for the 
Fe3O4 NPs were reported in eight studies. According to Table S1.A (Appendices), data 
extracted from Guichard et al.138 and Könczöl et al.139 were highly reliable. Nevertheless, the 
two studies reported contradictory results. Other five data points fired the NM to be genotoxic. 
These data points met all the criteria to be highly reliable except for uptake studies. Expert 
WOE results for Fe3O4 were genotoxic. For ZnO NPs highly reliable data points assigned 
genotoxic call 140.  
The same approach has been undertaken for the reports that included NiO, Co3O4, CuO, V2O3, 
V2O5, MgO, ZrO2, Bi2O3, and SnO2 as shown in Table S1.A (Appendices). If there were no 
highly reliable data points available, moderately reliable data were taken into consideration.  
3.3.4 Computational Analysis of nanomaterials Structure and Descriptor Generation: 
Quantum-chemical Descriptors 
The computational analysis of the structure of the metal oxides and the calculation of various 
molecular descriptors have been successfully conducted in the present study. A total of eleven 
descriptors were calculated by quantum chemical methods (quantum-chemical descriptors) for 
all the metal oxide NMs present in our data set. 
Quantum-mechanical calculations of metal oxide clusters were performed based on 
experimental crystal lattice parameters obtained from the Crystallographic Open Database 141. 
We adapted the method presented by Gajewicz et al.142. In order to have cubic clusters with an 
acceptable size that represent the molecular models of the NMs studied, the lattice parameters 
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were then increased in all three dimensions. We used GaussView for the generation of the 
molecular structures of all examined metal oxide clusters 143. 
The quantum-mechanical calculations of the descriptors has been performed on the clusters of 
metal oxides in two phases: i) optimization of the molecular geometry, and ii) calculation of 
quantum chemical descriptors based on the optimized geometry. 
It is important to notice that the generated clustered are too large for analysis by ab initio 
methods. For this reason, the semi-empirical level of theory has been employed, utilizing the 
efficient PM7 that has been re-parameterized for the elements considered in this investigation 
144. Additionally, the PM7 approach outcomes are more accurate compared to the DFT level, 
since it uses a novel parameterisation of the previously used PM3 Hamiltonian 145. The PM7 
method is implemented in the MOPAC2012 software package 144. 
The following molecular descriptors were calculated for each metal oxide NM: heat of 
formation (HF), dipole moment (), total energy (ET), electronic energy (EE), the total solvent 
accessible surface area of the cluster (SASA), energy of the highest occupied molecular orbital 
of the oxide cluster (EHOMO), energy of the lowest unoccupied molecular orbital of the oxide 
cluster (ELUMO), ∆H of cluster and molecular weight of metal oxide cluster (MW). The total 
solvent accessible surface area (SASA) of the cluster was calculated by COnductor-like 
Screening MOdel, implemented in MOPAC 2012. The definition of each descriptor and the 
results are reported respectively in Table 6 (page 70) and (Table S3, Appendices). 
3.3.5 Classification SAR Modelling Methods  
The limitation in the number of data samples is an unavoidable problem with the metal oxide 
NM databases. The restriction of size is a challenge in building a reliable model of genotoxicity 
with high prediction accuracy. Even if a high number of molecular descriptors is calculated for 
the small data set of NMs, still we deal with the issue of “under sampling induced collinearity”, 
which means a high degree of collinearity in descriptors 146,147. Collinearity will be present in 
the model as the number of samples is very small compared to the number of descriptors. 
Additionally, other problems such as over-fitting and noise in the data with negative effects on 
the model will arise. Considering the abovementioned complications, in order to find the most 
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appropriate model to fit the data, it is better to focus on a limited set of hypotheses. In other 
words, in case of small data, it is better to start from a small set of possible hypotheses, e.g. a set 
of decision trees with depth <= four. Thus, we opted for a simple tree classification analysis for 
(Q)SAR modelling of our data set, in particular, Recursive Partitioning and Regression Trees 
(rpart) model was used to classify the data set. 
3.3.5.1 Recursive Partitioning and Regression Trees  
The rpart programs build classification and regression models in two phases and the result is a 
binary tree. To build the tree classification model the first phase is identifying the variable 
which contributes the most to the splitting the data into two groups. After dividing the data into 
two groups, the algorithms continues the splitting separately for each group. The procedure 
continues recursively until each group contains a minimum number of samples or no more 
improvement can be achieved. During the second phase, a cross-validation evaluation is 
performed on the data to trim the full tree and make is simpler 148.  
Considering the small data set of metal oxide NMs with their associated set of their quantum-
mechanical descriptors and the classification endpoint we need to model, the factor of 
“randomness” is likely to play a role in the built model. To overcome this situation, we decided 
to develop a model to analyse the importance of each variable in relationship with the 
genotoxicity property of the NMs, rather than a model to estimate the genotoxicity of the metal 
oxide NPs. The (Q)SAR models in addition to their predictive ability, help us to identify the 
more effective physico-chemical attributes of a chemical related to toxicological and biological 
properties of the substances. In the present study, (Q)SAR models are employed to study the 
effect of each quantum-chemical descriptors in amplifying or reducing the genotoxicity of the 
NMs. Considering the limitations mentioned above, we decided to use all the data as training set 
and study the importance of each descriptor in amplifying the genotoxicity property of the metal 
oxide NPs. All the quantum-chemical descriptors have been standardized in the data set prior to 
the modelling process. All analyses were done in R version 3.2.3 (R Foundation for Statistical 
Computing, Vienna, Austria), using the ‘rpart’ library.  
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Table 4. Criteria for the usefulness and quality assessment of the data set for the (Q)SAR 
modelling: extent of Comet assay conditions checklist. General parameters have been used to 
assess each data point and the results are reported in Table S1.A (Appendices) where all questions 
are answered in a yes or no fashion. 
General parameters Further details to assess 
Comet protocol type: 
I) The pH of unwinding: alkaline, neutral, 
very alkaline. 
II) Incubation with the enzymes: FPG, 
8oxodG, Endo III. 
Concentrations expressed in at least one of the 
units: 
I) Mass per volume, per area, per cell 
(µg/ml, µg/cm2, µg/cell)  
II) Number of NMs per ml, per cm2, per 
cell (ENMs/ml or ENMs/cm2 or 
ENMs/cell) 
III) Surface area per ml, per cm2, per cell 
(cm2/ml or cm2/cm2 or cm2/cell) 
Cytotoxicity tests performed?  
Performed trend test for dose-response 
relationship? 
 
Microscopic analysis in the Comet assay:  
Analyzed at least 50 Comets per gel divided on 
two different slides (parallel gels per sample)? 
Comet count performed at least by one of the 
methods?): 
I) % DNA in the tail 
II) Tail length 
III) Tail moment 
IV) Tail intensity (classified as belonging to 
one of five classes depending on their tail 
intensity?) 
At least 3 hours for treatment time was 
respected? 
 
Performed comparison between treated samples 
and controls? 
 
 
 
I) Positive control  
II) Negative control 
III) Both negative and positive controls 
Information on uptake (demonstrated cellular 
uptake?) 
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Table 5. Comet assay experimental results for all selected metal oxide nanomaterials used for 
(Q)SAR modelling*.  
No Metal oxide 
Number of 
genotoxic reports 
Number of non-
genotoxic reports 
Overall 
assessment** 
1 Al2O3 1 1 + 
2 NiO 1  + 
3 Co3O4 2  + 
4 CuO 6 2 + 
5 Fe2O3 1 5 - 
6 Fe3O4 6 3 + 
7 TiO2 32 6 + 
8 ZnO 16 1 + 
9 SiO2 3 9 - 
10 V2O3 1  + 
11 V2O5  1 - 
12 MgO  1 - 
13 ZrO2  1 - 
14 CeO2 5 1 + 
15 Bi2O3 1  + 
16 SnO2  1 - 
* Data were extracted from 128. 
** The “positive” and “negative” signs are assigned according to the number of genotoxic and 
nongenotoxic “reports” per each NM. The assessment column represents the variable used to 
model, based upon the global evaluation (weight of evidence) of all the reports related to a single 
NM (i.e. row): “+” means positive, i.e. genotoxic, whereas “-“means negative, i.e. not genotoxic. 
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Table 6. Acronyms, short definitions and units of the molecular descriptors calculated by 
MOPAC2012. 
Symbol Descriptors Unit 
HF Heat of formation Kcal/mol 
TE Total energy of the oxide cluster Ev 
EE Electronic energy of the oxide cluster Ev 
Core Core-core repulsion energy of the oxide cluster Ev 
COSMO 
Surface charge distribution based on Conductor-like 
Screening Model 
Cubic 
Angstroms 
COSMO-
SA 
Area of the oxide cluster calculated based on COSMO 
Square 
Angstroms 
IP Ionization Potential Ev 
HOMO 
Energy of the highest occupier molecular orbital of the 
oxide cluster 
Ev 
LUMO 
Energy of the lowest unoccupied molecular orbital of the 
oxide cluster 
Ev 
No.Fl Number of Filled Levels adimensional 
MW Molecular Weight g/mol 
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3.4 Weight of Evidence Approach in the Analysis of Results of Different In Silico Methods 
for the Mutagenicity Assessment of Chemicals 
In a WOE approach the prediction results of two (Q)SAR platforms which include nine 
mutagenicity models are assessed to reach a conclusion about the mutagenic effect of two 
chemical substances as case studies. The results of each mutagenicity model are considered 
pieces of evidence. The goal is to integrate the results to reach a conclusion on mutagenicity of 
the chemical under investigation. These pieces of evidence form a line of evidence to be used in 
further investigations together with other types of lines of evidence such as in vitro or in vivo 
mutagenicity results to help the assessors to reach a reliable answer for a toxicity question. Two 
drugs are selected for the present practice: Valproic acid and Diclofenac.  
Two methodologies are integrated for the proposed WOE framework. The results of the 
(Q)SAR and read-across in silico models are documented and integrated and additionally, the 
most similar compounds identified by the (Q)SAR platforms and ToxRead are analysed. The 
comparison between the target chemical and each individual source chemical is conducted by 
means of ToxRead and ToxDelta. The identified SAs as dissimilar fragments in the structure of 
each chemical are studied to explore their role in affecting or reducing toxicity (in this case 
mutagenicity effect). 
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CHAPTER 4 
4. Results and Discussions 
4.1 Part 1- Carcinogenicity Models 
4.1.1 R Model 
From each training set a collection of active SAs has been extracted. These collections or active 
rules of molecular substructures are the new models. Each SA is associated with a likelihood 
ratio, which is a statistical value for illustration of the goodness of the rule. The final model 
which is a result of merging all the rule sets consisted of 127 active SAs. Table 7 (page 75) 
shows the statistics of the prediction results of five models developed base on five different 
splits of the ANTARES database. The performance of each model is evaluated using its own 
test set. The average of the predictive values of all the five models have been reported in Table 
7 (page 75), as well. The averages of accuracy (Formula 2), sensitivity (Formula 3) and 
specificity (Formula 4) for the 778 compound internal cross-validation using five rule sets 
extracted from the ANTARES dataset were 71%, 73% and 69%, respectively. The average of 
accuracy, sensitivity and specificity for 337 compounds in the test set as an external validation 
of these models, were 63%, 63% and 62%, respectively.  
The results of cross-validation of the R model on the whole training set were 66% accuracy, 
83% sensitivity, 48% specificity and 0.34 the MCC (Formula 5) (Table 8-page 76). The R 
model produced better results for the external evaluation of the model using the ECHA 
database. In fact, analysis of the external validation for the R model demonstrated that the 
concordance between experimental and predicted value on the ECHA dataset is higher than 
using the ISSCAN-CGX dataset. The accuracy of the R model on the ECHA dataset was 67%, 
compared to 58% of accuracy for the ISSCAN-CGX dataset. The complete list of these alerts 
are presented in the VEGA platform. 
4.1.2 E Model 
SARpy extracted 43 active SA from the ISSCAN-CGX training set. Analysis of the cross-
validation for the E model demonstrated that the second model produced an accuracy of 73%, 
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with a sensitivity of 77% and a specificity of 62% (Table 8-page 76). The MCC value for this 
analysis is 0.36. The accuracy values for the external evaluation of the E model on the 
ANTARES dataset and the ECHA database were 59% and 64%, respectively. Analysis of the 
external validations for the E model demonstrated that the model produced a higher sensitivity 
(77%) compared with the specificity (41%) of the R model. On the contrary, the specificity of 
the external evaluation on the chemicals from the ECHA database was higher (72%) compared 
to its sensitivity (48%) (Table 8-page 76). The complete list of the SAs present in this model is 
accessible through VEGA. 
4.1.3 Analysis of the Combination of the Prediction Results of the R and E Models 
In addition to the separate analysis of the prediction results of the R and E model, another 
combined evaluation has been conducted. In this analysis of the prediction results of the R 
model and the E model, we considered the final results as correctly predicted only in case both 
models have predicted them consistently. Table 9 (page 76) summarizes the results of 
combining the R and E model external validation predictions on the chemicals from the ECHA 
database. 
The results showed that in case both models had a concordant result on a negative prediction the 
reliability of the results is higher than in case the positive predictions. 
We observe an improvement of the results compared to the use of the individual models, for 
accuracy (72%) and specificity (79%). In fact, combining the predictions of the two models the 
MCC is increased to 0.37, compared to 0.31 for the R model and 0.20 for the E model. Only 
sensitivity is higher using the R model (62%). Thus, users may choose a solution or another 
depending if they prefer a conservative or a realistic assessment. 
 
𝑎𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =  
𝑇𝑃+𝑇𝑁
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑜𝑛𝑠
   (Formula 2) 
 
𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =  
𝑇𝑃
𝑇𝑃+𝐹𝑁
    (Formula 3) 
 
𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 =  
𝑇𝑁
𝑇𝑁+𝐹𝑃
    (Formula 4) 
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𝑀𝐶𝐶 =  
𝑇𝑃×𝑇𝑁−𝐹𝑃×𝐹𝑁
√(𝑇𝑃+𝐹𝑃)(𝑇𝑃+𝐹𝑁)(𝑇𝑁+𝐹𝑃)(𝑇𝑁+𝐹𝑁)
   (Formula 5) 
 
4.1.4 Fragments Analysis 
4.1.4.1 Comparison of the SAs in the R and E Models 
We compared all the SAs in the R and E models in order to identify the SA in common between 
the two models. The common SAs have been categorized into chemical classes. The SAs in the 
R model are presented with their ID number and written in order of their correspondence to the 
identical SAs in the E model.  
1) Aromatic amine (R model: 6, 41, 36, 22, 10 / E model: 27, 31, 33, 38, 104) 
2) Aromatic heterocyclic  (R model: 12, 19, 2 / E model: 75, 108, 117)   
3) Hydrazide (R model: 28, 27 / E model: 2, 50) 
4) N-Nitroso (R model: 1 / E model: 8) 
5) Phenyl-Hydrazine (R model: 32 / E model: 48)   
6) α,β- Haloalkanes (R model: 25 / E model: 56)   
7) Sulfite (R model: 8 / E model: 68) 
8) Nitrogen Mustard like (R model: 11 / E model: 73) 
9) Phosphonite (R model: 15 / E model: 98) 
4.1.4.2 Categorization of the SAs in the R and E Models 
All the SAs of the R and E models are categorized into chemical classes. The substructures 
within each category are presented with their ID number in their original rule set and are as 
follows: 
Nitrogen containing substructures (Azo type): 
1) Aromatic amine (R model: 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38, 
40, 42, 83, 104, 110, 113 / E model: 6, 10, 22, 31, 35, 36, 41, 42)  
2) Aromatic heterocycles containing Nitrogen (R model: 74, 75, 80, 81, 83, 95, 113, 122 / 
E model:12, 17, 43) 
3) Azine (Hydrazine) (R model:46, 47, 49, 50, 51, 53, 54, 55, 101 / E model: 27, 32) 
4) Azide (Hydrazide) (R model: 2, 3, 44, 45, 52 / E model: 3, 28)  
5) Nitrosamine (R model:4, 5, 7, 9, 10 / E model: not found (NF)) 
6) Nitrogen or sulfur mustard (R model: 72, 73, 115 / E model: 11, 34)  
7) Aromatic methylamine (R model: 30, 34, 36 / E model: NF)  
8) Aliphatic N-Nitroso (R model: 62, 63/ E model: NF) 
9) Aromatic Nitro (R model: 90, 123 / E model: NF) 
10) 1 aryl 2 monoalkyl hydrazine (R model: 48 / E model: NF) 
11) Aziridine (R model:120 / E model: NF)  
12) Aromatic hydroxylamine (R model: 32 / E model: NF)  
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13) Diazo (R model:92 / E model: NF) 
14) Aromatic Azo (R model: 71 / E model: NF) 
15) Aromatic Nitroso (R and E models: NF) 
16) Other substructures: 
17) (1,2, and 3 membered) Aromatic Heterocycles (R model: 74, 75, 80, 81, 83, 90, 95, 103, 
108, 113, 117, 121, 122, 123 / E model: 2, 12, 17, 19, 43) 
18) Aliphatic halide (R model: 57, 58, 59, 70, 125 / E model: 18, 25) 
19) Heterocyclic Alkane (R model: 84, 105, 109, 120 / E model: 23) 
20) Polycyclic aromatic systems (R model: 39, 43, 60, 61 / E model: 30) 
21) Sulfonate bonded carbon (R model: 67, 68 / E model: 8) 
22) Epoxide (R model: 105 / E model: 23) 
23) Β propiolactone (R model: 114 / E model: NF) 
 
SARpy had successfully identified most of the already known carcinogenic substructures that 
were presented by Kazius et al. In addition a number of SAs have been extracted by SARpy for 
the first time. Table 10 (page 77) demonstrates the new identified SAs that have been classified 
into seven chemical classes. The substructures within each category are listed with their ID 
number and are as follows: 
1) Nitrosurea (R model: 12, 13, 14, 19 / E model: NF) 
2) Nitrogen or sulfur mustard like (R model: 72, 115 / E model: 34)   
3) Benzodioxole and Benzendiol (R model: 17, 18 / E model: 9)   
4) Teritiary amine substituted by a Sulfur atom (E model: 24) 
5) α,β-oxy and carboxy substitutions (R model: 20, 21, 76 / E model: NF)  
6) α,β-haloalkanes (R model: 56, 69 / E model: 25) 
7) Oximes (R model: 78 / E model: NF) 
 
As an example, we illustrated the chemicals from which the SA 24 (from the chemical class 
teritiary amine substituted by a Sulfur atom) in the E model has been extracted (Table 11-page 
78). It is important to notice that all the chemicals that contain the above mentioned SA in the 
ISSCAN-CGX data set are carcinogenic. 
Table 7. R model internal and external validation for five different splits and the average of the 
model performance 
  1° split 
(59 active 
rules) 
2° split  
(65 active 
rules) 
3° split 
(61 active 
rules) 
4° split  
(58 active 
rules) 
5° split  
(57 active 
rules) 
Average 
Learning set 
(778 
compounds) 
Accuracy 71 % 72 % 71 % 70 % 71 % 71 % 
Sensitivity 75 % 75 % 71 % 73 % 70 % 73 % 
Specificity 65 % 69 % 71 % 66 % 72 % 69 % 
Test set 
(337 
compounds) 
Accuracy 63 % 60 % 64 % 65 % 62 % 63 % 
Sensitivity 68 % 58 % 62 % 67 % 61 % 63 % 
Specificity 56 % 63 % 66% 61 % 64 % 62 % 
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Table 8. R model and E model internal and external validation  
 R model  
(127 active rules) 
E model  
(43 active rules) 
 
Cross-
validation 
external 
validation on 
ISSCAN and 
CGX data 
external 
validation 
on ECHA 
data 
Cross-
validation 
external 
validation 
on 
ANTARES 
data 
external 
validation 
on ECHA 
data 
Accuracy 66% 58% 67% 73% 59% 64% 
Sensitivity 83% 76% 62% 77% 77% 48% 
Specificity 48% 40% 70% 62% 41% 72% 
TPa 651/783 593/735 55/89 562/735 599/783 43/89 
TNb 367/760 142/254 119/169 157/254 315/760 121/169 
FPc 393/760 112/254 50/169 95/254 445/760 48/169 
FNd 132/783 142/735 34/89 172/735 184/738 46/89 
MCCe 0.34 0.35 0.31 0.36 0.19 0.20 
a True positive; b True negative; c False positive; d False negative; e Matthews Correlation 
Coefficient 
 
Table 9. The combination of the predictions of the R and E models on the ECHA external 
validation set  
Combined model 
TPa 33/89 
TNb 96/169 
FPc 25/169 
FNd 24/89 
Accuracy 72% 
Sensitivity 58% 
Specificity 79% 
MCCe 0.37 
Coverage 178/258 
a True positive; b True negative; c False positive; d False negative; e Matthews correlation 
coefficient 
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Table 10. New carcinogenic structural alerts identified by SARpy in the R and E models 
Nitrosurea (R model: 12, 13, 14, 19) 
 
Nitrogen or sulfur mustard like (R model: 72, 115 / E model: 34)  
 
Benzodioxole and Benzendiol (R model: 17, 18 / E model: 9) 
 
α,β-oxy and carboxy substitutions (R model: 20, 21, 76) 
 
Teritiary amine substituted by a Sulfur atom (E model: 24) 
 
 
α,β-haloalkanes (R model: 56, 69 / E model: 25) 
 
Oximes (R model: 78) 
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Table 11. Chemicals structures in the ISSCAN-CGX data set from which structural alert 24 has 
been extracted 
   
O=C1c2ccccc2C(=O)N1SC(Cl)(
Cl)Cl  
O=C1N(C(=O)C2CC=CCC12)SC(C(Cl)Cl
)(Cl)Cl  
O=C1N(C(=O)C2CC=CCC12)SC(Cl)(Cl)Cl  
 
 
 
O1CCN(C(=S)SN2CCOCC2)C
C1  
O=C(O)c1ccc(cc1)S(=O)(=O)N(CCC)CCC  O=C(O)c1cc(ccc1Cl)S(=O)(=O)N1CC(C)C
C(C)C1 
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4.2 Part 2- ToxDelta 
In the stand-alone version of ToxDelta, the user can insert two chemical compounds and 
compare their molecular structure. The two chemical compounds can be introduced as SMILES 
115. The MCS is the biggest common part between two molecules in input and is shown in Table 
12 (page 85). Usually the assessment of a target molecule in a read-across approach is based on 
the comparison of the structure of the compound under investigation and another source 
compound with known toxicity property. In our program, the MCS is the common part in both 
molecules which is analysed and processed by ToxRead in the initial phase of read-across 
process. Indeed, the application of ToxDelta is useful for substances that are structurally similar. 
The MCS typically is an important part in read-across procedure. In this scheme, ToxDelta 
complements the conceptual strategy of ToxRead. The problem with the existing read-across 
tools is the risk of missing the differences between two similar molecules. The similarity should 
not minimize the fact that the possible opposed behaviour of the two similar compounds. In 
order to avoid the lack of attention to the opposite behaviour, ToxDelta makes a thorough 
assessment about the differences of the similar compounds under read-across examination. The 
theoretical basis is closely related to the SA paradigm. Thus, ToxDelta is an interdependent part 
of the ToxRead software, which exploits all the SAs of the target compound.  
ToxDelta makes is possible to take a closer look at the two substances (i.e. the target and the 
reference compounds), in particular, when they may have opposite toxicological properties. 
Indeed, it should be reminded that ToxRead predicts the toxicological property of the target 
compound, and thus the predicted value of the target compound may be the completely different 
from the experimental value of the similar compound.  
To investigate the utility of ToxDelta in read-across we provide two examples of mutagenicity 
endpoint. Each example includes two chemicals. For convention, we label one of the chemicals 
“Target molecule” and the other chemical “Source molecule”.  
4.2.1 Case Study 1: Benzodiazepine Derivatives  
Target molecule 1: Diazepam  
Systematic name: 1-methyl-5-phenyl-7-chloro-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
SMILES: O=C1N(c3ccc(cc3(C(=NC1)c2ccccc2))Cl)C 
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Experimental activity: nonmutagenic in Ames test 52 
CAS number: 439-14-5 
Source molecule 1: Flunitrazepam 
Systematic name: 1,3-dihydro-5-(o-fluorophenyl)-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-
one 
SMILES: c12C(=NCC(=O)N(c1ccc(c2)[N+](=O)[O-])C)c1c(cccc1)F 
Experimental activity: mutagenic in Ames test 52 
CAS number: 1622-62-4 
The first pair are Diazepam (we suppose with unknown mutagenic property) as the target 
molecule and Flunitrazepam (mutagenic in Ames test) as the source molecule. We suppose 
that we have no information about the mutagenic effect of the target molecule and the aim is to 
investigate the possibility of assigning the mutagenicity property of the source molecule to the 
target molecule. The similarity index between the first pair of molecules is 0.871, and the MCS 
between the target and source molecule is extracted by ToxDelta (“1-methyl-5-phenyl-2,3-
dihydro-1H-1,4-benzodiazepin-2-one”) (Table 12-page 85). Since ToxDelta is a complementary 
tool implemented in ToxRead, prior to using ToxDelta the user have the possibility to illustrate 
the common SAs between the target and the source molecular structures. Indeed, ToxRead 
identifies the SA in common between the two molecules as following: 
 
Name: SM203 
Description: Sarpy alert n. 203 for NON-Mutagenicity, defined by the SMARTS: 
N(C)(CCN)c1ccccc1 
Experimental accuracy: 0.52 
Fisher test p-value: 0.55052 
 
Since the SA in common between the two molecules is not an active mutagenicity rule, it is 
important to investigate the dissimilarities between the molecules. At this point ToxDelta is 
used to identify the differences and to extract all the dissimilar fragments, which do not belong 
to the MCS in both molecules. 
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ToxDelta extracts the following SA as one of the dissimilar fragments from Flunitrazepam 
from the mutagenicity SA dataset of ToxRead/ToxDelta 122,123: 
 
Name: SA27 
Description: Nitro aromatic (Benigni/Bossa structural alert no. 27) 
Experimental accuracy: 0.87 
Fisher test p-value: < 10e-6 
 
Given that there are no other significant SA in Flunitrazepam, the Nitro aromatic mutagenicity 
rule with 0.87 experimental accuracy is likely to be the reason of the mutagenicity effect of the 
source compound.  
The other dissimilar fragment identified in the source molecule (Fluorobenzene) is also present 
in the target molecule (Chlorobenzene). This dissimilar fragment is halogenated benzene with a 
low experimental accuracy for mutagenicity effect, thus is not likely to trigger mutagenicity. 
 
Name: SA31a 
Description: Halogenated benzene (Benigni/Bossa structural alert no. 31a) 
Experimental accuracy: 0.48 
Fisher test p-value: 0.00735  
 
Considering that no other significant mutagenicity SA is identified in the structure of 
Diazepam, the user may conclude that although the similarity index between Diazepam and 
Flunitrazepam is high (0.871), the molecular structure investigation of the two molecules do 
not provide evidence to the possibility of assigning the property of the source molecule to the 
target. Not being available any other SA with high mutagenicity accuracy inside the MCS or the 
dissimilar fragments extracted from the target after the comparison with the source, the user 
may conclude that Diazepam is not mutagenic. Indeed, we already have the Ames test value for 
Diazepam, which is negative for this endpoint. 
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As a conclusion, ToxDelta immediately reports as a key difference the presence of the 
nitroaromatic fragment, which is at the basis of the different mutagenicity value of the two 
substances. 
4.2.2 Case Study 2: Androstane Derivatives 
Target molecule 2: Mepitiostane 
Systematic name: 5-alpha-Androstane, 2-alpha,3-alpha-epithio-17-beta-(1-
methoxycyclopentyloxy)- 
SMILES: O(C)C6(OC2CCC3C4CCC1CC5C(CC1(C)C4(CCC23(C)))S5)(CCCC6) 
CAS number: 21362-69-6 
Experimental activity: nonmutagenic in Ames test 149 
Source molecule 2: Cholestan-6-one, 3-bromo-, cyclic 1,2-ethanediyl mercaptole, S,S,S',S'-
tetraoxide, (3-beta,5-alpha)- 
Systematic name: Cholestan-6-one, 3-bromo-, cyclic 1,2-ethanediyl mercaptole, S,S,S',S'-
tetraoxide, (3-beta,5-alpha)- 
SMILES: 
O=S5(=O)(CCS(=O)(=O)C35(CC1C4CCC(C(C)CCCC(C)C)C4(C)(CCC1C2(C)(CCC(CC23)B
r))) 
CAS number: 133331-34-7 
Experimental activity: mutagenic in Ames test 149 
The second pair are Mepitiostane (we suppose with unknown mutagenic property) as the target 
molecule and Cholestan-6-one, 3-bromo-, cyclic 1,2-ethanediyl mercaptole, S,S,S',S'-
tetraoxide, (3-beta,5-alpha)- (mutagenic in Ames test) as the source molecule. We suppose 
that we have no information about the mutagenic effect of the target molecule and the aim is to 
investigate the possibility of assigning the mutagenicity property of the source molecule to the 
target molecule. The similarity index between the second pair of molecules is 0.774, and the 
MCS between the target and source molecule is extracted by ToxDelta (Table 12-page 85). 
ToxDelta can be used as a stand-alone tool or an auxiliary tool inside ToxRead. ToxRead 
illustrates the common SAs between the target and the source molecular structures. Indeed, SAs 
in common between the two molecules identified by ToxRead are as following: 
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Name: SM153 
Description: Sarpy alert n. 153 for NON-Mutagenicity, defined by the SMARTS: SCCCC 
Experimental accuracy: 0.83 
Fisher test p-value: 0.00005 
It is evident that the common substructure between the molecules under investigation is not a 
potential mutagenic SA, thus the dissimilarities of the two molecules need to be explored for the 
potential mutagenic substructure.  
ToxDelta identifies the androstane tetracyclic system as MCS shared by these two chemicals 
and extracts five fragments of dissimilarity (Table 12-page 85). Three of these are aliphatic 
rings: the thiirane, 1,1-dimethoxycyclopentane, and 1,3-Dithiolane 1,1,3,3-tetraoxide rings and 
two are aliphatic chains: the 2-methylheptyl group and a bromine atom, both linked to an 
aliphatic carbon ring. The cyclic moieties and the alkyl carbon chain do not match any rule 
potentially responsible for mutagenic/nonmutagenic activity listed in the ToxRead software. 
Conversely, the bromine atom linked to an aliphatic carbon ring corresponds to two 
ToxRead/ToxDelta SAs both referring to bromo-/halo-ethyl moieties with different levels of 
specificity and a prevalence of mutagenic activity of 71% and 67%, respectively. The identified 
SA extracted by ToxDelta in the source molecule are as following: 
 
Name: MNM16 
Description: IRFMN alert n. 16 for Mutagenicity, defined by the SMARTS: 
[Cl,Br,I][C;H1;D3][$([C;H3;D1]),$([C;H2;D2][C,O,N,S,Cl,Br,I])] 
Experimental accuracy: 0.71 
Fisher test p-value: 0.00704 
 
Name: SM93 
Description: Sarpy alert n. 93 for Mutagenicity, defined by the SMARTS: C(C)Br 
Experimental accuracy: 0.67 
Fisher test p-value: 0.0036 
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These rules, which are present in the source molecule but not in the target chemical, give a first 
indication of different toxicological profiles for these chemicals.  
Considering that no other significant mutagenicity SA is identified in the structure of 
Mepitiostane, the user may conclude that although the similarity index between these 
molecules is high (0.774), the similarity and dissimilarity investigation do not provide evidence 
to the possibility of assigning the property of the source molecule to the target. Not being 
available any other SA inside the MCS or the dissimilar fragments extracted from the target 
after the comparison with the source, the user may conclude that Mepitiostane is not 
mutagenic. Indeed, we already have the Ames test value for Mepitiostane, which is negative for 
this endpoint. 
Considering the two case studies, it is notable that sometimes the identified dissimilar 
substructure is not an entire SA. In many cases the dissimilarity substructures are fractions of 
the whole SA (i.e. a rule which is present in the database of mutagenicity or any other toxicity 
endpoint SAs), and the remaining of the SA are in the MCS. This concern has been solved by 
ToxRead. In fact, the examination of ToxDelta of the dissimilarities happens after the 
visualization of ToxRead results. 
ToxRead outcome comprises all the existing SAs that are matched with the target molecule and 
are in common between the target molecule and a set of structurally similar molecules. 
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Table 12. The two case studies: Case study 1) target molecule: Diazepam, source molecule: 
Flunitrazepam; Case study 2) target molecule: cholestan-6-one, 3-bromo-, cyclic 1,2-ethanediyl 
mercaptole, S,S,S',S'-tetraoxide, (3-beta,5-alpha)-, source molecule: mepitiostane, and the results 
of ToxDelta: maximum common substructure and dissimilar fragments. 
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4.3 Part 3 – Metal Oxide NMs Genotoxicity Model 
The aim of this study is the collection of all the metal oxide NMs with genotoxicity data 
available in reliable peer reviews and the development of computational grouping model for the 
created dataset. The prepared dataset is based on evaluation of genotoxicity results from the 
comet assay results, gathered by the authors128.  
The availability of a relatively high number of publications of Comet assay data for the 
assessment of genotoxicity of NM, had been the reason of choosing this genotoxicity test in our 
investigation.  
To conclude an accurate result from the various number of studies conducted on 16 metal oxide 
NMs in the field of genotoxicity by Comet assay, we needed to examine the significant factors 
that could affect the reliability of the data. Moreover, this scheme made maximum use of pre-
existing data from in vitro methods, for (Q)SAR modelling. 
4.3.1 Data Quality Assessment 
Table S1.A in Appendices, contains the results of both physico-chemical properties and Comet 
assay adherence assessment. Each datum point corresponds to the summary of results from the 
Comet assay for a nano metal oxide (or silica), with a common core chemical composition and a 
unique size/ size range.  
As part of this assessment, we extracted data for the size of various metal oxide NMs and 
provided in Table S1.B (Appendices). In a few publications, size was reported as nominal size 
as provided by the suppliers whilst other authors measured the size with one or more tools 
including (TEM, SEM, etc.).  
Information on the crystallography is also included in this table. Metal oxides that had different 
crystallographic properties in the assessed data were TiO2, and SiO2. The anatase or rutile 
forms of TiO2 and amorphous or crystalline forms of SiO2 were tested.  
Physico-chemcial properties of the NMs such as size, shape, charge, and surface coating, and 
various components present in the medium, such as serum proteins that dispersion and stability 
of NMs depend on them, influence the assay results. Considering the importance of these 
factors in Comet assay results, it is essential to characterize NMs in the relevant medium and to 
use the appropriate treatment conditions.  
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Recent studies in the field of NMs show that significant size-dependent changes in NMs’ 
properties happens in the NM smaller than 5 nm 150–152. NMs with sizes between 15 and 90 nm 
do not show a meaningful correlation between the factor of size and activity. On the other hand, 
all nanopowders when suspended in water resulted in same sized aggregated particles, 
regardless of their initial size 153. Thus, we decided to exclude NMs smaller than 15 and bigger 
than 95 nm from the consecutive data analysis. 
In data quality assessment section the aim was to examine the already existing data and 
establish a data set of metal oxide NMs with their assigned genotoxicity properties, based on the 
minimum criteria. This dataset was aimed to be used for (Q)SAR modelling purpose 154. It is 
important to notice that until the current time there are no official guidelines for the in vitro 
Comet assay 155. After assessing the quality of the tests presented in the literature, we propose a 
scheme employing a WOE approach 133. This approach is an appropriate solution to make a 
conclusion for the hundreds of reports that have been published without a concrete outcome 156. 
Finally, a binary classification of genotoxic or nongenotoxic has been assigned to each metal 
core composition. 
We established some criteria to make a possible comparison of data obtained from the reports of 
different laboratories and studies. Table 5 (page 69) shows the existing trend for genotoxicity of 
each type of the metal oxide NM as identified by the Comet assay. The differences of Comet 
assays methods in different laboratories have been investigated in past 157–163. In our approach, 
we selected the results with sufficient number of necessary factors for the performed test. These 
important factors of the Comet assays make their results more reliable. We have undertaken two 
phases to evaluate the experimental data: those criteria to be respected for a reliable in vitro 
Comet assay and a WOE approach applied to the reports that have met the criteria established. 
Previously, Huk et al.154 establish the minimum considerations in performing the in vitro Comet 
assay experimentally for NMs. These considerations are listed in Table S1.A (Appendices). For 
instance, data points that are not associated with the three important physico-chemical 
characterisations (i.e. chemical composition and purity, surface area and particle size/size 
distribution) are known to be less reliable comparing to the NMs for which this kind of 
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information was provided. The data lines without any physico-chemical properties of tested 
metal oxide NMs, were excluded from the list of data. Therefore, the data points assessed for in 
vitro Comet assay minimum protocol were satisfactory from this point of view. 
After applying the established criteria to the data points, 48 data belonged to the “high 
reliability” class of which 18 data points had also uptake analysis. 8 data points belonged to the 
“moderate reliability” class, of which 2 had an uptake analysis. 4 data points belonged to the 
“low reliability” class, of which 1 had an uptake analysis. Table 13 (page 91) shows the 
assignment of the reliability of Comet assays based on the criteria list defined by Huk et al. 154. 
Details of this analysis are reported in Table S1.A (Appendices). Table S4 (Appendices) reports 
the number of total studies evaluated for each metal oxide core (all sizes) together with the 
number of studies with size range 5-100 nm, the number of studies in each reliability class and 
the overall genotoxicity for each metal oxide nanoparticles. 
4.3.2 Quantum Mechanical Descriptor Calculations 
The size of the NPs under investigation in this study is 15-90 nm in the laboratories’ analysis. 
Calculation of the quantum-mechanical descriptors of these NMs is not possible, since the 
systems are too large. For this reason we decided to simplify the structural models used for the 
calculation of the descriptors. Smaller metal oxide clusters of the same size have been 
considered for the calculation of the descriptors and one of the descriptors was calculated on the 
basis of the characteristic of the considered NMs. In the current study, we adopted the same 
method used by Puzyn et al.164 for a predictive cytotoxicity model. In our study we used the 
same 10 metal oxides that Puzyn et al. used in their cytotoxicity dataset. Puzyn et al. utilized 16 
NMs in genotoxicity and 17 NMs in cytotoxicity dataset. The same concepts in considering 
experimental results performed on different sizes from 15 to 90 nm has been adopted in the 
present study. In addition, Puzyn et al. have given a strong justification for the use of the size 
rage of 15-90 nm outcomes in a singular modelling approach. In precedent studies it is shown 
that genotoxicity of many NMs is directly related to oxidative stress (by elevated ROS levels, 
reduced antioxidant levels and increased lipid peroxidation) and subsequent inflammation 
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(leading to apoptosis)165,166. Hence, the descriptors that were selected by the machine learning 
approaches were evaluated to illustrate their role in the oxidative stress process.  
4.3.3 Recursive Partitioning and Regression Trees  
In order to maintain the simplicity of the model, we built a simple classification tree on the data 
set of 16 metal oxide NPs. Table S3 (Appendices) reports the scaled values on the dataset used 
for the classification model. In the developed model tree descriptors have been used and the 
NMs are classified into two classes: genotoxic and nongenotoxic. Figure 8 (page 89) shows the 
tree representation of the developed model. Since the model is fitted with scaled data, for 
making predictions the new observations should be scaled according to the scale attributes 
(Table S3, Appendices) of the dataset used to build the model. The thresholds used in this 
model are as following: 
First split:  
 NPs with HF < -1.145 (original value: -5199.7) are nongenotoxic; the rest of the NPs will be 
processed in the second split. 
Second split: 
 NPs with MW < 0.3601 (original value: 1492.2) are nongenotoxic; the rest of the NPs will 
be processed in the third split. 
Third split:  
 NP with COSMO-SA >= 1.176 (original value: 960.9) are nongenotoxic; and the rest are 
genotoxic 
 
 
Figure 8. The ‘rpart’ classification tree model on the data set of 16 metal oxide nanomaterials. 
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All the eleven descriptors reported in Table 4 (page 68) are given as input to the rpart algorithm. 
The method is set to classification, as the endpoint is a binary value (i.e. genotoxic and 
nongenotoxic). Three control parameters are set in the command line of building the model. 
“Minsplit” that is the minimum number of observations in a node for which the routine will 
even try to compute a split is set to 3, “minbucket”, which is the minimum number of 
observations in a terminal node is set to 1, and “cp” that is the threshold complexity parameter 
is set to 0.001. The resultant model successfully separated the sixteen NPs into two groups using 
three quantum-chemcial descriptors: heat of formation (HF), molecular weight (MW), and 
surface area of the oxide cluster based on conductor-like screening model (COSMO-SA). The 
other eight descriptors did not appear in the final model.  
The selected descriptors very well conform to overall toxicity model for metal oxide NM, while 
this selection also can be beneficial for explanation of genotoxicity mechanisms of action. The 
results show that NM with small MW and HF are less genotoxic, comparing to heavier metal 
oxide NM. Enthalpy of formation or heat of formation is the only structural descriptor used in 
the nano-(Q)SAR model developed by Puzyn et al.164. From an initial set of 12 quantum-
chemically calculated structural descriptors, ΔHMe+ representing the enthalpy of formation of a 
gaseous cation with the same oxidation state as that in the MO structure was used to establish 
the linear equation of the model. HF is associated with the stability of the NM. Possibly, NMs, 
which are less stable, release ions more easily, and this increase the effect. COSMO solvent 
accessible surface area (COSMO-SA) is a continuous surface of the molecule, which can be 
reached by the centre of charge of a solvent molecule. The correlation between the lower 
COSMO-SA values and the higher DNA damage can be explained by the fact that the metallic 
ion has to be supplied via solution to DNA. The solubility and the dissolution rate of the metal 
oxides are essential for the metal supply. For the same type of metal ion (Fe), more metal ions 
are accessible in Fe3O4 comparing to Fe2O3. Assuming the surface area is equal, different 
number of oxygen, the metal type and the crystal structure (number of oxygens for each atom of 
metal), play an important role. This information are encoded in COSMO-SA. In other words, 
two different metal oxides having equal surface area can have different number of metal ions on 
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the surface depending on the length of the inter-intra molecular bonds, volume/molecular 
weight of the metal ion, and the proportion of the number of oxygens to the number of metals. 
Because of the small size of the dataset in our study in addition to the classification endpoint, 
we decided to maximize the amount of data in the process of model training and consequently 
there were no data considered as test set. Nevertheless, all the principles of the OECD for the 
validation of (Q)SAR models 73 have been fulfilled in our new model, except the model 
validation for stability and predictivity. In fact, the developed model has a defined endpoint: 
genotoxicity, an unambiguous algorithm, and an applicability domain. The most important goal 
of developing a new (Q)SAR model for the provided data set is to evaluate the correlation of 
each quantum-mechanical descriptor with the genotoxicity endpoint of the NMs. Indeed, feature 
selection is a crucial phase of (Q)SAR modelling. The developed model reveals the most 
significant descriptors related to the genotoxicity risk assessment of the NMs from a quantum-
mechanical point of view.  
Table 13. Assignment of the reliability of in vitro Comet assays based on the criteria defined in 
Huk et al. The assignment questions were treated in a “yes” or “no” fashion. In a weight of 
evidence approach, data points that presented 1st class property were used to assign the genotoxic 
or non-genotoxic fate to the metal oxide nanomaterials with the same chemical core composition. 
Comet assay main principals to follow 
for obtaining reliable test results 
1st class 
data 
2nd class 
data 
3rd class 
data 
Unreliable 
data 
Exposure to the nano metal oxides 
expressed in at least one of the units 
mentioned in Table 6 (page 70) 
yes yes yes no 
Cytotoxicity tests performed? (results 
were in a range from nontoxic to 
around 80% viability) 
yes no no no 
At least exposure for (3h) treatment 
time 
yes yes no no 
Performed trend test for dose-response 
relationship? 
yes no no no 
Performed comparison between treated 
samples and controls or both? 
yes yes yes no 
Information on uptake (demonstrated 
cellular uptake?) 
yes 
(prioritized 
results) 
and no 
yes 
(prioritized 
results) 
and no 
yes 
(prioritized 
results) 
and no 
no 
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4.4 Weight of Evidence Approach in In Silico Models for the Mutagenicity Assessment of 
Chemicals 
There can be two methodologies for the assessment and integration of the prediction results of 
the in silico models. In the WOE section of the present dissertation, to develop a conclusion in a 
WOE approach: i) first the (Q)SAR and read-across results as reported by the prediction models 
are documented and integrated, considering the reliability, relevance and consistency of each 
prediction, ii) then the structurally similar compounds indicated by the in silico software, as 
most similar chemicals to the target chemical under investigation are explored in order to 
evaluate the relevance and the reliability of the similar chemical to be used in a read-across way. 
We employed the both methodologies to the pieces of evidence. First we considered the 
prediction results of each individual in silico model with their corresponding applicability 
domain index as a measure of reliability. Then the similar chemicals indicated by different in 
silico models are taken into consideration for a further investigation to assess their relevance in 
terms of read-across. This assessment is based on their structure characterization or the presence 
or absence of active or inactive mutagenic rules and the similarities and dissimilarities between 
the target and the source molecules. At the end, the consistency of the various results has been 
evaluated together with their reliability and relevance to develop a conclusion for the 
mutagenicity effect of each drug. The results of the two case studies are presented in Chapter 6. 
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CHAPTER 5 
5. Conclusions 
5.1 Part 1- Carcinogenicity Models 
Based on SARpy as an automatic SA extraction tool, we developed two carcinogenicity models 
from two different training sets. The ANTARES learning set contained rodent bioassay 
carcinogenicity data of 1543 compounds, while ISSCAN-CGS dataset consisted of 986 
chemical substances with human-based assessments and data retrieved from different types of 
assays. We thoroughly evaluated the predicitivity of each model, this was evaluated on its 
related test set and additionally on an external test set composed of 258 chemical compounds 
obtained from the ECHA inventory. These two newly developed models are implemented in the 
VEGA platform and are freely accessible to all users.  
The already existing carcinogenicity models in the VEGA platform 167 before adding the two 
developed models (ANTARES and ISSCAN-CGX) were CAESAR and ISS. The CAESAR 
model is built as a CP ANN model. The neural network output consists of two values labeled as 
Positive and Non-Positive. The CP ANN uses twelve molecular descriptors. The ISS model is 
indeed the Toxtree carcinogenicity module version 2.6 52 introduced by Benigni et al. 43. When 
at least one carcinogen rule is matching with the target compound, “carcinogen” prediction is 
given; otherwise, the prediction will be “non-carcinogen”. The carcinogenicity developed 
models are the only structure-based models of the VEGA platform, except the ISS model which 
is indeed the implementation of Toxtree carcinogenicity module in this platform. The SAs of the 
ISS model are exactly the same as SAs of the Benigni and Bossa ruleset 43.  
Automated discovery of SAs associated with toxicology has been made great progresses due to 
the evolution of data mining tools. The statistically-based methods for the identification of new 
SAs are helpful in improving the already existing rule sets. While the most known 
carcinogenicity rule sets 43 are collected on the basis of human expert judgement, the SAs 
identified in our study are extracted by SARpy with no a priori knowledge about the MoA of 
the chemicals. This approach highlighted some new clues about genotoxic and non-genotoxic 
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SAs. Some primary analyses have been provided on the SA lists; chemical classes of the 
identified SAs have been evaluated, however, further study for the new SAs should be 
performed.  
In addition to the newly discovered SAs in the present study, the results obtained by the SARpy 
SAs extraction based on the analysis on the ANTARES and ISSCAN-CGX data sets are 
completely in line with the SAs presented by Kazius et al.46. 
Furthermore, the models are developed on the basis of two learning sets with different 
carcinogenicity data from the point of view of origin and provenance. Concerning the training 
sets with variant carcinogenicity data assessed within different properties, each set of the 
extracted SAs constituted a purpose oriented model. The user may consider the results of the 
model with more realistic predictions (ISSCAN-CGX) or the one with more conservative 
assessments (ANTARES).  
From a decision-making point of view, the most logical approach is combining the evidences 
obtained from different sources of information such as (Q)SAR model predictions, in vitro and 
in vivo test results. Scientists instead of accepting a singular judgement or prediction from one 
source of information, may acquire a WOE approach and consider more methodologies before 
determining the level of toxicity of a target substance. An example of the latter approach is 
implemented for mutagenicity (Ames test) endpoint, in the VEGA platform, in which the results 
of different models are combined and the output is based on different existing models 167. These 
two developed models for carcinogenicity are also implemented in VEGA where other models 
for the same endpoint are available. This implementation increases also the possibility of 
performing a similar activity to make a conclusion. 
Finally, the SAs explored in this study will be used for the construction of the carcinogenicity 
ruleset in ToxRead (http://www.toxgate.eu), a platform that uses set of rules for different 
endpoints to filter and select similar compounds and assist the user in performing read-across 
studies 122,123. 
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5.2 Part 2- ToxDelta 
ToxDelta is a complementary tool to be used in a parallel way together with the other prediction 
tools. It can be used alone and also is aimed to match some important features of ToxRead. 
ToxDelta addresses the dissimilarities between two similar molecules, and it does not make a 
conclusion on the evidences found in the dissimilar fragments of two substances. The 
conclusion on the outcome of the prediction may be accomplished by other prediction or read-
across tools such as ToxRead. The main advantage of this new read-across tool is the emphasis 
on the differences in addition to the similarities and the resembling properties between two 
structurally similar molecules. In other words, it exploits the adverse effects of the dissimilar 
fragments that may trigger the toxicological properties or biological activities of the chemicals. 
ToxDelta analyses the modulations of the effects related to the presence of the specific 
fragments in one of the two structures under investigation. ToxDelta executes in a “local” way. 
This functionality is important to evaluate the metabolites and the impurities related to a target 
compound in a comparative approach to the parent compound. Two important fields of the 
application of this strategy are impurities in pharmaceutics and pesticides. The FDA has 
provided a guideline for industry about the mutagenicity of the pharmaceutical impurities 168 
that describes a practical framework for identification and control of the identified mutagenic 
impurities in order to limit potential carcinogenic risk. Another appropriate field of application 
for this tool is in pesticides assessment. The EFSA has discussed the use of in silico models for 
the evaluation of the effects of metabolites of pesticides. ToxDelta’s methodology is useful in 
the toxicity assessment of pesticides, biocides and pharmaceuticals. The experimental toxicity 
properties of the parent compound is requested by the regulatory bodies and ToxDelta is able to 
provide this information. In these cases data for the parent compound is available and user 
requires the possible increase of effect caused by an impurity in the structure of a chemical 
instead of the absolute effect of the related compound. If the toxicity level of the impurities is 
similar to the parent compound, there must not be differences in the regulations and laws related 
to the target compound. Conversely, if the impurities have potential hazard effect the compound 
under the investigation must go through more analysis for the hazard assessment. To resolve 
these problems, local tools that are able to measure the relative increase or decrease of the 
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effects are more accurate than absolute de novo predictions. Despite the widespread use of read-
across tools, still the acceptance of the dossiers based on read-across approaches is not 
straightforward. A detailed documentation is required to be provided by the expert. The main 
concept of read-across is constructed by the analysis of two (or more) substances, the target 
compound, with missing data, and the source compound(s) which is assumed to represent the 
properties of the target compound. The already existing read-across tools to this moment are all 
focused on the similarities between the target and the source compounds. The main idea is the 
higher the similarity is, the greater is the likelihood that the two compounds share the same 
biological properties/activities. Indeed, the authorities often discuss the fact that even minor 
differences may provoke crucial change in the properties of the substances. In order to 
complement the existing read-across tools, we put emphasis on the differences between two 
structurally similar compounds, introducing ToxDelta. 
Another noticeable difference between ToxRead and ToxDelta with the other read-across 
programs, is that they do not contain exclusively active SAs, but also inactive SAs. This allows 
the examination of any positive or negative modulations of the effect. To each SA statistical 
characterizations are assigned. These statistical values show the accuracy and p-value of the 
SAs and are calculated based on the number of chemicals containing that SA, and the 
prevalence of the toxic or non-toxic category. Consequently, the tool provides not only the SAs 
present in the compounds, but also the statistical significance of the association of the found SA 
to a certain effect. ToxRead contains data related to mutagenicity and BCF endpoints and 
permits the user to move in different levels of reasoning in a read-across approach. ToxDelta 
offers additional focus on all the dissimilar fragment that may affect the properties and the 
activities of the molecules. 
Currently, a beta version of ToxDelta is freely available on the VEGA platform 
(https://www.vegahub.eu/) and the toxicity endpoint for which this tool can be used is 
mutagenicity. Other endpoints will be added to the software in the future. 
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5.3 Part 3- Metal Oxide NMs Genotoxicity Model 
NMs are complicated and exploring the relationships between their properties and their toxicity 
is challenging comparing to the small organic substances. This study is the first attempt in the 
field of computational nanotoxicology for modelling the genotoxicity of metal oxide NMs.  
Even though sufficient experimental data on genotoxicity of metal oxide NMs are available, 
there is no reliable model (or theory) for the prediction of genotoxicity of these NMs. In the 
present study, (Q)SAR modelling has been conducted based on experimental data obtained from 
a wide range of tests done on metal oxide NMs by in vivo and in vitro methods, mainly the in 
vitro Comet assay. We applied data quality assessment techniques on the experimental data 
based on in vitro models to create a reliable data base for use in computational modelling.  
The results of our WOE assessments confirm that it is important to fill the gaps of physico-
chemical characteristics of NMs used in in vitro Comet assay. In our analysis the range of size 
that has been mostly covered in experimental testing has been reported. We aimed at ranking the 
potential genotoxic category by material class, focusing on the within and between class 
variability. Within our investigation, we examined the role of the size of the same metal 
composition chemical core (size range or 1 to 90 nm) in genotoxicity effect of these chemicals 
as measured by Comet assay, and the possible statistical inferences that can be obtained from 
those data. 
While there are numerous progresses in the field of traditional (Q)SAR analysis, nano-(Q)SAR 
modelling is still at its primitive phase, due to the lack of sufficient knowledge about the 
measurements and modelling standards. The most problematic part of nano-(Q)SAR modelling 
is defining a series of consensus characterizations for the toxicity tests. The standardization of 
NMs characteristics and test methodologies is a great step towards the realization of successful 
nano-(Q)SAR models. 
In this study, for the first time we introduce a genotoxicity model which relates the experimental 
genotoxicity property of a set of metal oxide NMs to the quantum-mechanical calculated 
descriptors of these NMs. We successfully built a classification nano-(Q)SAR model based on a 
simple tree modelling approach. The aim of this model is to identify the most significant 
quantum-mechanical descriptors of the NMs that affect the genotoxicity properties assigned to 
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each NM based on a WOE study applied to a number of peer review resources. To the best of 
our knowledge, this study is the first example of NMs genotoxicity modelling by nano-(Q)SAR 
approach. In consequence of the small number of samples in the data set and the classification 
endpoint, we decided to use all the available data as training set in order to study the variable 
importance, rather than focusing on prediction ability of the model. Even though the model is 
simple and does the classification in a straightforward mode by using only three quantum-
chemical descriptors, it is still based on a small data set and the model validation still needs to 
be accomplished using a test set. Although the initial findings are encouraging, there is a strong 
need to verify and validate the results in order to make them acknowledged by regulatory bodies 
and users. Concerning the restraints, the developed model demonstrates a high potential of 
current chemo-informatic approaches for toxicological assessment of various metal oxide NMs. 
The design and manufacture of safer NMs require detailed analysis. The use of this model 
during the early stages of risk assessment can be very helpful to prioritize the NMs, which may 
impose adverse effects on human health. 
Although the mechanisms of nanoparticles genotoxicity are still not fully discovered but direct 
DNA damage and oxidative stress are considered important 169,159. Direct DNA damage 
mechanism is assumed to be more nano-specific because small nanoparticles may reach the 
nucleus through the nuclear pore complexes 170. However, the observation of larger 
nanoparticles in the nucleus hints that larger nanoparticles may get access to the DNA in 
dividing cells during the nuclear membrane dissemblance 171. Oxidative stress is induced by 
overproduction of ROS, resulting in the loss of normal physiological redox-regulated functions 
in the cells. This triggers DNA damage, unregulated cell signalling, change in cell motility, 
cytotoxicity, apoptosis, and cancer initiation 172. The relationship between DNA adducts and 
oxidation-induced DNA fragmentation and exposure to metal oxide nanoparticles is confirmed 
in numerous studies 173-177. Huang et al. 178 reported a detailed description of the genotoxic 
mechanisms of action of metal oxide nanoparticles. 
Enhancement of systematic risk assessment for NM is one of the main emphasis of the topic-
related (EU)-funded projects. The ongoing “Nanosafety Cluster” aims at identifying key areas 
for further research on risk assessment procedures for NM. The NanoSafety Cluster Working 
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Group 10 outcome was concern-driven integrated approaches for the (eco)-toxicological testing 
and assessment of NM 179. A set of tiers using standardized protocols for preparation and testing 
was introduced. Tier 1 included determining physico-chemical properties, non-testing methods 
such as QSAR and evaluating existing data. Tier 2 consisted of performing a limited set of in 
vitro and in vivo tests that are used to clarify the known risks of a relative concern or to 
highlight the need for performing further tests. A concern-driven guidance for investigating 
potential risks of NM is based on the idea of focusing research on NM that may induce some 
concerns based on exposure, use and already available toxicological information driven form 
non-testing methods ((Q)SAR, pharmacokinetic modelling and read-across). A testing strategy 
should consider the possibility to apply “read-across” methodology, to omit the “non-necessary” 
tests based on the relative category of a NM. The aim is to improve the risk assessment strategy 
in order to require less testing whenever the available information is sufficient to reach a 
conclusion in a decision-making process.  
Based on the factors determined that contribute to the genotoxicity of metal oxide NMs further 
studies will be performed to determine structural features which may help to derive mode of 
action knowledge from the data, i.e. prove a key mechanism that can describe a DNA damage. 
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5.4 Overall Conclusion 
The growing number of chemicals requring risk assessment, envisions increased efficiency in 
toxicity testing and the way toxicity testing is currently conducted may need major changes. In 
fact, acquiring a full set of toxicity results needed for regulatory bodies and decision-making 
procedures at the same pace these chemicals are introduced to the market, is becoming ever 
more challenging. Several approaches have been introduced in recent years, including the use of 
robotic high-throughput screening and computational toxicology studies to overcome this issue 
while decreasing the animal usage and increasing the required time for testing. Additionally, 
relibale non-testing methods, including (Q)SAR and read-across are becoming more and more 
acknowledged by risk assessors and regulators. The OECD experience with non-testing 
methods illustrates that grouping chemicals into categories and filling data gaps by read-across, 
interplolation or extrapolation are a winning strategy. Grouping approach relies on the 
assumption that not all the chemicals belonging to a group need to be tested for all toxic effect, 
and data gaps can be filled by means of read-across and grouping, saving “unnecessary” in vivo 
or in vitro tests. The flexibility and the transparency of the read-across approach make it a 
successful tool in many toxicological fields, especially regulatory decision-making. 
Consequently, these tools contribute to the realization of the Russell and Burch’s “3Rs 
principles” (Replacement, Reduction and Refinement) of animal use in toxicological studies. 
The use of the proposed WOE framework is illustrated by two drugs as case studies for 
mutagenicity assessment (Chapter 6). ToxDelta and ToxRead as two read-across tools are 
powerful means for the exploration of the active and inactive SAs present in the target molecule 
and the similar chemicals used as sources in read-across terms. These new tools help the 
assessors to overcome the shortcomings related to the interpretation of the results of in silico 
prediction models. The results show that the combination of the methodologies: (Q)SAR and 
read-across methods, with ToxRead and ToxDelta develops more interpretable data that can be 
utilized as lines of evidence in a WOE approach. The structure-based carcinogenicity models 
introduced in the first part and the new read-across tool, ToxDelta introduce in the second part, 
are completely in line with the aim of improving the current methodologies in WOE 
approaches.  
101 
 
In the third part of the study, the new genotoxicity model developed for the metal oxide NPs 
provides assistance for identifying and prioritizing the NMs which pose toxic effects to human 
health and environment. Safety assessment of NM and their modifications (shape, size, surface, 
coating, etc.) needs a full-blown testing program for each NM. This leads to a huge amount of 
testing with their relative costs and testing time. Some hazard information of NM can be 
deduced from the similar bulk materials or similar NM. In general, read-across and category 
approaches are used to predict properties and/or biological effects of chemicals. This is a way to 
fill the data gaps to characterize the adverse effects of NM. The WOE approach is also an 
effective tool for the integration of the conflicting and different results collected from the 
literature. From a regulatory point of view, the European projects which aim at introducing new 
strategies for further investigation on NM toxicity, point at a concern-driven guidance. This 
concern-driven guidance for investigating potential risks of NM is based on the idea of focusing 
research on materials that may induce some concerns based on exposure, use and toxicological 
information driven form non-testing methods ((Q)SAR, pharmacokinetic modelling and read-
across). Whenever possible, a testing strategy should consider the application of “read-across” 
methodology, to reduce the number of assays based on the potential risk associated with a NM. 
The aim is to improve the risk assessment strategy of NM in decision-making processes, and we 
believe that our classification tool can be used as an effective QSAR model to prioritize the 
metal oxide NM with high concern. 
The main goal of (Q)SAR and read across studies is to improve the risk assessment strategy in 
order to require less testing whenever developing new data is feasible. Using data integration 
approaches can help scientists and regulators in decision-making processes, and enable them to 
reach conclusions. The results obtained during my studies and presented in this dissertation are 
useful progresses in the field of structure-based genotoxicity non-testing methods. In particular, 
new approaches to read-across studies, achieved and implemented during my Ph.D studies, 
provide new scientific contributions to a transparent and structured framework for chemicals 
and NM risk assessment. 
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CHAPTER 6 
6. Example of the Use of Non-Testing Methods within a Weight of Evidence 
Framework 
In this section two case studies are selected for demonstrating the use of non-testing methods 
within a WOE approach. The prediction results for mutagenicity effect of a target compound are 
considered as pieces of evidence, while the objective is integrating these results to reach a 
conclusion on mutagenicity of the chemical under investigation. These pieces of evidence form 
a line of evidence to be used in further investigations together with other types of lines of 
evidence to help the assessors to support an adequate answer to a toxicity question. Two drugs 
are selected for the present practice: Valproic acid and Diclofenac. 
The evaluation and integration of the in silico model results in order to develop a conclusion in 
a WOE approach can be performed in two ways: i) first evaluating the (Q)SAR and read-across 
results as reported by the prediction models and integrating the results, considering the 
reliability, relevance and consistency of each prediction, ii) analysing the structurally similar 
compounds indicated by the in silico software, as most similar chemicals to the target chemical 
under investigation in order to evaluate the relevance and the reliability of the similar chemical 
to be used in a read-across way. In the present study, we employed both methodologies to the 
pieces of evidence. First we considered the prediction results of each individual in silico model 
with their corresponding applicability domain index as a measure of reliability. Then the similar 
chemicals indicated by different in silico models are taken into consideration for a further 
investigation to assess their relevance in terms of read-across. This assessment is based on their 
structure characterization or the presence or absence of active or inactive mutagenic rules and 
the similarities and dissimilarities between the target and the source molecules. At the end the 
consistency of the various results has been evaluated, together with their reliability and 
relevance to develop a conclusion for the mutagenicity effect of each drug. 
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6.1 First Case Study: Valproic Acid 
For the first case study we chose Valproic acid (Figure 9-page 103) as a target molecule for its 
mutagenicity assessment (as assessed through bacterial reverse mutation test) by non-testing 
methods, such as (Q)SAR models and read-across. For the estimation of mutagenicity we opted 
two platforms: VEGA (http://www.vega-qsar.eu) and T.E.S.T. 
(http://www.epa.gov/nrmrl/std/qsar/qsar.html#TEST). The VEGA platform contains four 
mutagenicity models (CAESAR, SARpy, ISS and KNN) and a consensus model which makes a 
conclusion on the basis of the four models predictions. The T.E.S.T. platform encloses three 
mutagenicity methods (Hierarchical, FDA and Nearest Neighbour). The Hierarchical and FDA 
methods are (Q)SAR structure-based methods, while Nearest neighbour is a read-across model. 
The mutagenicity property of the molecule under investigation is also assessed by ToxRead 
(http://www.toxread.eu/), to provide additional support for the predictions. Further T.E.S.T.’s 
outcome provides a few examples of similar molecules to the target molecule along with their 
similarity index, experimental and predicted values to be examined by the user. In the present 
practice, we applied both methods to our investigation in a WOE approach. Here we reported 
some of these similar examples presented by T.E.S.T. and evaluated their structural similarity 
and dissimilarities and the effect of the dissimilar fragments in the properties of the source 
molecules comparing with the target.  
 
 
Figure 9. Valproic acid chemical structure (CAS number: 99-66-1) 
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Table 14. Summary of the prediction results of non-testing models for Valproic acid  
Software Model/method Experimental 
value 
Results Predicted value Applicability Domain 
Index 
VEGA CONSENSUS  NON-
Mutagenic 
 
Non-mutagenic score: 
0.9 
CAESAR N/A** NON-
Mutagenic 
 
0.98 
SARpy/IRFMN N/A NON-
Mutagenic 
 
0.98 
ISS N/A NON-
Mutagenic 
 
0.90 
KNN/Read-
across 
N/A NON-
Mutagenic 
 
0.96 
T.E.S.T.* Consensus  
 
NON-
Mutagenic 
-0.04 Internally checked 
Hierarchical  Non-mutagenic NON-
Mutagenic 
-0.01 Internally checked 
FDA  Non-mutagenic NON-
Mutagenic 
-0.1 Internally checked 
Nearest 
neighbour  
Non-mutagenic NON-
Mutagenic 
0 Internally checked 
ToxRead Read-across  NON-
Mutagenic 
 N/A 
*the test chemical was present in the training set. 
**Not available 
 
Table 14 (page 104) shows the predictions of all models. All the models of VEGA and all the 
methods of T.E.S.T. predicted the substance as non-mutagenic. The applicability domain 
indices for each model in present in the table and they illustrate the level of reliability for each 
prediction. All the models agree on the non-mutagenic effect of the chemical. These results are 
based on experimental values, structurally similar compounds and the results of (Q)SAR 
models. The target substance was present in the training set of T.E.S.T. as non-mutagenic. 
Among with the predictions of all the models and the consensus method of T.E.S.T. also a 
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number of similar substances in the training set and external test set are reported in the outcome 
panel. For sake of example we reported four similar substances identified by T.E.S.T. in Table 
15 (page 106). For each similar substance the corresponding similarity coefficient, experimental 
value and predicted values are reported. Oryzalin metabolite and 2-[Ethyl(nitroso)amino]ethanol 
are two similar substances with high similarity coefficient (0.74 and 0.81, respectively) which 
reports positive mutagenicity effect for the experimental and also predicted values. The reason 
for the conflicting mutagenicity result for these two molecules is evaluated by ToxDelta. 2-
[Ethyl(nitroso)amino]ethanol (CAS 13147-25-6) (mutagenic) is selected to be compared to 
Valproic acid (non-mutagenic). Figure 10 (page 107) reports the outcome of ToxDelta for the 
MCS extraction and dissimilarities identification. After the subtraction of the MCS form the 
target and the source substances, the dissimilar substructures are shown in the outcome panel. 
The two dissimilar substructures extracted from the target substance do not present any 
mutagenic potentiality, but the dissimilar substructure extracted from the source molecule is 
known to be an active mutagenicity rule in the CRS4 mutagenicity rule base with accuracy=1.  
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Table 15. Experimental and prediction values for some examples of similar chemicals to Valproic 
acid (CAS number: 99-66-1) in the training set and test set of T.E.S.T. 
CAS Structure 
Similarity 
Coefficient 
Experiment
al value 
Predicted value 
621-64-7 
 
0.81 1.00 0.97 
110-58-7 
 
0.79 0.00 -0.02 
106-27-4 
 
0.74 0.00 -0.00 
13147-25-6 
 
0.74 1.00 0.90 
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A       B 
Figure 10. A) ToxDelta outcome for the comparison between Valproic acid (molecule #1) and 
2-[Ethyl(nitroso)amino]ethanol (CAS 13147-25-6) (molecule #2) The maximum common 
substructure is at the top of the panel. The dissimilar substructures are listed below their 
corresponding molecule. B) The identified dissimilar substructure extracted from the molecule 
#2 is a mutagenicity structural alert in the CRS4 dataset of mutagenicity ruleset with 
accuracy=1.  
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Figure 11. ToxRead chart for the target molecule Valproic acid (CAS number: 99-66-1). The 
numbers refer to CAS identifiers. Straight arrows link the target chemical to rules, while curved 
arrows link to chemicals 
 
ToxRead as a read-across tool can integrate the results from (Q)SAR and read-across models in 
a WOE approach. While some of the similar substances identified by T.E.S.T. are not 
structurally so similar to Valproic acid, the similar substances identified by ToxRead in the 
process of read-across are more compatible with the target (Figure 11-page 108). Indeed, the 
target chemical does not contain any structural rule for mutagenicity. The presence of 
nitrosamine substructure in the source substances triggers a remarkable difference in biological 
effect of the molecules form the mutagenicity point of view. This crucial differences and their 
role in reducing or amplifying toxicity effects of the molecule (not only mutagenicity but also 
other endpoints) can be precisely established by ToxDelta and can have an important role in the 
process of decision-making and the expert judgement in terms of WOE. Indeed, risk assessors 
can make use of this tool in order to minimize or even eliminate the eventual uncertainties 
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during the assessments with non-testing methods. Considering the differences between Valproic 
acid and the similar compounds identified by T.E.S.T. we can draw the overall conclusion that 
the substance under investigation is non-mutagenic. Table 16 (page 109) is the tabular format 
for summarizing WOE.assessment of Valproic acid in a qualitative way. 
Table 16. Optional tabular format for summarizing weight of evidence assessment of Valproic 
acid 
Question Hazard identification 
Assemble the evidence Select evidence Nine (Q)SAR models from two in silico 
platforms, a read-across tool, ToxRead and a 
tool to investigate the dissimilarities between 
the similar compounds and the target, 
ToxDelta, are chosen for testing mutagenicity 
effect of Valproic acid. The used platforms 
provide both predicted values from several 
models, and indicate similar substances with 
experimental values, which can be used for 
read-across. 
Lines of evidence All the models estimated the chemical as non-
mutagen. The exception were a few examples 
of similar compounds in the T.E.S.T prediction 
outcome. To evaluate the relevance of these 
similar molecules in a read-across approach we 
used ToxDelta. The dissimilar substructures 
between the target and the source molecules 
are investigated. Valproic acid do not contain 
any mutagenic structural alert, so the similar 
compounds assigned by T.E.S.T. to the target 
are not relevant for the assignment of the same 
property to the target molecule. 
Weight the evidence Methods VEGA provides applicability domain index 
that is a sort of quantitative measurement of 
reliability and values higher than 0.8 are 
considered more reliable. T.E.S.T. applies a 
filter to eliminate not reliable predictions. 
ToxRead indicates the structural alerts found in 
the target which are associated with the effect 
and an arbitrary number of similar compounds 
which share that rule with the target. ToxRead 
also reveals the structure alerts present in the 
source compounds, and by using ToxDelta user 
can check if these active moieties belong to the 
dissimilarities between the two molecules. For 
Valproic acid this further evaluation is 
performed on the similar compounds identified 
by T.E.S.T. to check the relevance and the 
reliability of the similar compounds to be used 
in terms of read-across.  
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Results All the predictions obtained from VEGA and 
T.E.S.T.are reliable in terms of applicability 
domain index. No structural alert in the 
structure of Valproic acid is identified by 
ToxRead. A further evaluation is performed on 
the similar compounds suggested by T.E.S.T. 
with contrary mutagenic effect using ToxDelta 
to check the relevance of the similar 
compounds. The results showed that the 
potential structure alert found in the source 
compound was not present in Valproic acid, 
and therefore is not relevant. 
Integrate the evidence Methods Considering the reliability and relevance of 
each estimation obtained from individual 
mutagenicity prediction models, the results are 
integrated, together with the consistency of the 
predictions. These results can be used by an 
expert judgement to reach a conclusion on the 
probability of mutagenicity effect. 
Results All the in silico methods used in this practice 
are in concordance with high level of reliability 
and relevance. Considering the evidence 
obtained from these predictions, it can be 
concluded by expert judgement that the target 
compound is not mutagenic. 
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6.2 Second Case Study: Diclofenac 
 
Figure 12. Diclofenac, CAS number: 15307-86-5 
The second case study presented in this dissertation is Diclofenac (Figure 12-page 111) (CAS 
number: 15307-86-5). Herein the use of WOE approach when information is derived from non-
testing methods, such as (Q)SAR and read-across is described. For the estimation of 
mutagenicity we used two in silico platforms: VEGA (http://www.vega-qsar.eu) and T.E.S.T. 
(http://www.epa.gov/nrmrl/std/qsar/qsar.html#TEST). Also ToxRead (http://www.toxread.eu) 
as a read-across tool is used for the further investigation of the target molecule. Table 17 (page 
112) shows all the predictions of the (Q)SAR models used in this study. All the VEGA models 
estimate the compound as non-mutagenic with applicability domain index higher than 0.77, 
except KNN/read-across with applicability domain equal to 0.65. The VEGA Consensus model 
predicts the target substance as non-mutagenic based on the presence of experimental value in 
two models (CAESAR and SARpy/IRFMN) even though one of the models outcome does not 
agree with the other. The VEGA models whenever the experimental value is available for a 
molecule, give the experimental value as an output of the prediction, while T.E.S.T. presents the 
experimental value along with the results of the predictions. Contrarily, T.E.S.T. overall 
estimation for Diclofenac is mutagenic. The compound is not present in the training set either in 
the external test set of T.E.S.T. The consensus overall result of T.E.S.T. is the result of the 
integration of the predictions of the three models predictions (Hierarchical, FDA and Nearest 
neighbour). The Hierarchical model predicts the substance as non-mutagenic, while FDA and 
Nearest neighbour predictions are mutagenic. Together with these predictions also two tables of 
similar compounds extracted from the training and test sets are provided by T.E.S.T. Table 18 
(page 113) reports the first two similar chemicals obtained from this table of similar 
compounds, with their similarity coefficient, experimental and predicted values. We selected the 
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first chemical similar to Diclofenac: N-[(2,4,5-Trichlorophenoxy)acetyl]-L-aspartic acid (CAS 
number: 66789-80-8), to further analyse the similarities and the differences between this 
chemical and the target chemical making use of ToxDelta. 
Table 17. Summary of the prediction results of non-testing models for Diclofenac 
Software Model/method Experimental 
value 
Results Predicted value Applicability Domain 
Index 
VEGA CONSENSUS  Non-mutagenic   
CAESAR Non-mutagenic Non-mutagenic  1 
SARpy/IRFMN Non-mutagenic Non-mutagenic  1 
ISS N/A* Non-mutagenic  0.772 
KNN/Read-
across 
N/A Mutagenic  0.652 
T.E.S.T.* Consensus  
 
Mutagenic 0.53 Internally checked 
Hierarchical  N/A Non-Mutagenic 0.40 Internally checked 
FDA  N/A Mutagenic 0.51 Internally checked 
Nearest 
neighbour  
N/A Mutagenic 0.67 Internally checked 
ToxRead Read-across  4 SAs:Non-
mutagenic 
1 SA: 
mutagenic 
 N/A 
*Not availbale 
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Table 18. Experimental and prediction values for N-[(2,4,5-Trichlorophenoxy)acetyl]-L-aspartic 
acid (CAS 66789-80-8) and N-[4-(4-Amino-3-chlorobenzyl)-2-chlorophenyl]acetamide (CAS 
91575-28-9) as examples of similar chemicals to Diclofenac in the outcome of T.E.S.T. 
CAS Structure 
Similarity 
Coefficient 
Experimental value Predicted value 
66789-80-8  
 
0.61  0.00  0.02 
91575-28-9 
 
0.70 1.00 0.80 
 
As shown in Table A.4 N-[(2,4,5-Trichlorophenoxy)acetyl]-L-aspartic acid (CAS 66789-80-8) 
and N-[4-(4-Amino-3-chlorobenzyl)-2-chlorophenyl]acetamide (CAS 91575-28-9) are the most 
similar chemicals identified by T.E.S.T (similarity coefficient: 0.61 and 0.70, respectively). 
While the experimental value and the predicted value of the first molecule are non-mutagenic, 
mutagenicity effect of the second molecule is indicated as positive. ToxDelta is used to 
investigate the structural similarities and dissimilarities, and the presence of mutagenic or non-
mutagenic rules in Diclofenac and each similar substance. Figure 13 (page 115) shows the 
results of ToxDelta for the comparison between the target and each similar molecule. The MCS 
extracted from the two structures is illustrated on the top of the panel, while the dissimilar 
substructures of each molecule are listed below the corresponding molecules. In the case of the 
mutagenic similar compound (CAS 91575-28-9), on the right part of the figure, there are four 
fragments not in common between the target and the similar compound, two fragments present 
in the target, and two in the similar compound. The two fragments related to Diclofenac appear 
also as fragments in the comparison with the first similar compound, and we know that both 
Diclofenac and the similar compound are not toxic. Thus, we focus our attention to the other 
two fragments. The fragment CH3-C=O is not associated with any mutagenic activity. This can 
be verified for instance with ToxRead, studying Acetone. Figure 14 (page 116) reports the 
114 
 
dissimilar substructure in the target and the second similar chemical (CAS 91575-28-9) with 
mutagenic result. The presence of p-toluidine may trigger mutagenicity in a chemical. We also 
notice that the fragment Diphenylamine present in Diclofenac is a non-mutagenic SA.  
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(a)                                                                          (b) 
Figure 13. ToxDelta outcome for the comparison between Diclofenac and a) N-[(2,4,5-
Trichlorophenoxy)acetyl]-L-aspartic acid (CAS 66789-80-8), b) N-[4-(4-Amino-3-
chlorobenzyl)-2-chlorophenyl]acetamide (CAS 91575-28-9)  
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Figure 14. ToxDelta outcome of the dissimilar substructure remaining after the subtraction of the 
MCS and the structural rules identified inside the dissimilar substructure of N-[4-(4-Amino-3-
chlorobenzyl)-2-chlorophenyl]acetamide (CAS 91575-28-9) (molecule #2)  
 
Additionally, Diclofenac is analyzed by ToxRead to identify all the SAs present in the 
molecular structure, either mutagenic or non-mutagenic, together with the most structurally 
similar substances present in the database of ToxRead. Figure 15 (page 117) shows the outcome 
chart of ToxRead with the target substance in the middle, encircled by three similar substances 
(two mutagenic and one non-mutagenic). In addition, six SAs are identified and are connected 
to the target by straight arrows. These SAs consist of five non-mutagenic rules and one 
mutagenic rule. The list of the identified rules is reported in Table 19 (page 118). In fact, the 
mutagenic rule identified by ToxRead (MNM37) is a substructure of the non-mutagenic rule 
(SM197) present in the target substance, similar to the mutagenic rule identified by ToxDelta 
(Figure 16-page 118). The two mutagenic similar compounds indicated by ToxRead are 
analysed by ToxDelta for investigating the dissimilarities (Figure 17-page 118). Both similar 
chemicals contain Phenylamine SA as a mutagenic rule. As implied in the preceding section, 
this active SA is a part of a bigger SA identified in Diclofenac with non-mutagenic effect. This 
means the effect of the smaller SA is overcome by the parent SA which has a larger overlap 
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with the target compound. This important difference between the target and the similar 
compounds explains the different mutagenicity effect by means of a structure-based method, 
analysing the active and inactive rules inside the structure of the chemicals. Table 20 (page 119) 
is the tabular format for summarizing WOE assessment of Diclofenac in a qualitative way. 
 
Figure 15. ToxRead chart for the target molecule Diclofenac. The target substance molecule is 
shown on the right side and the identified non-mutagenic and mutagenic rules are listed below 
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Table 19. The mutagenicity and non-mutagenicity rules identified by ToxRead in the structure of 
Diclofenac 
Name Effect Source Experimental 
accuracy 
SMARTS P-value 
SM183 Non-mutagenic SARpy 0.75 c1(cc(ccc1)Cl)Cl <10e-6 
CRM6 Non-mutagenic CRS4 0.55 CC(=O)O 0.00075 
CRM60 Non-mutagenic CRS4 0.72 c1cc(cc(c1)Cl)Cl 0.00009 
SM195 Non-mutagenic SARpy 0.68 C(=O)(O)Cc1ccccc1 0.00511 
SM197 Non-mutagenic SARpy 0.65 N(c1ccccc1)c2ccccc2 0.00477 
MNM37 Mutagenic IRFMN 0.68 N- Ar <10e-6 
 
Figure 16. (a) SM197, Diphenylamine: non-mutagenic rule, (b) MNM37, Phenylamine: 
mutagenic rule identified by ToxRead 
 
 
 
 
 
 
 
 
Figure 17. The two similar chemicals to Diclofenac extracted by ToxRead with mutagenic effect 
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Table 20. Optional tabular format for summarizing weight of evidence assessment of 
Diclofenac 
Question Hazard identification 
Assemble the evidence Select 
evidence 
Nine (Q)SAR models from two in silico platforms, 
a read-across tool, ToxRead and a tool to 
investigate the dissimilarities between the similar 
compounds and the target, ToxDelta, are chosen for 
testing mutagenicity effect of Diclofenac. The used 
platforms provide both predicted values from 
several models, and indicate similar substances 
with experimental values, which can be used for 
read-across. 
 Lines of 
evidence 
The consensus model of VEGA estimated the 
chemical as non-mutagen. All the models in VEGA 
except KNN predicted the target as non-mutagenic. 
The consensus model of T.E.S.T. predicted the 
target as mutagenic. All the models in T.E.S.T. 
except Hierarchical predicted the compound as 
mutagenic with moderate predicted values. A 
number of similar compounds are suggested by 
T.E.S.T. The first two similar compounds are 
selected for a further investigation. The 
dissimilarities between the target and each similar 
compound is evaluated. Further analysis by 
ToxDelta, shows the presence of phenylamine in 
the similar mutagenic chemical which trigger the 
mutagenic effect. Although Phenylamine as a 
mutagenic SA with accuracy=0.68 exist in 
Diclofenac, it is a part of a bigger SA 
(Diphenylamine) with non-mutagenic effect. Due 
to this difference, the similarity of this chemical is 
not relevant to be used in a read-across way. 
Further evaluation by ToxRead, indicates five non-
mutagenic rules and one mutagenic rule in the 
structure of the target. Similarly, in the results of 
ToxRead the mutagenic SA is Phenylamine which 
is present in the bigger non-mutagenic SA, 
Diphenyamine.  
Weight the evidence Methods VEGA provides ADI that is a sort of quantitative 
measurement of reliability and values higher than 
0.8 are considered more reliable. T.E.S.T. applies a 
filter to eliminate not reliable predictions. ToxRead 
indicates the structural alerts found in the target 
which are associated with the effect and an 
arbitrary number of similar compounds which 
share that rule with the target. ToxRead also 
reveals the SAs present in the source compounds, 
and by using ToxDelta user can check if these 
active moieties belong to the dissimilarities 
between the two molecules. For Diclofenac a 
further evaluation is performed on the similar 
compound indicated by T.E.S.T. and ToxRead to 
check the relevance and the reliability of the 
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similar compounds to be used in terms of read-
across.  
 Results All the predictions obtained from VEGA and 
T.E.S.T. are reliable in terms of ADI. A further 
evaluation is performed on the similar compound 
suggested by T.E.S.T. and ToxRead to check the 
relevance of the similarity to be used in read-across 
terms. Five non-mutagenic and one mutagenic rules 
in the structure of Diclofenac are identified by 
ToxRead. The results of dissimilarities indicated 
the presence of a mutagenic SA in Diclofenac 
which is a substructure of a bigger non-mutagenic 
SA, and therefore its toxic effect is not relevant. 
Integrate the evidence Methods Inconsistency is present in the results of the two 
main platforms. ToxDelta and ToxRead both 
indicate the presence of a mutagenic rule in the 
structure of Diclofenac, but VEGA estimates the 
compound as non-mutagenic based on two 
experimental values present in its models. High 
ADI are assigned to individual predictions of the 
models, the conflict in the results is assessed by 
ToxDelta. Further investigation on the similar 
compounds suggested by T.E.S.T. and ToxRead is 
performed to evaluate the similarities and the 
differences between each pair of molecules and to 
reach a conclusion based on read-across. The 
reliability and relevance of all the similar 
compounds can be evaluated in this way. The non-
relevance of phenylamine SA in the target makes 
the process of decision-making easier. Also the 
expert may find confidence in experimental results 
(in this case non-mutagenic effect). 
 Results The in silico methods used in this practice are not 
in concordance. The similar compounds suggested 
are useful for defining the reliability and relevance. 
Considering the evidence obtained from these 
predictions, it can be concluded that Diclofenac is 
not mutagenic. 
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Appendices 
Metal Oxide nanomaterials Genotoxicity Model Supplementary Information 
Table S1 A. Assessment of the quality of the data points. Adherence to the minimum comet assay requirements (yellow boxes) and minimum physicochemical 
characterization (green boxes) of nanomaterials was evaluated by answering the questions in the header. Each data point represents a study reporting comet assay 
results for one or more metal oxides with the same or different core composition. The comet assay procedure and the characterization was done in the same way for 
nano metal oxides of the same data point. For a data point, genotoxicity results of the test may differ between the metal oxides with different core composition. If the 
question in the header was answered in the data point, then it is assigned by “Y” and if not by “N”.  
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CuO 1 Alkaline None Y Y Y Y Y Y Y Y Y Y N Y Wang et al., 
2012 
+ 
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Fe2O3 1 Alkaline None Y Y Y Y Y Y Y Y Y Y Y Y Auffan et 
al., 2006 
- 
TiO2 1 Alkaline None Y Y Y Y Y Y Y Y Y Y Y Y Barillet et 
al., 2010 
+ 
TiO2 1 Alkaline FPG Y Y Y Y Y Y Y Y Y Y N N Shukla et 
al., 2011 
+ 
TiO2 1 Alkaline FPG Y Y Y Y Y Y Y Y Y Y Y Y Shukla et 
al., 2013 
+ 
TiO2 1 Neutral None Y Y Y Y Y Y Y Y Y Y Y Y Saquib et 
al., 2012 
+ 
TiO2 1 Alkaline 
EndoIII 
and 8oxoG 
Y Y Y Y Y Y Y Y Y Y N Y Woodruff 
et al., 2012 
+ 
ZnO 1 Alkaline 8oxodG Y Y Y Y Y Y Y N Y Y N N 
Valdiglesia
s et al., 
2013 
+ 
ZnO 1 Alkaline None Y Y Y Y Y Y Y Y Y Y Y Y Sharma et 
al., 2009 
+ 
MgO 1 - - Y Y Y Y Y Y Y Y Y Y Y Y Mahmoud 
et al., 2016 
+ 
TiO2 2 Alkaline None Y Y Y Y Y Y N Y Y Y Y N Roszak et 
al., 7 
- 
TiO2 2 Alkaline None Y Y Y Y Y Y N N Y Y Y Y Chen et al., 
Febbraio 5 
- 
TiO2 2 Alkaline 
FPG and 
EndoIII 
Y Y Y Y Y Y N N Y Y Y N Reeves et 
al., 2008 
+ 
TiO2 2 Alkaline None Y Y Y Y Y Y N Y Y Y Y Y Rajapakse 
et al., 2013 
+ 
TiO2 2 Alkaline None Y Y Y Y Y Y N Y Y Y Y Y Prasad et 
al., 2013 
+ 
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ZnO 2 Alkaline None Y Y Y Y Y Y N Y Y Y Y N 
Hackenberg 
et al., 
2011b 
+ 
Al2O3 2 Very alkaline None Y Y Y Y Y Y N N Y Y N N Kim et al., 
2009 
+ 
Bi2O3 2 Alkaline None Y Y Y Y Y Y N N Y Y Y N Liman, 
2013 
+ 
CeO2 2 Very alkaline None Y Y Y Y Y Y N Y Y Y Y Y De Marzi et 
al., 2013 
+ 
SiO2 2 Alkaline None Y Y Y Y Y Y N N Y Y Y N Choi et al., 
2011 
+ 
TiO2 2 Neutral 
FPG and 
EndoIII 
Y Y Y Y Y Y N Y Y Y Y Y Petković et 
al., 2011a 
+ 
ZnO 2 Alkaline 
FPG and 
EndoIII 
Y Y Y Y Y Y N Y Y Y Y N Demir et 
al., 2014b 
+ 
SiO2 2 Alkaline FPG Y Y Y Y Y Y N Y Y Y Y Y Gehrke et 
al., 2011 
+ 
TiO2 2 Alkaline None Y Y Y Y Y Y N Y Y Y Y Y 
Bernardesc
hi et al., 
2010 
+ 
TiO2 2 Alkaline None Y Y Y Y Y Y N Y Y Y Y N Falck et al., 
2009 
+ 
TiO2 2 Alkaline FPG Y Y Y Y Y Y N Y Y Y Y Y Petković et 
al., 2011b 
+ 
TiO2, ZnO 2 Alkaline FPG Y Y Y Y Y Y N Y Y Y Y Y 
Kermaniza
deh et al., 
2013 
TiO2 (+), 
ZnO (+) 
ZnO 2 Alkaline None Y Y Y Y Y Y N Y Y Y Y N Alarifi et 
al., 2013c 
+ 
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V2O3 2 Alkaline None Y Y Y Y Y Y N Y Y Y Y N Lansiedel et 
al., 2009 
+ 
V2O5 2 Alkaline None Y Y Y Y Y Y N Y Y Y Y N Lansiedel et 
al., 2009 
- 
SiO2 3 Alkaline None Y N Y Y Y Y N N Y Y Y N Wang et al., 
2007a 
- 
TiO2, ZnO 3 Alkaline None Y N Y Y Y Y N Y Y Y Y N Demir et 
al., 2014a 
TiO2 (+), 
ZnO (+) 
TiO2, ZnO 2 Very alkaline None Y N Y Y Y Y N N Y Y N N Gopalan et 
al., 2009 
TiO2 (+), 
ZnO (+) 
TiO2 2 Alkaline None Y N Y Y Y Y Y Y Y Y Y N Prasad et 
al., 2014 
+ 
Al2O3, 
TiO2, ZrO2 
2 Alkaline 
FPG and 
EndoIII 
Y Y N Y Y Y N Y Y Y Y Y Demir et 
al., 2013 
Al2O3 (-), 
TiO2 (+), 
ZrO2 (-) 
CuO 3 Alkaline 
FPG and 
EndoIII 
Y Y N Y Y Y N Y Y Y Y Y 
Di 
Bucchianic
o et al., 
2013 
+ 
ZnO 2 Alkaline None Y Y N Y Y N Y Y Y Y N Y Mu et al., 
2014 
+ 
TiO2 2 Alkaline 8oxodG Y Y N Y Y N Y Y Y Y Y Y Jugan et al., 
2012 
+ 
CuO, 
TiO2, ZnO 
2 Alkaline FPG Y Y N Y Y Y Y Y Y Y Y Y Bayat et al., 
2014 
CuO (+), 
TiO2 (+), 
ZnO (+) 
SiO2 2 Alkaline None Y Y N Y Y Y Y Y Y Y Y N Barnes et 
al., 2008 
- 
TiO2 2 Alkaline None Y Y N Y Y Y Y Y Y Y Y Y 
Hamzeh 
and 
Sunahara, 3 
- 
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TiO2 2 Alkaline None Y Y Y Y Y N N Y Y Y Y N Kang et al., 
2008 
- 
CuO, 
Fe2O3, 
Fe3O4, 
TiO2 
2 Alkaline FPG Y Y Y Y Y N N Y Y Y Y Y 
Karlsson et 
al., 2009 
CuO (+), 
Fe2O3 (-), 
Fe3O4 (-), 
TiO2 (+) 
SiO2, ZnO 2 Alkaline None Y Y Y Y Y N N Y Y Y Y Y Yang et al., 
2009 
SiO2 (+), 
ZnO (+) 
CuO, 
Fe2O3, 
Fe3O4, 
TiO2, ZnO 
2 Alkaline FPG Y Y Y Y Y N N Y Y Y Y Y 
Karlsson et 
al., 2008 
CuO (+), 
Fe2O3 (-), 
Fe3O4 (-), 
TiO2 (+), 
CuO (-), 
ZnO (+) 
Fe3O4 2 Alkaline None Y Y Y Y Y N N Y Y Y Y N Ahamed et 
al., 2013 
+ 
CuO 2 Alkaline None Y Y Y Y Y N N Y Y Y Y Y Isani et al., 
Gennaio 11 
- 
Fe2O3 2 Alkaline None Y Y Y Y Y N N Y Y Y Y Y Freyria et 
al., 2012 
+ 
SiO2 2 Very alkaline None Y Y Y Y Y N N N Y Y N N Wang et al., 
2007b 
- 
TiO2 2 Very alkaline None Y Y Y Y Y N N N Y Y N N Wang et al., 
2007c 
- 
CeO2 2 Alkaline None Y Y Y Y Y N N Y Y Y Y Y Kumari et 
al., 2014 
+ 
CeO2 2 Alkaline None Y Y Y Y Y N N Y Y Y Y Y Auffan et 
al., 2009 
+ 
Co3O4 2 Very alkaline None Y Y Y Y Y N N Y Y Y Y Y Alarifi et 
al., 2013b 
+ 
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Fe3O4 2 Alkaline None Y Y Y Y Y N Y Y Y Y N Y Könczöl et 
al., 2011 
+ 
SiO2 2 Alkaline 8oxodG Y Y Y Y Y N Y Y Y Y N N Jin et al., 
2007 
- 
TiO2 2 Alkaline None Y Y Y Y Y N Y Y Y Y Y Y Ghosh et 
al., 2013 
+ 
Fe2O3, 
Fe3O4, 
TiO2 
2 Alkaline FPG Y Y Y Y Y N Y Y Y Y Y Y Guichard et 
al., 2012 
Fe2O3 (-), 
Fe3O4 (-), 
TiO2 (+) 
TiO2, ZnO 2 Alkaline FPG Y Y Y Y Y N Y N Y Y Y Y 
Kermaniza
deh et al., 
2012 
+ 
TiO2 2 Alkaline None Y Y Y Y Y N Y Y Y Y N N Ghosh et 
al., 2010 
+ 
CuO 2 Alkaline None Y Y Y Y Y N Y Y Y Y Y Y Alarifi et 
al., 2013a 
- 
SiO2 2 Alkaline 
FPG and 
8oxoG 
Y Y Y Y Y N Y N Y Y N Y Gonzalez et 
al., 2010 
- 
TiO2 2 Very alkaline 8oxodG Y Y Y Y Y N Y N Y Y Y Y Wan et al., 
2012 
- 
SiO2 2 Alkaline FPG Y Y Y Y Y N Y Y Y Y Y Y Lankoff et 
al., 2013 
- 
ZnO 2 Alkaline None Y Y Y N Y N Y Y Y Y Y N Sarkar et 
al., 2014 
+ 
TiO2 2 Alkaline None Y Y Y Y Y N N Y Y Y Y Y 
Hackenberg 
et al., 
2011a 
- 
MgO, 
SiO2, 
TiO2, ZnO 
2 Alkaline FPG Y Y N Y Y N Y Y Y Y Y Y 
Gerloff et 
al., 2009 
MgO (-), 
SiO2 (-), 
TiO2 (+), 
ZnO (+) 
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Fe3O4 3 Alkaline None Y N N Y N Y Y Y Y Y Y N Gomaa et 
al., 2013 
+ 
CeO2 3 Alkaline None Y N Y N Y Y N Y Y Y Y Y Courbiere 
et al., 2013 
+ 
TiO2 3 Alkaline FPG Y Y N N Y N Y Y Y Y Y N Gurr et al., 
2005 
+ 
TiO2 3 Alkaline None Y Y N Y Y N N Y Y Y N N Botelho et 
al., 2014 
+ 
CuO 3 Alkaline None Y Y N Y Y N N Y Y Y Y Y Midander et 
al., 2009 
+ 
Fe2O3, 
TiO2 
3 Alkaline 8oxodG Y Y N Y N N Y Y Y Y Y Y 
Bhattachary
a et al., 
2009 
Fe2O3 (-), 
TiO2 (+) 
SiO2 3 Alkaline None Y Y Y N Y N N Y Y Y Y Y Gong et al., 
2012 
- 
CeO2 NR Alkaline None Y N N Y Y N N Y Y Y N N Pierscionek 
et al., 2010 
- 
CeO2, 
Co3O4, 
Fe3O4, 
NiO, SiO2 
NR Alkaline FPG Y N N Y Y N N Y Y Y Y Y 
Kain et al., 
2012 
CeO2(+), 
Co3O4 (+), 
Fe3O4 (+), 
NiO (+), 
SiO2 (-) 
SnO2 NR Alkaline None Y N Y N Y N N Y Y Y N Y 
Khan and 
Husain, 
2014 
- 
Fe3O4 NR _ _ _ _ _ _ _ _ _ _ _ _ _ _ Hong et al., 
2011 
excluded 
TiO2 NR Alkaline 
FPG and 
EndoIII 
Y N N Y N N N Y Y Y Y Y Sekar et al., 
2014 
+ 
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Table S1 B. Assessment of the size measurement and crystallographic characterization as was reported in the related literature sources: transmission electron 
microscopy (TEM), dynamic light scattering (DLS), SEM, PCS, expressed in nm, Brunette-Emmet- Teller (BET) and X ray diffraction analysis expressed in m2g-1, 
Metal oxides core Nominal size TEM analysis DLS analysis, SEM PCS BET specific surface area (m2g-1) X ray diffraction analysis (m2g-1) - Crystallographic 
shape is reported in the corresponding column. 
References 
Metal 
oxides 
core 
Nominal size 
(nm) 
Genotoxicity for each 
size reported in the 
same paper 
TEM (nm) 
DLS 
(nm) 
SEM PCS 
BET 
(m2g-1) 
XRD 
(m2g-1) 
Crystallographic shape 
Wang et al., 
2012 
CuO 10 + 20-40 276.4      
Auffan et al., 
2006 
Fe2O3 6 - 6       
Könczöl et al., 
2011 
Fe3O4 20-60 +    311    
Jin et al., 2007 SiO2 50 -        
Wang et al., 
2007a 
SiO2 12.2 -       Quarz 
139 
 
Roszak et al., 
2013 
TiO2 25 -  300   27.1  
Mixture of rutile and 
anatase 
Chen et al., 
2014 
TiO2 75±15 -  
473.6 
and 
486.5 
(depen
ding on 
the 
mediu
m) 
     
Hackenberg et 
al., 2011a 
TiO2 <25 - 285 ± 52       
Ghosh et al., 
2013 
TiO2 100 + 58.93±7.08 
6180.7
3      
Botelho et al., 
2014 
TiO2 21 and <25 +  
160.5 
and 
420.7 
     
Barillet et al., 
2010 
TiO2 NR + 12±3    17  
Anatase (75%), Anatase 
(100%) 
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Gurr et al., 
2005 
TiO2 10 and 20 +       Anatase 
Kang et al., 
2008 
TiO2 25 + 
Between 15 
and 30, 
agglomerati
on size 
285±52 
   50  
Mixture of Anatase (70%) 
and Rutile (85%) 
Reeves et al., 
2008 
TiO2 5 +       Anatase 
Shukla et al., 
2011 
TiO2 NR + 50 
124.9 
(water)      
Shukla et al., 
2013 
TiO2 NR + 30 to 70 
124.9 
(water) 
and 
192.5 
(mediu
m) 
    Anatase 
Rajapakse et 
al., 2013 
TiO2 NR + 15 820   190-290  Anatase 
Saquib et al., 
2012 
TiO2 NR +  
13 
(water), 
152 
   30.6 Polyhedral rutile 
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(mediu
m) 
Prasad et al., 
2013 
TiO2 27.5 +     49  
Mixture of anatase (86%) 
and rutile (14%) 
Hackenberg et 
al., 2011b 
ZnO <100 + 
86 ± 41 x 
42 ± 21       
Karlsson et al., 
2009 
CuO 42 + 
Between 20 
and 40 
200      
Karlsson et al., 
2009 
Fe2O3 29 - 30-60 1600      
Karlsson et al., 
2009 
Fe3O4 29 - 30-60 1600      
Karlsson et al., 
2009 
TiO2 63 + 20 to 100 300      
Yang et al., 
2009 
SiO2 NR + 20.2±6.4       
142 
 
Yang et al., 
2009 
ZnO NR + 20.2 ± 6.4       
Demir et al., 
2013 
Al2O3 16.7 -  
16.7±1.
3      
Demir et al., 
2013 
TiO2 2.3 +  1.8-2.8      
Demir et al., 
2013 
ZrO2 6 - 6 ± 0.8       
Pierscionek et 
al., 2010 
CeO2 NR - 5.5     6.3  
Kain et al., 
2012 
CeO2 <25 + 4-25 225      
Kain et al., 
2012 
Fe3O4 30 + 20-40 200      
Kain et al., 
2012 
NiO <50 + 
Between 2 
and 67 
167      
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Kain et al., 
2012 
SiO2 15 - 
Between 11 
and 27 
8.7      
Midander et 
al., 2009 
CuO 28 +   50     
Karlsson et al., 
2008 
CuO 42 + 20-40 220      
Karlsson et al., 
2008 
Fe2O3 29 - 30 and 60 1580      
Karlsson et al., 
2008 
Fe3O4 20-30 - 20-40 200      
Karlsson et al., 
2008 
ZnO 71 + 20-200 320      
Di 
Bucchianico et 
al., 2013 
CuO NR 
in RAW 264.7 + in 
PBL cells - 
7±1 
(spheres), 
7±1 x 
40±10 
(rodes), 
1200±250 x 
270±50 x 
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30±10 
(spindles) 
Bayat et al., 
2014 
CuO <50 +  
1511±4
68 
(water), 
3475±3
57 
(mediu
m) 
    Monoclinic crystals 
Bayat et al., 
2014 
TiO2 3-17 +  
99.20±
6.2     
Rutile 
Bayat et al., 
2014 
ZnO <100 +  
612±10
.9 
(water) 
5294 ± 
3184 
(mediu
m) 
    Hexagonal wurtzite 
Guichard et al., 
2012 
Fe2O3 NR - 35±14 
900 
(water)   
39   
Guichard et al., 
2012 
Fe3O4 NR - 27±8 Betwee
n 700 
  40   
145 
 
and 
800 
Guichard et al., 
2012 
TiO2 NR + 
14 ± 4 and 
25 ± 6    
149   
Bhattacharya 
et al., 2009 
Fe2O3 90 - 93 68      
Ahamed et al., 
2013 
Fe3O4 NR + 24.83 
247 
(water), 
213 
(mediu
m) 
     
Gomaa et al., 
2013 
Fe3O4 NR + 8±2       
Gerloff et al., 
2009 
MgO 8 -     200   
Gerloff et al., 
2009 
SiO2* 50±3 -        
146 
 
Gerloff et al., 
2009 
TiO2 20-80 +     50  Mixture of anatase (80%) 
Gerloff et al., 
2009 
ZnO 10 and 20 +     70 and 50   
Barnes et al., 
2008 
SiO2 
Five 
different 
samples of 
nominal size 
: 30-400 
-       Amorphous 
Kermanizadeh 
et al., 2012 
TiO2 
Different 
samples of 7, 
10 and 94 
+ 
4-8/50-100, 
80-400, 1-
4/100/100-
200 
Differe
nt 
sample
s: 185, 
742, 
203-
1487, 
339 
     
Kermanizadeh 
et al., 2012 
ZnO 100 + 
20-250/50-
350 
306      
Demir et al., 
2014a 
TiO2 21 and 50 +  
21 ± 
0.8 and 
50 ± 
0.5 
    
Respectively the two 
samples are anatase and 
mixture of anatase and 
rutile 
147 
 
Demir et al., 
2014a 
ZnO ≤35 and 50 +  35±1.1      
Sekar et al. 
(2014) 
TiO2 NR +   
10–20 
(anatas
e), 20-
150 
(anatas
e and 
rutile) 
 
132.73 
(anatase), 
20.75 
(anatase 
and 
rutile) 
 Anatase and rutile 
Mu et al., 2014 ZnO NR + 40±20     90 - 160 Uncoated zincite 
Ghosh et al., 
2010 
TiO2 100 +        
Courbiere et 
al., 2013 
CeO2 3 +  350      
Kim et al., 
2009 
Al2O3 <50 +        
Liman, 2013 Bi2O3 90-210 +        
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De Marzi et 
al., 2013 
CeO2 40 +   
16 to 
22 nm.     
Isani et al., 
Gennaio 11 
CuO NR +  
500 ± 
20 nm 
20 to 
200 nm     
Alarifi et al., 
2013a 
CuO 10 + 
Between 20 
and 40 
276.4 
(water)      
Freyria et al., 
2012 
Fe2O3 <100 +  
50 
(water)      
Wang et al., 
2007b 
SiO2 NR -       Crystalline 
Choi et al., 
2011 
SiO2 10 +        
Gonzalez et al., 
2010 
SiO2 25 - 
16.4± 2.5 
and 60.4± 
8.3 
110 
and 70     
Crystalline 
Gopalan et al., 
2009 
TiO2 NR +   40-70    Anatase 
149 
 
Gopalan et al., 
2009 
ZnO NR +   40-70     
Wang et al., 
2007c 
TiO2 NR +  
6.57 
nm; 8.2 
nm; 
196.52 
nm 
    Crystalline 
Woodruff et 
al., 2012 
TiO2 NR - 10x30      Anatase 
Wan et al., 
2012 
TiO2 28 -  280     
Anatase (90%) and rutile 
(10%) 
Petković et al., 
2011a 
TiO2 
<25 and 
<100 
+     
129.3 and 
116.7  
Rutile and anatase 
Valdiglesias et 
al., 2013 
ZnO 100 +  243.7   100   
Sarkar et al., 
2014 
ZnO NR - 
45-150 (75 
± 5 average 
diameter) 
45-150      
150 
 
Demir et al., 
2014b 
ZnO 
35 nm; 50-
80 nm 
+  
36.42; 
50.75      
Kumari et al., 
2014 
CeO2 <25 + 25±1.512 269.7      
Auffan et al., 
2009 
CeO2 7 +  15      
Alarifi et al., 
2013b 
Co3O
4 
NR + 21 264.8     ? 
Lankoff et al., 
2013 
SiO2 NR -   
Averag
e size 
10 to 
50 
 640-260  
SiO2 with three types of 
functionlaisation, 
amorphous 
Gong et al., 
2012 
SiO2 15, 30, 100 + 
14.6; 20.4; 
169.2 
14.6±0.
3, 
20.4±1.
7 and 
169.2±
3.1 (M
edium) 
    Amorphous 
Gehrke et al., 
2011 
SiO2 12; 40 - 
16-40 and 
50-100 
165 
and 
271 
  
200; 50; 
4  
Amorphous 
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Khan and 
Husain, 2014 
SnO2 NR - 25-32     11.2 Crystalline 
Bernardeschi 
et al., 2010 
TiO2 <25 +       Anatase 
Falck et al., 
2009 
TiO2 <25 +     222  Anatase (99.7%) 
Jugan et al., 
2012 
TiO2 12, 20, 25 + 12, 21, 24    
92; 73; 
46  
Anatase and rutile 
Hamzeh and 
Sunahara, 2013 
TiO2 
5.9, 34.1, 
15.5, 1-10 
+  
460, 
400, 
420, 
600 
    Anatase and rutile 
Prasad et al., 
2014 
TiO2 27.5 +     49  
Anatase (86%) and rutile 
(14%) 
Petković et al., 
2011b 
TiO2 <25 +     129.3 18 Anatase 
Kermanizadeh 
et al., 2013 
TiO2 NR + 4-8/50-100, 
80-400, 80-
      
152 
 
400, 80-
400 
Sharma et al., 
2009 
ZnO NR + 17 263      
Alarifi et al., 
2013c 
ZnO NR + 
20-250/50-
350    
14 
70 to > 
100 
Zincite 
Kermanizadeh 
et al., 2013 
ZnO NR + 
20–200/10–
450 and 
20–200/ 
10–450 
   14 and 18 
70 to 
>100 and 
58–93 
nm 
 
Kain et al., 
2012 
Co3O4 <50 + 9-62 222      
Landsiedel, 
2009 
V2O3 <50 +     
Average 
diameter 
25 nm 
Length 
100 – 
1.000 nm 
  
Landsiedel, 
2009 
V2O5 70 -     
Rod-
shaped, 
spherical 
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diam.170
–180 nm 
*luminescent silica nanoparticles 
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Table S2. Calculated values of the MOPAC descriptors reported in Table 6 (page 70), for all the nanomaterials reported in Table 5 (page 69)  
Metal 
oxides  
HF 
(KCAL/MOL) 
TE 
(eV) 
EE 
(eV) 
CORE 
(eV) 
COSMO-SA 
(A°2) 
COSMO 
(A°3) 
IP 
(eV) 
HOMO 
(eV) 
LUMO 
(eV) 
N.Fl 
(adimensional) 
MW 
(g/mol) 
Al2O3 -5162.20 -15398.50 -175859.00 160460.10 679.16 1280.89 7.32 -7.32 -1.37 180 1529.42 
Bi2O3 -277.49 -17963.90 -234375.00 216410.80 852.64 1858.52 6.43 -6.44 -2.48 224 7455.34 
CeO2 -4031.46 -20269.60 -286812.00 266542.40 878.68 1998.51 7.07 -7.07 -0.29 240 5507.67 
Co3O4 -445.89 -19078.70 -265366.00 246287.20 517.86 883.12 7.36 -7.36 -1.90 204 1926.38 
CuO -1947.87 -46652.20 -967883.00 921230.80 619.14 1027.11 6.84 -6.84 -3.62 408 3818.18 
Fe2O3 -5235.58 -57293.30 -1510297.00 1453004.00 1003.65 2418 8.51 -8.51 -5.22 578 5429.54 
Fe3O4 -1300.94 -19023.70 -233472.00 214448.10 538.81 968.38 8.76 -8.76 -4.39 192 1852.31 
MgO -3334.27 -10296.80 -101052.00 90755.60 516.44 948.36 7.29 -7.29 -3.84 128 1289.74 
NiO -1783.99 -21622.30 -415687.00 394064.50 462.73 749.07 3.46 -3.46 0.83 256 2390.7 
SiO2 -10558.30 -44533.20 -1040743.00 996210.20 1306.9 2961.68 7.74 -7.74 -3.67 512 3845.4 
SnO2 -3521.02 -32654.60 -652905.00 620250.90 1043 2362.53 6.94 -6.94 -1.54 384 7233.06 
TiO2 -4946.57 -21549.70 -320025.00 298475.60 823.4 1688.85 6.57 -6.57 -3.61 256 2556.76 
V2O3 -4329.18 -27328.50 -540060.00 512731.70 862.78 1869.59 4.94 -4.94 -1.80 336 3597.15 
V2O5 -2379.90 -13846.20 -158034.00 144188.10 501.4 816.4 6.05 -6.05 -1.90 160 1455.04 
ZnO -1666.65 -11658.30 -108506.00 96847.25 688.93 1058.82 6.10 -6.10 -2.52 144 2929.66 
ZrO2 -6591.16 -20819.40 -325388.00 304568.80 824.22 1875.04 2.18 -2.18 1.52 250 3669.34 
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Table S3. Scaled values of the quantum-chemically calculated descriptors of the metal oxide nanomaterials data set and the scale attributes 
Metal oxides 
core 
HF 
(kcal/mol) 
TE 
(eV) 
EE 
(eV) 
CORE 
(eV) 
COSMO
-SA 
(A°2) 
COSMO 
(A°3) 
IP 
(eV) 
HOMO 
(eV) 
LUMO 
(eV) 
N.Fl 
(adimensional) 
MW 
(g/mol) 
Al2O3 -1.1367 -0.5281 -0.2843 0.2719 0.8312 0.7381 1.0607 -1.0606 -0.4633 0.5696 0.3691 
Bi2O3 -0.0611 -0.6161 -0.3789 0.3666 1.0435 1.0710 0.9318 -0.9331 -0.8387 0.7088 1.7991 
CeO2 -0.8877 -0.6952 -0.4636 0.4516 1.0754 1.1516 1.0245 -1.0244 -0.0981 0.7595 1.3291 
Co3O4 -0.0982 -0.6544 -0.4290 0.4173 0.6338 0.5089 1.0665 -1.0664 -0.6425 0.6455 0.4649 
CuO -0.4289 -1.6001 -1.5646 1.5608 0.7578 0.5919 0.9912 -0.9911 -1.2242 1.2911 0.9214 
Fe2O3 -1.1529 -1.9651 -2.4415 2.4617 1.2284 1.3934 1.2332 -1.2331 -1.7653 1.8290 1.3102 
Fe3O4 -0.2865 -0.6525 -0.3774 0.3633 0.6594 0.5580 1.2694 -1.2693 -1.4846 0.6076 0.4470 
MgO -0.7342 -0.3532 -0.1634 0.1538 0.6321 0.5465 1.0564 -1.0563 -1.2986 0.4050 0.3112 
NiO -0.3928 -0.7416 -0.6720 0.6676 0.5663 0.4316 0.5014 -0.5013 0.2807 0.8101 0.5769 
SiO2 -2.3250 -1.5274 -1.6824 1.6878 1.5995 1.7067 1.1216 -1.1215 -1.2411 1.6202 0.9280 
SnO2 -0.7753 -1.1200 -1.0555 1.0508 1.2765 1.3614 1.0057 -1.0056 -0.5208 1.2151 1.7455 
TiO2 -1.0893 -0.7391 -0.5173 0.5057 1.0078 0.9732 0.9520 -0.9520 -1.2208 0.8101 0.6170 
V2O3 -0.9533 -0.9373 -0.8730 0.8687 1.0560 1.0773 0.7158 -0.7158 -0.6087 1.0632 0.8681 
V2O5 -0.5241 -0.4749 -0.2555 0.2443 0.6137 0.4704 0.8767 -0.8766 -0.6425 0.5063 0.3511 
ZnO -0.3670 -0.3999 -0.1754 0.1641 0.8432 0.6101 0.8839 -0.8839 -0.8522 0.4557 0.7070 
ZrO2 -1.4514 -0.7141 -0.5260 0.5160 1.0088 1.0805 0.3159 -0.3159 0.5140 0.7911 0.8855 
Scale Attribute 4541.26 29155.80 618599.8 590239.50 817.06 1735.37 6.90 6.90 2.96 316.02 4143.91 
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Table S4. The number of total studies evaluated, studies with size range 5-100 nm, categorized 
in each reliability class and the overall genotoxicity for each metal oxide nanoparticles. 
 
  
Metal 
oxides 
core 
All 
studies 
studies 
with 
sizes 5-
100 Nm 
Class
1 
Class
2 
Class
3 
Class
4 
Positive 
results 
Negative 
results 
Overall 
genotox-
icity 
Al2O3 2 2 
 
2 
  
1 1 + 
NiO 1 1 
   
1 1 
 
+ 
Co3O4 2 2 
 
1 
 
1 2 
 
+ 
CuO 8 6 
 
5 1 
 
5 1 + 
Fe2O3 6 6 1 4 1 
 
1 5 - 
Fe3O4 7 7 
 
5 1 1 4 3 + 
TiO2 35 12 3 8 1 
 
8 4 + 
ZnO 15 15 2 13 
  
15 
 
+ 
SiO2 12 12 
 
10 1 1 3 9 - 
V2O3 1 1 
 
1 
  
1 
 
+ 
V2O5 1 1 
 
1 
   
1 - 
MgO 1 1 
 
1 
   
1 - 
ZrO2 1 1 
 
1 
   
1 - 
CeO2 6 5 
 
3 
 
2 4 1 + 
Bi2O3 1 1 
 
1 
  
1 
 
+ 
SnO2 1 1 
   
1 
 
1 - 
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Introduction 
Identification, classification, and risk assessment of carcinogenic chemicals by international 
organizations and national agencies of health and safety have made remarkable progress in 
recent years. The European Commission (EC) substantially modified and replaced the Directive 
67/548/EEC and 93/101/EEC with Regulation (EC) 1272/2008 on risks and hazards of 
carcinogens and mutagens [1]. The new regulation introduced the globally harmonized system of 
classification and labelling of chemicals. Under these directives experimental data studies on 
chemical carcinogens have been digitally collected with the aim of harmonizing national 
ABSTRACT 
In this study, new molecular fragments associated with genotoxic 
and nongenotoxic carcinogens are introduced to estimate the 
carcinogenic potential of compounds. Two rule-based 
carcinogenesis models were developed with the aid of SARpy: 
model R (from rodents’ experimental data) and model E (from 
human carcinogenicity data). Structural alert extraction method of 
SARpy uses a completely automated and unbiased manner with 
statistical significance. The carcinogenicity models developed in 
this study are collections of carcinogenic potential fragments that 
were extracted from two carcinogenicity databases: the 
ANTARES carcinogenicity dataset with information from 
bioassay on rats and the combination of ISSCAN and CGX 
datasets, which take into accounts human-based assessment. The 
performance of these two models was evaluated in terms of cross-
validation and external validation using a 258 compound case 
study dataset. Combining R and H predictions and scoring a 
positive or negative result when both models are concordant on a 
prediction, increased accuracy to 72% and specificity to 79% on 
the external test set. The carcinogenic fragments present in the two 
models were compared and analyzed from the point of view of 
chemical class. The results of this study show that the developed 
rule sets will be a useful tool to identify some new structural alerts 
of carcinogenicity and provide effective information on the 
molecular structures of carcinogenic chemicals. 
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measures on classification, packaging, and labelling of dangerous substances, to facilitate the 
establishment of a single market and to provide protection for public health and the 
environment. The new regulation complements the REACH regulation on the registration, 
evaluation, authorization, and restriction of chemicals. 
Research has provided evidence that chemicals may cause cancer in animals and humans by 
one of several general mechanisms of action (MoA), generally classified into genotoxic and 
nongenotoxic. Genotoxic carcinogens cause damage to DNA, thus, many known mutagens are 
in this category, and often mutation is one of the first steps in the development of cancer [2]. 
Epigenetic or nongenotoxic carcinogens do not bind covalently to DNA, and are usually 
negative in the standard mutagenicity assays [3]. The unifying feature of all genotoxic 
carcinogens is that they are either electrophiles or can be activated to electrophilic reactive 
intermediates. On the contrary, nongenotoxic carcinogens act through a large variety of different 
and specific mechanisms. 
For more than 35 years, many chemicals have been tested by government agencies, private 
companies, and research institutes using the two-year rodent carcinogenesis bioassay. Most of 
the chemicals or processes that have been associated with human carcinogenicity, as studied by 
epidemiological investigations, are shown to cause tumors in rats and mice [4–6]. However, all 
compounds shown to induce cancer in laboratory rats and mice are not necessarily human 
carcinogens [7]. 
In the past ten years, research into the MoA and carcinogenesis has increased and the 
relevance of the carcinogenicity findings in rodents to human risk has been investigated in many 
publications [8–10]. The results of research demonstrated that doses used in the bioassays may do 
not develop toxicity in humans exposed to same levels of these chemicals; in addition, rats and 
mice tumors occur in a sex, age, and strain- or stock-dependent manner. In consequence of these 
points, the regulatory agencies consider that the high occurrence of tumors in the standard 
twoyear rodent carcinogenesis bioassay is often not relevant to risk evaluation of human 
carcinogenesis [11]. Variability of the tumors in rodents is another problem of this assay. To deal 
with the problems of two-year rodent carcinogenesis bioassay alternative methods are suggested 
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by scientists and regulatory agencies. These methods include use of the toxicity level (LD50) in 
rodents, [12] in vitro cell transformation and other assays, in silico methods, or computerized 
prediction of carcinogenicity based on structure and chemical class [13] .Each method has its own 
strengths and weaknesses, and analysis of carcinogenicity of a specific chemical and its MoA in 
human is better to be assessed based on the weight of evidence. 
Among the in silico methods, the use of various computational techniques such as 
(quantitative) structure-activity relationship ((Q)SAR) modelling is supported by several 
legislative authorities [14–16]. (Q)SAR models consist of mathematical relationships between 
physicochemical properties of chemicals and their biological activity, thus being able to 
calculate a quantitative value (for the activity) given the structure of a chemical. These 
mathematical relationships can be simple linear regression equations, or more complex 
nonlinear algorithms, and can be developed using several approaches such as neural networks, 
support vector machines, decision trees, and many others. Conversely, SAR identifies the 
differences of compounds in two categories (e.g., active or inactive) and predicts an untested 
compound as “toxic” in case it has a toxic potential or “nontoxic” if not. Overall, (Q)SAR 
models are useful for the prediction of toxicity of untested chemicals saving costs and the need 
for testing on animals [17,18]. 
Following the theory of electrophilic reactivity of (many) carcinogens of James and Elizabeth 
Millers, [19,20] the advancement of the knowledge of carcinogenic chemicals have received 
distinguished contributions from many scientists. The salmonella typhimurium mutagenicity 
assay by Bruce Ames [7] and the compilation of the lists of carcinogenic and mutagenic 
structural alerts (SA) by John Ashby [21] were two fundamental contributions to this field. SAs 
identified and collected by John Ashby’s are indeed reactive functional groups responsible for 
the induction of mutation or cancer, and are so-called genotoxic carcinogens. On the other hand, 
the Salmonella assay is the most predictive assay for genotoxic carcinogens and no other 
nongenotoxic mutagenicity test exists [22]. Despite the extensive knowledge of genotoxic SAs, 
the use of SAs for identifying nongenotoxic carcinogens is restricted. Nongenotoxic carcinogens 
use many different MoA and they lack an apparent unifying mechanism. According to this 
diversity, different (Q)SAR models have been developed and made available for analysis and 
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identification of SAs. A number of nongenotoxic SAs and their characteristics have been 
published in Woo and Lai [3]. 
One of the most recent rule sets defined by human expert for mutagenic carcinogenicity has 
been developed by Benigni and Bossa [23,24]. The updated version of this rule set [24] is 
implemented in Toxtree version 2.6.13,[25] a software application that investigates the presence 
of the genotoxic and nongenotoxic SAs in the chemical structures of the compounds. Alongside 
the rule-based (Q)SAR software that check the presence of human expert SAs in the chemical 
structures, there are statistically based (Q)SARs, which create models by using categorized 
active and inactive chemicals in a learning set to identify SAs that are associated with a 
particular toxicological activity. The high accuracy of the predictions performed by data mining 
and artificial intelligence has made these methods important tools to be used for preliminary 
research and for discovery of the mechanism of action that are still unknown. These methods, 
however, comparing to rule-based models are less transparent to the end user. Historically, the 
Computer Automated Structure Evaluation (CASE/MultiCASE) [26] program is a SAR expert 
system that identifies two-dimensional structural features or biophores, which can be used for 
the prediction of unknown compounds as potential toxins. This statistically based program does 
not use the knowledge on the mechanisms of action, but reanalyze the dataset of chemicals 
trying to link the structures of chemicals into their toxic activity. On the other hand, SAs 
developed by human experts were integrated in software such as OncoLogic [27] and DEREK [28]. 
In this study we used SARpy, [29] a commercially free statistically based program, for the 
extraction of potential carcinogenic SAs from two different learning sets. The approach that we 
have taken in developing the two new carcinogenicity models is mainly based on statistical 
evaluation of the chemicals in our learning sets categorized in two groups of carcinogens and 
noncarcinogens. The SARpy’s method of identification of the SAs that are associated with a 
particular biological or toxicological activity does not demand a priori knowledge about MoA of 
the compounds and performs purely on a statistical basis. Two different carcinogenicity datasets 
have been prepared as learning sets and SARpy extracted two different models from these two 
datasets. The internal and external evaluation of the models have been assessed 
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thoroughly.Thechoiceoftakingintoconsiderationtwosubstantiallydifferentlearning sets and 
developing two models is due to different characterization of these data. The first dataset 
contains exclusively rodent carcinogenicity data based on presence of carcinogenic effects in 
male or female rats, while the second dataset takes into account human-based assessments and 
data retrieved from different assays. This suggests to obtain two different carcinogenicity 
models. 
Finally, the SAs in the two rule sets are analyzed from the point of view of chemical class 
and the same SAs present in both rule sets are revised. The two developed models have been 
made available inside VEGA (http://www.vega-qsar.eu/), [30] an open source platform that 
already offers several (Q)SAR models. 
Material and methods 
Carcinogenesis data sources 
ANTARES carcinogenicity dataset: Rat carcinogenesis learning set 
Compounds for the first model’s learning set were obtained from the carcinogenicity database 
of EU-funded project ANTARES [31]. The ANTAREs’ carcinogenicity database is a collection of 
chemical rat carcinogenesis data (presence of carcinogenic effects in male or female rats) 
obtained from the EU-funded project CAESAR[32] dataset and the “FDA 2009 SAR 
Carcinogenicity—SAR Structures” database. The CAESAR toxicity values were originated 
from the Distributed Structure-Searchable Toxicity DSSTox database, which was built from the 
Lois Gold’s Carcinogenic Potency Database [33]. The compounds with a definite TD50 (which is 
the dose that produces an increase of 50% of the tumors in animals) value for rat in this dataset 
were labeled as carcinogenic, while the remaining were labeled as noncarcinogenic. Additional 
738 chemicals different from the 805 CAESAR compounds were added. The added chemicals 
are from the “FDA 2009 SAR Carcinogenicity— SAR Structures” database using the 
Leadscope database [34]. Here a categorical label for carcinogenicity was already contained in the 
original dataset and again the compound was labeled as carcinogenic if a positive outcome was 
detected in male or female rats. So a total number of 1543 compounds constituted the 
ANTARES dataset. 
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ISS carcinogenicity database and carcinogenicity genotoxicity experience dataset: 
Different species carcinogenesis learning set 
The ISS Carcinogenicity (ISSCAN) database [35] is provided by the Istituto Superiore di Sanità 
(ISS). It is originally aimed at developing predictive models for carcinogenicity of chemicals. 
The great part of the chemicals in this database are classified as carcinogens by various 
regulatory agencies and scientific bodies. The database has been specifically designed as an 
expert decision support tool and contains information on chemicals tested with the long-term 
carcinogenicity bioassay on rodents (presence of carcinogenic effects in male or female rats and 
mice). This carcinogenicity dataset contains 622 carcinogens, 210 noncarcinogens and 58 
equivocals. 
Compounds for the second model’s learning set were obtained by merging the ISSCAN 
database and the Carcinogenicity Genotoxicity eXperience (CGX) database. More information 
on the CGX database can be found in Kirkland and colleagues [36]. In this study, compounds 
used for development of the new models had to be either positive or negative; thus, compounds 
with equivocal results in the databases have been removed. In particular, from the original 
ISSCAN dataset with 890 compounds, we removed 58 compounds, while the CGX database did 
not contain any equivocal result. 
All compounds in the combined dataset have been checked for their consistency between the 
two sources. We found 651 compounds in common, 15 of them with inconsistent 
carcinogenicity values. These compounds have been removed from the combined dataset. 
Comparison with the ANTARES dataset 
We compared the final list of compounds with the ANTARES carcinogenicity dataset prepared 
for the development of the first model. We found 105 compounds with conflicting values when 
compared with the compounds in the ANTARES dataset. In order to develop a more 
conservative model, we opted to remove only 15 compounds which had positive result in the 
ANTARES dataset and negative results in the combined second dataset, and left as carcinogenic 
those that had carcinogenicity result the opposite way. Consequently, there are 90 positive 
compounds in the combined database which are negative in the ANTARES dataset. Afterward, 
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we checked and cleaned the structures manually, and by the help of the istMolBase [37] and 
InstantJChem [38] software formed the final dataset. 
In addition, the compounds have been checked for their molecular structure. We adopted only 
the substances with connected molecular structure; those which had unconnected structures 
have been removed from the dataset. The overall dataset consisted of 986 compounds with 734 
carcinogens and 252 noncarcinogens. Each compound in the list had a chemical name, a CAS 
number, a Simplified Molecular Input Line Entry Specification (SMILES), [39] and its 
categorical designation (i.e., carcinogen or noncarcinogen). In the present study, this combined 
dataset is conventionally called ISSCAN-CGX. 
Data for model validation 
ECHA database 
We prepared an external test set for the validation of the developed models from carcinogenicity 
the eChemPortal inventory [40]. For this purpose, we made two queries on this database. The first 
query contained the following restrictions: 
• Study result type: experimental result 
• Reliability: 1 and 2 
• Species: mouse and rat • Maximum number of studies: 4 The second query consisted of: 
• Study result type: experimental result 
• Reliability: 1 and 2 
• Species: mouse and rat 
• Sources: any guideline and exposure route 
The list resulted from the first query comprised 308 compounds, whereas the second query 
returned a list of 166 compounds, which were mostly in common with the results of the first 
query. The studies conducted for the first list of compounds have been manually evaluated. 
Afterward, we looked into the Classification Labelling and Packaging (CLP) inventory [41] for 
the positive (i.e., carcinogenic) chemicals collected by the previous queries. Inside the CLP 
inventory we found 68 compounds, which were already present in our data collection. The latter 
search confirmed the carcinogenic property of these compounds. 
 170 
 
The dataset consisted of 64 positive compounds, 169 negative compounds, and 90 equivocal 
compounds. The equivocal results are due to the presence of conflicting information in different 
sources or different studies in the same source. 
It should be noticed that for already classified compounds (no conflicting information), the 
level of uncertainty in the assignment is not homogeneous, because some of the compounds 
were classified on the basis of a single study (i.e., data present in one single source). 
From the reliability point of view, in the data collected in our dataset, 49 positive compounds 
have positive carcinogenic effect in at least two sources. Fifty-seven negative compounds are 
noncarcinogenic in both lists, and they are not present in the list of compounds retrieved from 
the CLP inventory. Sixty-four compounds are considered as noncarcinogens because of the 
presence of only one single study in the two lists. 
SARpy 
The SAR in Python (SARpy) program is a Python script based on the OpenBabel chemical 
library. SARpy creates classification models by using categorized active and inactive chemicals 
in a learning set to identify molecular fragments that are associated with a particular biological, 
pharmaceutical, or toxicological activity. The algorithm generates molecular substructures of 
arbitrary complexity, and the fragments candidates to become SAs are automatically selected on 
the basis of their prediction performance in a learning set. 
The output of SARpy consists in a set of rules in the form: 
IF contains THEN, 
where the SA is expressed as a SMARTS string, for use by human experts or other chemical 
software. SMARTS notations are text representations of substructures [36] that allow 
specification of wildcard atoms and bonds, which can be used to formulate substructure queries 
for a chemical database. Those rules can be used as a predictive model simply by calling a 
SMARTS matching program. For the matching phase, SMILES and the SMARTS strings are 
translated into graphs and the two graphs are compared to each other [42]. 
Extracting active fragments 
R (rat) model 
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To obtain a more comprehensive collection of potential carcinogenic fragments, five learning 
sets were randomly created from the ANTARES carcinogenicity dataset with 1543 compounds, 
preserving 80% for the learning set and 20% for the evaluation set. In other words, for each 
model a random set of 20% of chemicals in the learning set was removed, with the remaining 
80% of the compounds a model was developed and the activity of the compounds left out was 
predicted with the same model. We combined the five models and put together the lists of the 
potential active fragments, removed the duplicates and eliminated the SAs with likelihood ratio 
lower than two. We opted for the likelihood ratio threshold of two in order to retain the SAs that 
are statistically more significant. A measure of each fragment’s association with biological 
activity is determined by SARpy as “training likelihood ratio,” and it is given along with the list 
of the potential fragments or the rule set in the output. The likelihood ratio can be taken into 
account to determine the goodness of a SA identified by SARpy. Even if a SA that is associated 
with activity (i.e., carcinogenicity) is present in a molecular structure, the molecule may contain 
other fragments that make it inactive (i.e., noncarcinogen), thus the specific SA might not be 
expected to be found only in active compounds. This evidence is the basis of the determination 
of the likelihood ratio. 
Using the SARpy software, each chemical in the learning set was fragmented in silico into all 
possible fragments meeting user-specified criteria. For this study we extracted only the 
“ACTIVE” fragments (or SAs) and the default values for the minimum and maximum number 
of atoms in a fragment were set for the fragment extractions of each model (minimum = 2; 
maximum = 18). Another configuration to establish by the user is the minimum number of 
compounds in the learning set in which an active (or inactive) fragment is found. In our 
analysis, the minimum number of compounds that contain a potential active fragment was set to 
three. Conventionally, in this study we call this model R. 
E (expert) model 
SARpy was used for model development and statistical analysis using the ISSCANCGX 
dataset. 
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The extraction settings are as follows: the minimum number of atoms in a fragment is equal 
to four, whereas the maximum number of atoms is equal to 10, and the minimum number of 
compounds containing the active fragment is six. These configurations have been set in favor of 
a model with a more balanced sensitivity and specificity values. In order to assess the 
predicitivity of the model, statistical analysis have been conducted in terms of accuracy, 
sensitivity, and specificity using cross validation routine as an internal evaluation, in addition to 
an external evaluation using an external test set. In this article, we name this model E. 
Internal evaluation of the models 
Accuracy, sensitivity, and specificity have been determined for the internal evaluation of each 
model using the SARpy program. For the internal validation, fivefold cross-validation routine 
was conducted for each model. In the five-fold cross validation the learning set is randomly 
partitioned into five equal sized subsets. For each iteration, a single subset of chemicals was 
retained as the validation data for testing the model, and the remaining subsets were used as 
training data. The cross validation process was repeated five times (the folds). The evaluation 
results of five iterations were then averaged to produce a single estimation. Accuracy, 
sensitivity, and specificity of the internal evaluation are assessed in addition to the Matthews 
correlation coefficient (MCC). 
External evaluation of the models 
The predictability of the models has been evaluated on two external test sets: the first external 
set is the dataset used as the learning set of the opposite model (e.g., for the R model we used 
ISSCAN-CGX dataset and vice versa), and the second dataset is a collection of 258 compounds 
collected from the eChemPortal inventory. Accuracy, sensitivity, specificity, and the MCC for 
the external evaluation are determined using SARpy. Although the external evaluation is 
considered the best mean for the assessment of the predictive ability of a (Q)SAR model,[43,44] 
the results of the external evaluation of any model are highly related to the relative similarity of 
the external evaluation set in relation to the learning set. 
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Table 1. R model internal and external validation for five different splits and the average of the model 
performance. 
  1° split (59 
active rules) 
2° split (65 
active rules) 
3° split (61 
active rules) 
4° split (58 
active rules) 
5° split (57 
active rules) 
Average 
Learning set 
(778 compounds) 
Accuracy 71% 72% 71% 70% 71% 71% 
 Sensitivity 75% 75% 71% 73% 70% 73% 
 Specificity 65% 69% 71% 66% 72% 69% 
Test set (337 
compounds) 
Accuracy 63% 60% 64% 65% 62% 63% 
 Sensitivity 68% 58% 62% 67% 61% 63% 
 Specificity 56% 63% 66% 61% 64% 62% 
 
Results and discussions 
R model 
Each learning set produced its own model, which is a collection of active SAs with their 
likelihood ratios. The final model merging all sets of SAs consisted of 127 active SAs. Table 1 
shows the predictive performance of five models developed based on five different splits of the 
ANTARES database. The performance of each model has been evaluated on its own learning 
set using cross-validation analysis. Further, an external evaluation using the corresponding test 
set is performed on each model. To have an overview of the statistical analysis of the 
performance of the models, we calculated the average of the predictive values of all the five 
models, and reported in Table 1 as well. The averages of accuracy, sensitivity, and specificity 
for the 778 compound internal cross-validation using five rule sets extracted from the 
ANTARES dataset were 71%, 73%, and 69%, respectively. The average of accuracy, 
sensitivity, and specificity for 337 compounds in the test set as an external validation of these 
models, were 63%, 63%, and 62%, respectively. 
Using the R model, the results of cross-validation on the whole training set were 66% accuracy, 
83% sensitivity, 48% specificity, and 0.34 the MCC (Table 2). Analysis of the external 
validation for the R model demonstrated that the concordance between experimental and 
predicted value on the ECHA dataset is higher than using the ISSCAN-CGX dataset. The 
accuracy of the R model on the ECHA dataset was 67%, compared to 58% of accuracy for the 
ISSCAN-CGX dataset. The complete list of these alerts are presented in the VEGA platform. 
 174 
 
Table 2. R model and E model internal and external validation. 
 
External 
 Crossvalidation validation 
on 
ISSCAN 
and CGX 
data 
External 
validation 
on 
ECHA data 
Crossvalidation External 
validation 
on 
ANTARES 
data 
External 
validation 
on 
ECHA 
data 
Accuracy 66% 58% 67% 73% 59% 64% 
Sensitivity 83% 76% 62% 77% 77% 48% 
Specificity 48% 40% 70% 62% 41% 72% 
TPa 651/783 593/735 55/89 562/735 599/783 43/89 
TNb 367/760 142/254 119/169 157/254 315/760 121/169 
FPc 393/760 112/254 50/169 95/254 445/760 48/169 
FNd 132/783 142/735 34/89 172/735 184/738 46/89 
MCCe 0.34 0.35 0.31 0.36 0.19 0.20 
aTrue positive; bTrue negative; cFalse positive; dFalse negative; eMatthews Correlation Coefficient. 
 
E model 
With the configuration set as mentioned above, SARpy extracted 43 active rules from the 
ISSCAN-CGX learning set. Analysis of the cross-validation for the E model demonstrated that 
the second model produced an accuracy of 73%, with a sensitivity of 77% and a specificity of 
62% (Table 2). The MCC value for this analysis is 0.36. The accuracy values for the external 
evaluation of the E model on the ANTARES dataset and the ECHA database were 59% and 
64%, respectively. Analysis of the external validations for the E model demonstrated that the 
model produced a higher sensitivity (77%) compared with the specificity (41%) of the R model. 
On the contrary, the specificity of the external evaluation on the chemicals from the ECHA 
database was higher (72%) compared to its sensitivity (48%) (Table 2). The complete list of the 
SAs present in this model is accessible through VEGA. 
Analysis of the combination of the prediction results of the R and the E models 
Another analyses has been done on the prediction results of the R model and the E model. In 
this new approach, we considered the final results as correctly predicted only in case both 
models have predicted them consistently. Table 3 summarizes the results of combining the R 
and E model external validation predictions on the chemicals from the ECHA database. 
The results suggested that when both models are concordant on a negative prediction for a 
compound the reliability of the result is much higher than in case a positive prediction is done. 
We observe an improvement of the results compared to the use of the individual models, for 
accuracy (72%) and specificity (79%). In fact, combining the predictions of the two models the 
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MCC is increased to 0.37, compared to 0.31 for the R model and 0.20 for the E model. Only 
sensitivity is higher using the R model (62%). Thus, users may choose a solution or another 
depending if they prefer a conservative or a realistic assessment. 
Table 3. The combination of the predictions of the R and E models on the ECHA external validation 
set. 
 Combined model  
TPa  33/89 
TNb  96/169 
FPc  25/169 
FNd  24/89 
Accuracy  72% 
Sensitivity  58% 
Specificity  79% 
MCCe  0.37 
Coverage  178/258 
aTrue positive; bTrue negative; cFalse positive; dFalse negative; eMatthews correlation coefficient. 
 
Fragments analysis 
Comparison of the SAs in the R and E models 
The SAs present in the R and E models have been compared and those that are in common 
between the two rule sets categorized into chemical classes and listed as follows. The SAs in the 
R model are presented with their ID number and written in order of their correspondence to the 
identical SAs in the E model. 
1. Aromatic amine (R model: 6, 41, 36, 22, 10 / E model: 27, 31, 33, 38, 104) 
2. Aromatic heterocyclic (R model: 12, 19, 2 / E model: 75, 108, 117) 
3. Hydrazide (R model: 28, 27 / E model: 2, 50) 
4. N-Nitroso (R model: 1 / E model: 8) 
5. Phenyl-Hydrazine (R model: 32 / E model: 48) 
6. α,β- Haloalkanes (R model: 25 / E model: 56) 
7. Sulfite (R model: 8 / E model: 68) 
8. Nitrogen Mustard like (R model: 11 / E model: 73) 
9. Phosphonite (R model: 15 / E model: 98) 
Categorization of the SAs in the R and E models 
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The SAs present in the models R and E are categorized from a chemical class point of view. The 
substructures within each category are presented with their ID number in their original rule set 
and are as follows: 
Nitrogen containing substructures (Azo type): 
1. Aromatic amine (R model: 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36,37, 38, 40, 
42, 83, 104, 110, 113 / E model: 6, 10, 22, 31, 35, 36, 41, 42) 
2. Aromatic heterocycles containing Nitrogen (R model: 74, 75, 80, 81, 83, 95,113, 122 / E 
model:12, 17, 43) 
3. Azine (Hydrazine) (R model:46, 47, 49, 50, 51, 53, 54, 55, 101 / E model: 27,32) 
4. Azide (Hydrazide) (R model: 2, 3, 44, 45, 52 / E model: 3, 28) 
5. Nitrosamine (R model:4, 5, 7, 9, 10 / E model: not found (NF)) 
6. Nitrogen or sulfur mustard (R model: 72, 73, 115 / E model: 11, 34) 
7. Aromatic methylamine (R model: 30, 34, 36 / E model: NF) 
8. Aliphatic N-Nitroso (R model: 62, 63/ E model: NF) 
9. Aromatic Nitro (R model: 90, 123 / E model: NF) 
10. 1 aryl 2 monoalkyl hydrazine (R model: 48 / E model: NF) 
11. Aziridine (R model:120 / E model: NF) 
12. Aromatic hydroxylamine (R model: 32 / E model: NF) 
13. Diazo (R model:92 / E model: NF) 
14. Aromatic Azo (R model: 71 / E model: NF) 
15. Aromatic Nitroso (R and E models: NF)  
 
Other substructures: 
1. (1,2, and 3 membered) Aromatic Heterocycles (R model: 74, 75, 80, 81, 83, 90, 95, 103, 
108, 113, 117, 121, 122, 123 / E model: 2, 12, 17, 19, 43) 
2. Aliphatic halide (R model: 57, 58, 59, 70, 125 / E model: 18, 25) 
3. Heterocyclic Alkane (R model: 84, 105, 109, 120 / E model: 23) 
4. Polycyclic aromatic systems (R model: 39, 43, 60, 61 / E model: 30) 
5. Sulfonate bonded carbon (R model: 67, 68 / E model: 8) 
6. Epoxide (R model: 105 / E model: 23) 
7. B propiolactone (R model: 114 / E model: NF) 
 
Not only SARpy was able to find the already known carcinogen substructures that were 
represented by the SAs of Kazius and colleagues, [45] but a number of SAs have been identified 
for the first time. Table 4 demonstrates the new identified SAs that have been classified into six 
chemical classes. The substructures within each category are listed with their ID number and are 
as follows: 
1. Nitrosurea (R model: 12, 13, 14, 19 / E model: NF) 
2. Nitrogen or sulfur mustard like (R model: 72, 115 / E model: 34) 
3. Benzodioxole and Benzendiol (R model: 17, 18 / E model: 9) 
4. Tertiary amine substituted by a Sulfur atom (E model: 24) 
5. α,β-oxy and carboxy substitutions (R model: 20, 21, 76 / E model: NF) 
6. α,β-haloalkanes (R model: 56, 69 / E model: 25) 
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7. Oximes (R model: 78 / E model: NF) 
 
For the sake of example, we illustrated the chemicals from which the SA 24 (form the 
chemical class tertiary amine substituted by a Sulfur atom) in the E model has been extracted 
(Table 5). All the chemicals that contain the previously mentioned SA in the ISSCAN-CGX 
data set are carcinogenic. 
Discussion 
Automated extraction of SAs has been implemented by the statistically-based program SARpy 
on two learning sets. The ANTARES learning set collects rodent bioassay carcinogenicity data 
on 1543 chemicals, while ISSCAN-CGX database containing 986 chemicals takes into account 
human-based assessments and data retrieved from different assays. The predictive performance 
of the developed models were evaluated internally as well as using a 258 compound external 
validation dataset collected from the ECHA inventory. The two developed models for 
carcinogenicity have been implemented in the VEGA platform and are indeed freely available 
for end users. 
Recent progresses in data mining provide effective competence in the automated discovery of 
SAs associated with toxicological endpoints. An important contribution of the statistically based 
methods to the carcinogenicity field is identification of new SAs, which help us in refining the 
existing rule sets. While the most known carcinogenicity rule sets [23] are composed on the basis 
of human expert judgement, the SAs identified in our study are extracted in an unbiased manner 
by SARpy with no a priori knowledge about the MoA of the chemicals. This approach sheds 
light to the new clues about genotoxic and nongenotoxic SAs. Some primary analyses have 
been provided on the SA lists; chemical classes of the identified SAs have been evaluated; 
however, further study for the new SAs should be performed considering other collections of 
alerts [45]. SARpy SAs resulting from the current analysis on the ANTARES and ISSCAN-CGX 
data sets follow the SAs presented by Kazius and colleagues [46]. 
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Table 4. New carcinogenic structural alerts identified by SARpy in the R and E models. 
 
Further, the models are developed on the basis of two learning sets with different 
carcinogenicity data from the point of view of origin and provenance. Concerning the learning 
sets with substantially variant carcinogenicity data assessed within different properties, each set 
of the extracted SAs constituted a purpose-oriented model. The user may consider the results of 
the model with more realistic predictions or the one with more conservative assessments. 
  
 
 
 
 
 
 
α, β-oxy and carboxy substitutions 
α, β-haloalkanes: 
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Table 5. Chemicals structures in the ISSCAN-CGX data set from which structural alert 24 has been extracted. 
 
Generally, the best approach in making a conclusion to estimate the reliability of a prediction 
is combining evidence from different information sources such as (Q)SAR model predictions, in 
vitro and in vivo test results. This is reflected in the general trend of developing ensemble 
models and/or combining the output of different existing models. An example of the latter 
approach has been done on a similar endpoint, mutagenicity (Ames test), by the integration of 
the different models available on the VEGA platform [47]. The advantage of having the two 
presented models available on the VEGA platform, where other models for the same endpoint 
are available, is also the possibility of performing a similar activity to make a conclusion. 
Finally, the results of the presented models will be exploited for the improvement of 
ToxRead (http://www.toxgate.eu), a recent platform that uses set of rules for different endpoints 
to filter and select similar compounds and assist the user in performing read-across studies [48,49] . 
Also, these rules can be compared and possibly explained considering reasoning about 
mechanisms, including adverse outcome pathways [50]. 
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Structural Alerts for Carcinogen Compounds (R Model) 
Following, the list of the 127 rules for carcinogenicity, expressed as SMARTS strings: 
SA 1: CN[N+]=O 
SA 2: NNC=O 
SA 3: CN(C=O)N=O 
SA 4: CCCCCCN(C)N=O 
SA 5: CCCN(CCC)N=O 
SA 6: CNCCNN=O 
SA 7: CNCCN(C)N=O 
SA 8: CCNN=O 
SA 9: CCCCCN(C)N=O 
SA 10: CCCCN(C)N=O 
SA 11: CC(O)CNN=O 
SA 12: CN(N=O)C(=O)NCCO 
SA 13: NC(=O)N(CCO)N=O 
SA 14: CN(N=O)C(N)=O 
SA 15: CCCNN=O 
SA 16: O(c1ccccc1)c2ccccc2 
SA 17: COc1cccc(O)c1 
SA 18: CCc1ccc(OC)cc1O 
SA 19: CCCNCNN=O 
SA 20: CCOC(=O)C(C)(C)O 
SA 21: CC(C)(O)C(O)=O 
SA 22: Cc1ccccc1-c2ccc(N)cc2 
SA 23: Nc1ccc(cc1)-c2ccc(N)cc2 
SA 24: Nc1ccc(cc1)-c2ccccc2 
SA 25: Nc1ccc(C=C)cc1 
SA 26: Nc1cccc(c1)-c2ccccc2 
SA 27: Cc1ccc(N)c(C)c1 
SA 28: Cc1ccccc1N 
SA 29: Nc1ccc(Cc2ccc(N)cc2)cc1 
SA 30: CN(C)c1ccc(Cc2ccccc2)cc1 
SA 31: Cc1ccc(N)cc1 
SA 32: Cc1ccc(NO)cc1 
SA 33: Cc1cccc(N)c1 
SA 34: CNc1ccc(C=C)cc1 
SA 35: Nc1ccc2ccccc2c1 
SA 36: CNc1ccc(N)cc1 
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SA 37: Nc1ccccc1O 
SA 38: COc1ccccc1N 
SA 39: Oc1cccc2ccccc12 
SA 40: Nc1ccc(O)c(N)c1 
SA 41: CC(C)C(C)(O)CO 
SA 42: Nc1cccc(c1)S(O)(=O)=O 
SA 43: Cc1cccc2ccccc12 
SA 44: NNCO 
SA 45: CN(N)CO 
SA 46: CC(O)CNN 
SA 47: NNCCO 
SA 48: NNc1ccccc1 
SA 49: NNCC=C 
SA 50: CCNN 
SA 51: CCCNN 
SA 52: CC(=O)NN 
SA 53: CCCN(N)CCC 
SA 54: CCCN(C)N 
SA 55: NN 
SA 56: ClCCCl 
SA 57: CCl 
SA 58: CCBr 
SA 59: CBr 
SA 60: c1ccc2cc3c(ccc4ccccc34)cc2c1 
SA 61: c1ccc-2c(c1)-c3cccc4cccc-2c34 
SA 62: CN=O 
SA 63: N=O 
SA 64: NO 
SA 65: Oc1cccc(c1)-c2cccc(O)c2 
SA 66: OS(O)(=O)=O 
SA 67: COS(O)=O 
SA 68: COS(=O)=O 
SA 69: ClC1CCCC(Cl)C1Cl 
SA 70: CC(Cl)CCCCCl 
SA 71: c1ccc(cc1)N=Nc2ccccc2 
SA 72: CCNCCCl 
SA 73: ClCCNCCCl 
SA 74: Cc1ccncn1 
SA 75: c1cncnc1 
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SA 76: CC(=C)C(O)=O 
SA 77: CC=C(C)CO 
SA 78: CC(C)=NO 
SA 79: CC(C)=N 
SA 80: Cn1cncn1 
SA 81: c1ncnn1 
SA 82: COc1ccc(CC=C)cc1 
SA 83: Nc1ncc2ncn(CCCCO)c2n1 
SA 84: OCC1OC(CC1O)n2cnc3cncnc23 
SA 85: CC1CCC=C(C)C1 
SA 86: C1C=CCC=C1 
SA 87: O=C(OCc1ccccc1)c2ccccc2 
SA 88: CCOCc1ccccc1C 
SA 89: C(=Cc1ccccc1)c2ccccc2 
SA 90: [O-][N+](=O)c1ccco1 
SA 91: CCNCC(C)=O 
SA 92: N=[N+] 
SA 93: Cc1ccc(cc1)S(O)(=O)=O 
SA 94: O=C1c2ccccc2C(=O)c3ccccc13 
SA 95: Cc1cccnc1 
SA 96: CCCCC(O)CCCCC(O)CCC 
SA 97: Clc1cccc(Cl)c1Cl 
SA 98: COP=O 
SA 99: CC(CN)c1ccccc1 
SA 100: OCC#C 
SA 101: NNCc1ccccc1 
SA 102: C1CCc2ccccc2C1 
SA 103: c1ccsc1 
SA 104: Nc1ccccn1 
SA 105: C1CO1 
SA 106: CC(O)CCCC=O 
SA 107: C[S]=O 
SA 108: c1cscn1 
SA 109: CC1COCO1 
SA 110: Nc1ccc([S]c2ccccc2)cc1 
SA 111: Cc1ccc(cc1)C(N)=O 
SA 112: CN(C)P(N(C)C)N(C)C 
SA 113: [N+]c1cncn1 
SA 114: O=C1CCO1 
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SA 115: OCCNCC=C 
SA 116: CCNCCCC(C)C 
SA 117: c1ccoc1 
SA 118: CCOC(N)=O 
SA 119: C=CCCCCC=O 
SA 120: C1CN1 
SA 121: c1cc2ccccc2s1 
SA 122: Cc1ncc[nH]1 
SA 123: [O-][N+](=O)c1ccc(o1)-c2cscn2 
SA 124: C#C 
SA 125: CCF 
SA 126: CN=[N+] 
SA 127: CCCN=CN 
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Structural Alerts for Carcinogen Compounds (E model) 
Following, the list of the 43 rules for carcinogenicity, expressed as SMARTS strings: 
SA 1: O=NNCC 
SA 2: c1occc1 
SA 3: O=CN(N)C 
SA 4: CCCN(CC)CC 
SA 5: C1CC(=CC)CCC1 
SA 6: Nc1ccc(cc1C)C 
SA 7: NCCCN 
SA 8: O=S(=O)(OC) 
SA 9: c1ccc2OCOc2c1 
SA 10: Nc1ncccc1 
SA 11: N(CCCl)CCCl 
SA 12: c1cn(cnc1) 
SA 13: C=C(C=C)C 
SA 14: O=NNC 
SA 15: O=P(OC) 
SA 16: O(c1ccc(cc1)CC=C) 
SA 17: c1ncn(c1)C 
SA 18: C(CCCC(CC)Cl)Cl 
SA 19: c1ncsc1 
SA 20: C=CCN 
SA 21: O=Cc1ccccc1O 
SA 22: O(c1ccc(cc1N))C 
SA 23: O1CC1C 
SA 24: SN(C)C 
SA 25: C(CCl)Cl 
SA 26: c1c(cc(cc1Cl)Cl)Cl 
SA 27: NNCC 
SA 28: O=CN(N) 
SA 29: C(OC)C(C)C 
SA 30: c1ccc2cc(ccc2c1) 
SA 31: Nc1cccc(c1C)C 
SA 32: NNc1ccccc1 
SA 33: c1cc(ccc1C)Cl 
SA 34: N(CCO)CCO 
SA 35: Nc1ccc(cc1N) 
SA 36: c1ccc(cc1N)C 
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SA 37: O(c1ccc(cc1)C)C 
SA 38: C(c1ccccc1)CO 
SA 39: C(=CCC)CC 
SA 40: N(Cc1ccccc1)C 
SA 41: Nc1ccc(cc1)C 
SA 42: Nc1ccccc1 
SA 43: n1cccc(c1) 
 188 
 
Golbamaki et al., Drug Des 2017, 6:3  
Drug Designing: Open Access  
DOI: 10.4172/2169-0138.1000153 
Research Article OMICS 
International 
ToxDelta: A New Program to Assess How Dissimilarity Affects 
the Effect of Chemical Substances 
Azadi Golbamaki1*#, Alessio M Franchi2#, Serena Manganelli1, Alberto Manganaro1,3, Giuseppina Gini2 and 
Emilio Benfenati1 
1IRCCS – Istituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa, 19, 20156 Milan, Italy 
2Politecnico di Milano, Piazza Leonardo da Vinci, 32, 20133 Milan, Italy 
3Kode s.r.l., Via Nino Pisano, 14, 56124 Pisa, Italy 
#Contributed equally 
 
 
 
Abstract 
 
ToxDelta is a new tool for the evaluation of the toxicity of chemicals based on a modified version of the fmcs_R 
package. Two structurally similar molecules share a maximum common substructure (MCS). In order to evaluate if two 
similar molecules have different effects, we focused our attention on the molecular fragments which are not in the MCS. 
These parts may increase or decrease the value of the property. We considered a variation of the MCS concept of 
efficient relevance in toxicity assessment where the rings of molecules must not be broken. To assess the toxicity of the 
target chemical, ToxDelta extracts the MCS and delineates the remaining fragments. Each of these moieties represents 
a difference between two molecules and its relevance in the toxicity assessment is evaluated against a knowledge-
based list of active and inactive fragments. ToxDelta considers the dissimilarities of the molecules in a read-across 
approach. 
 
 
ISSN: 2169-0138 
 189 
 
ToxDelta: A New Program to Assess How Dissimilarity Affects the Effect of 
Chemical Substances 
 
Keywords: Read-across; (Q)SAR, SAR; Maximum Common Substructure; Molecular graph; 
Toxicity assessment; Mutagenicity; Structural alert 
 
Introduction 
The European REACH legislation for industrial chemicals promotes the use of alternative 
methods, and explicitly mentions and regulates the use of read-across and quantitative structure-
activity relationships (QSAR), jointly named non-testing methods (NTM). Often, one of the 
problems of QSAR models is their poor interpretability. Along with the assessment of the 
predictive power and statistical quality, the interpretability of the QSAR models is an important 
issue for the regulatory bodies. Furthermore, since read-across is related to the concept of 
similarity, it is closer to evidence and apparently easier to be accepted, although similarity 
cannot be univocally defined. The European Chemicals Agency (ECHA) published a document 
with the purpose to communicate the framework applied within the agency to evaluate the 
assessment done with read-across [1]. In 2014, it was reported that the most common and 
widely used NTM consisted in building categories and predicting properties by read-across. Up 
to 75% of the analysed dossiers contained read-across at least for one endpoint. The ECHA 
guidance on QSARs and grouping of chemicals introduces a flowchart [2] for the generation and 
use of non-testing data in the regulatory assessment of chemicals. This flowchart consists of a 
sequence of operations (eight steps), which starts with information collection and terminates 
with the final assessment exploiting the functionalities of a vast range of computational tools 
and databases. Depending on the chemical and property of interest these steps can be omitted or 
performed in a different order. In our new tool ToxDelta, we have addressed two of these steps: 
“Search for structural alerts” and “read-across”. Even though read-across has been used much 
more than QSAR for registrations, it has been studied much less than QSAR. There are many 
open issues on the use of this approach. Read-across is typically subjective, and strongly relies 
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on the individual expert, the expert’s background and experience, and is difficult to reproduce 
[3].  
In order to solve the above mentioned problems of interpretation and to help the expert to get a 
documented, transparent and reproducible evaluation on the activity of the target compound, our 
group developed a new read-across tool: ToxRead [3,4]. This tool assists experts in the 
evaluation of the biological activity/toxicity of compounds, offering known elements affecting 
the activity within the same picture. 
Recently, we published the results of an exercise on read-across. Participants made their 
assessment using the approach they preferred. The group of scientists who used ToxRead gave 
consistent assessment for the same chemical, while those who used other programs typically 
gave conflicting assessment [5]. This indicates that the subjectivity of the assessment may 
introduce a source of variability which may make read-across an unreliable strategy without a 
proper reproducible scheme. 
Generally, the programs assisting the expert in read-across are based on similarity measuring 
software. Examples of these programs are ToxRead, the OECD QSAR toolbox [6], ToxMatch 
[7] and AMBIT [8]. VEGA, which is commonly used for QSAR, can be also used as a read-
across tool, as it shows the similar compounds and in many of its models also the alerts [3]. 
Similarity is basically measured on the basis of the chemical structure. In some cases additional 
toxicological considerations are added. These programs just show the most similar compound(s) 
to the target substance, and the user can decide the biological activity/toxicity of the target 
compound on the basis of the activities of the similar compounds used as source compounds. 
Furthermore, some of these programs (e.g. ToxRead) provide the value predicted by the 
software. 
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In combinatorial chemistry, the use of similarity and diversity methods addresses the similarity 
property principle. This principle states that structurally similar molecules have similar 
biological activity [9]. This statement is questioned by various experiences with contradictory 
results [10]. In fact, structural similarity does not always imply similarity in either activity [11] 
or descriptors [12]. Minor modifications can make active molecules to lose their activities 
completely and vice versa. Intrinsically, the similarity concept includes the fact that the two 
molecules are different. Thus, the expert should evaluate not only how similar the two 
substances are, but also whether the differences trigger an opposite behaviour. 
Many similarity measuring methods have been proposed to quantify the similarity between 
chemical compounds especially in drug discovery research. One of the most famous methods is 
the study of substructure and superstructure relationships of the chemicals. Two molecules may 
share some common properties due to their common substructure. This search strategy does not 
provide any quantitative similarity measurement. Hence, it is a very knowledge-based approach 
in which every substructure used in a query needs to be well defined. Structural descriptor-based 
methods are another commonly used structural similarity searching approach in which the 
similarity of the chemical compounds can be quantified. Structure similarity search does not 
require an exact match and the search results are ranked by scores. One of the important 
structural-based search methods is fingerprint [13]. In this method, the chemical structure is 
disclosed in a highdimensional space. Many models for predicting biological activities are based 
on the similarity coefficient provided by such methods, such as neural networks [14], fuzzy 
adaptive least squares [15] and inductive logic programming [16]. Structural descriptor-based 
methods are computationally simple, but they are unable to identify local similarities between 
structures.  
Maximum common substructure (MCS) is an encouraging approach for similarity searching and 
biological activities predictions in chemoinformatics. The MCS is a problem of graph matching 
that involves 2D or 3D chemical structures of two chemicals and identifies the largest 
substructure present in both molecule structures. The MCS-based methods have all the 
advantages of the substructure and superstructure -based methods and in addition does not need 
an exact match procedure. Compared to structural descriptor–based methods, MCS provides a 
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similarity score for each comparison and can perform local similarity identification. MCS is a 
straightforward concept of determining similarities with a clear chemical meaning and is 
principally independent of the fingerprints. Several available MCS algorithms in the literature 
do not satisfy the graph representation of the chemical compounds. Barrow and Burstall in 1976 
[17] used the MCS concept for the sub-graph isomorphism for the first time. After that, Cone et 
al. [18] introduced the use of MCS for similarity search for molecular comparison. The 
approach did not receive a notable consideration due to its complexity. Later, other MCS-based 
similarity search algorithms have been presented [19-21]. The concept of MCS in the molecule 
structures has been applied in different chemoinformatic concepts, such as classification models 
using the structural similarities [22], enrichment of chemical libraries [23] and clustering 
molecules with similar structural features [24]. The MCS search methods are mainly divided 
into “clique” [17,25] and “backtracking” [26,27]. The computational problem of finding all the 
largest complete sub-graph(s) (maximal clique) is called the clique problem. The clique problem 
is NP-complete, i.e., no polynomial time algorithm has been found to solve the general problem. 
However, many algorithms for computing cliques have been developed, both complete and 
approximate. The basic algorithm is due to Ullmann [28] who introduced backtracking to reduce 
the size of the search space. The MCS extraction algorithm of the FMCS R package is based on 
backtracking search method. 
We considered a variation of the MCS concept of efficient relevance in toxicity assessment, 
where the rings of molecules must not be broken. We modified the MCS algorithm of the 
fmcs_R package [29] for finding the MCS between two given similar molecule graphs subject to 
this constraint. The similarity index is determined by the VEGA similarity indication which is 
described described by Floris et al. [30]. The new software, ToxDelta is a novel read-across tool 
developed to identify and extract the differences between the target and the reference 
compounds for the further evaluation of the biological activity/toxicity of the target molecule. 
These differences are depicted as molecular substructures. Their possible role in amplifying or 
reducing the activity/toxicity of a compound is queried in an a priori prepared data set of 
molecular structural alerts (SA). 
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We added the constraint of keeping the aromatic or aliphatic rings present in the target or the 
reference molecule complete during the process of the MCS extraction. Indeed, this decision is 
made due to the important role that rings play in the mutagenicity and carcinogenicity SAs. For 
example, polycyclic aromatic hydrocarbons (PAHs) that are composed of multiple aromatic 
rings are a class of mutagens. In addition, PAHs are linked to skin, lung, bladder, liver, and 
stomach cancers in confirmed animal models. The increasing number of aromatic rings in PAHs 
helps the metabolic activation to reactivate diol epoxide intermediates and consequently their 
binding to DNA [31]. In addition, the mutagenicity of the aliphatic epoxides has been 
determined by the Ames test [32]. Historically, a very effective list of the SAs has been created 
and revised by Ashby in 1985 and 1988, respectively [33,34]. The Ashby’s well-known poly-
carcinogen list contains aromatic nitro groups, aromatic azo groups, aromatic rings N-oxides, 
aromatic mono- and di-alkylamino groups, aromatic amines and aliphatic and aromatic 
epoxides. The extended SAs list according to Kazius et al. [35] contains groups of specific 
aromatic nitro and amine, aliphatic halide, polycylic aromatic system and other SA with 
aromatic or aliphatic rings. Also, the Benigni’s [36] list includes an important number of forms 
of aromatic and aliphatic rings. 
In our study, we combine a substructure identification tool with a tool for the assessment of the 
related fragments which are not in common, in order to evaluate the toxicity of the two chemical 
compounds under examination. 
At present, ToxDelta performs only mutagenicity assessment of the chemical substances. The 
mutagenicity SAs collection of this tool is extracted from the Ames test results. Ames test is the 
gold standard for initial examination for detecting chemically induced gene mutations of new 
chemicals and drugs. Bruce Ames created the Ames assay in the 1970s [37]. The assay’s 
sensitivity towards many types of mutagens has been improved over the years [38,39]. Specific 
distinct mutations in the histidine and tryptophan synthetic pathways of Salmonella typhimurium 
and Escherichia coli have been created respectively, that result in the requirement for an 
exogenous supply of those amino acids for growth. Using genetically bacterial strains, the Ames 
test produces a high rate of inter-laboratory reproducibility (85%-90%) [40]. This assay has 
been proved to be the most predictive in vitro assay for rodent and human carcinogenicity 
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[37,41]. Additionally, the Ames test results have been demonstrated to be in agreement with 
rodent carcinogenicity or in vivo genetic toxicity about 65% [42].  
Materials and Method 
Database of active and inactive structural alerts 
In a previous study, a very sophisticated collection of mutagenicity SAs has been created and 
implemented in ToxRead for the read-across mutagenicity assessment [4]. This set of rules 
associated to bacterial mutagenicity has been identified and extracted by analyzing more than 
6000 chemicals from different chemical classes. A set of rules related to both mutagenicity and 
lack of mutagenicity were found. These SAs have been sorted in a hierarchy of rules and used to 
identify the active or inactive mutagenic substructures present in the target compounds. The 
hierarchical order of the SAs makes it possible to identify first the exact rule that matches the 
target molecule and then other, more generic ones, which may match with the target molecule. 
Besides rules for mutagenicity and non-mutagenicity, the identified potential rules include 
exceptions and modulators of activity. These rules can be also used to predict mutagenicity 
concerning the influence of each SA found in the molecule. Accuracy and p-value are two 
statistical characterizations which are assigned to each SA of the mutagenicity list; these values 
show the accuracy of the SA based on the number of chemicals in the original training set 
containing the SA, and the prevalence of one of the categories: Mutagenic or non-mutagenic. 
These SAs are those implemented within ToxRead. In the case of the module for mutagenicity, 
there are about 800 SAs each with a high level of detail such as accuracy and statistical 
significance.  
The MCS algorithm: ToxDelta advances ToxRead for it supports the reasoning based on the 
differences, as well as similarity of molecules. The degree of similarity and dissimilarity 
between pairs of molecules is computed from their structures. Molecular structures can be 
encoded in several computer formats which basically contain the topological information about 
the structure, as well as other chemical information such as atom charges, aromaticity, etc. 
Among several available formats, we relied on SMILES strings [43] and structure data formats 
(SDF). 
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The algorithm proposed in the fMCS_R package [44] performs MCS computation via a novel 
backtracking algorithm by incrementally computing a search tree of correspondences between 
nodes of the two graphs under investigation. Each node in this tree is a set of atom 
correspondences while leafs are the connected sub-graphs we are looking for; the deepest leafs 
are the MCSs. 
The aromatic and non-aromatic rings as structural properties of molecules and their role in the 
biological activities of the molecules are important issues. Indeed, among the identified 
mutagenic and carcinogenic SA, aliphatic and aromatic rings play an important role. In this 
regard, an important number of forms of rings are established [36]. For this reason, we applied 
the constraint that the rings present in the input molecular graphs must be retained by the MCS 
by adding an additional check in the backtracking algorithm of the fmcs_R library, as opposed 
to the original R package (fmcs_R). In other words, we decided to maintain all the rings entire 
and not break these rings during the process of the MCS extraction. Our modification to the 
original code of this library consists mainly in adding a restriction during the process of the 
atom selection for the MCS. For each atom belonging to a ring, this restriction checks if the 
atom resides in an equivalent ring in the target and the reference molecule. Since the fmcs_R 
algorithm does not consider rings as such, it may break some rings, i.e. if it is necessary it 
selects only a subset of atoms in a ring. This leads to a significant loss of structural information 
and consequently the implication of the extracted MCS which is meant to be equal for both 
molecules may differ for each compound. We can finally extract the structural differences 
between the two compounds under investigation: we overlap each graph with the MCS and 
highlight all the sub-branches not in the MCS (Figure 1). 
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ToxDelta Implementation 
The user can evaluate the evidences obtained by ToxDelta and make a decision regarding the 
toxicity of a compound under evaluation, in a weight of evidence approach. Figure 2 shows the 
flow chart of the implementation of the ToxDelta program for the mutagenicity endpoint. The 
new tool relies on ToxRead for the evaluation of the degree of similarity between similar 
Figure 1: The MCS between two molecules is shown with bold lines and the other 
branches are the differences. 
Figure 2: The flow chart of ToxDelta: The molecular similarity/dissimilarity 
structure analysis software for the mutagenicity endpoint.  
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compounds. The similarity algorithm has been described elsewhere [30]. A stand-alone version 
of ToxDelta is accessible on the VEGA home page (https://www. vegahub.eu/). ToxDelta will 
be implemented inside ToxRead and the dissimilar substructures will be computed between the 
target molecule and any source molecule selected by the user. ToxRead associates the most 
similar molecules present in its data base to the target molecule, pointing out the mutagenic (or 
non-mutagenic) fragment(s) as toxicity rules present in both the target and the similar chemical 
compounds. ToxRead identifies the mutagenic or non-mutagenic SAs in common between the 
target and the source chemicals. Thus, these SAs belong by definition to the MCS of the pair of 
compounds under investigation. At this point, the integration of ToxDelta inside ToxRead will 
allow further investigation of the pair of compounds, identifying the dissimilar moieties and 
providing the most similar SAs for each of them in the collection of the known SAs. To obtain a 
conceivable result, the structure of the target and the source molecules in the comparison need to 
be sufficiently similar. If the structures of the molecules compared by ToxDelta do not share a 
significant MCS, the dissimilarities may not be interpretable to an acceptable level. In other 
words, whenever the structures of two molecules are strongly dissimilar, the user may not 
expect a significant MCS. In this regard the VEGA chemical similarity index 30 is used as a 
screening before applying the MCS approach. 
Provided that the identified dissimilar fragment in the target molecule is an SA along with the 
assigned active or inactive toxicity effect information, there are three possible scenarios that 
may help the user to move in a certain direction for toxicity decision-making. These three 
scenarios about the dissimilar fragment found in the target molecule are as following: 
1. The SA is an active fragment with strong evidence which increases the effect; 
2. The SA is an inactive fragment with strong evidence which decreases the effect; 
3. The SA is a fragment without any relevant impact on the effect. 
In case 1 and 2 the SA is more likely to modulate the effect of the whole molecule, while in case 
3 the SA is a neutral fragment and does not have an impact on the modulation of the effect. 
Nevertheless, the software provides documentation on the SAs of case 3, which indicates the 
existence of a certain fragment with no impact on the effect. Documentation is an important 
factor in the acceptance of the read-across results. This whole list of SAs is used by ToxDelta to 
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assess whether the fragments resulting from the subtraction of the MCS from the molecule are 
associated to an increased or decreased or neutral effect. 
The program returns as output all the possible MCSs of the same length (the number of the 
atoms is equal in all the MCSs) extracted from two molecules of interest. The user can choose 
one of the MCSs found and evaluate the dissimilarities calculated based on the chosen MCS. 
The different fragments present in both molecules, are the result of the subtraction of the MCS 
and the target or source molecules. 
Evaluation of ToxDelta  
In order to evaluate the new tool and to investigate its dissimilarity approach theory, we 
performed tens of in-house tests while studying and developing the proposed methodology. We 
selected two pairs of molecules with known mutagenicity (Ames test) experimental value as 
case studies, to show how our approach works and how it could be useful in the toxicity 
assessment. Even though there is no similarity threshold determined by this tool, for the 
molecules selected as case studies, we chose two pairs of molecules, case 1 and case 2, with a 
cut-off value of 0.7 for the VEGA similarity index [30]. The results provided by ToxDelta for 
the molecules with a small MCS may not have a significant interpretation. In both cases, we 
chose two compounds with different toxicity activity (one mutagenic and the other one non-
mutagenic), as this scenario represents exactly the type of situation in which ToxDelta can 
provide useful insight. To check whether the structural differences between these molecules 
have a significant role in their toxicity or non-toxicity property, we assume that one of the 
molecules in each pair is the target molecule and the other one is the source molecule. We 
selected two pairs of derivatives from two relevant pharmaceutical classes: benzodiazepines and 
androstane derivatives. We chose diazepam, first came on the market as Valium, a 
benzodiazepine drug typically producing a calming effect. It is commonly used to treat anxiety, 
alcohol withdrawal syndrome, benzodiazepine withdrawal syndrome, muscle spasms, seizures, 
trouble sleeping, and restless legs syndrome. Flunitrazepam, known as Rohypnol, is a 
benzodiazepine derivative that can cause anterograde amnesia; its importation has been banned 
by the U.S. Government (https://chem.nlm.nih.gov/ chemidplus/name/flunitrazepam). The 
similarity VEGA index value between these two benzodiazepines is 0.87. Despite this, they 
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exhibit different toxicological profiles: Indeed Diazepam is experimentally non-mutagenic while 
flunitrazepam is mutagenic. As second case study, we provided two androstane derivatives: 
mepitiostane and a structural analogue, cholestan-6-one, 3-bromo-, cyclic 1,2-ethanediyl 
mercaptole, S,S,S',S'-tetraoxide, (3-beta,5-alpha)-. Metpitiostane is an antineoplastic agent 
inhibiting the expansion of estrogen-stimulated cancers by a competitive inhibition mechanism 
for the estrogen receptor (https:// 
pubchem.ncbi.nlm.nih.gov/compound/mepitiostane#section=Pharm acology-and-Biochemistry). 
The similarity index value between these two chemicals is 0.77. We processed the selected 
molecules using ToxDelta to explain the discrepancy between mutagenic activities for each pair. 
The results of the ToxDelta tool are discussed in the results section.  
Results 
The new ToxDelta software uses the structures of the two chemicals to be compared as input. 
The two substances are introduced as SMILES [43]. The MCS is the common part present in 
both molecules and it is shown (Table 1). This MCS is usually a large part of the molecules to 
be assessed. Indeed, the application of ToxDelta is useful for substances that are structurally 
similar. The MCS typically, even if implicitly, represents the driving force in the read-across 
procedure. This is the logical process which identifies the analogies among substances. In this 
scheme, ToxDelta does not contradict but complements the read-across conceptual strategy. The 
risk of the read-across strategy is to miss the differences between two molecules. The similarity 
should not erase the possible opposed behaviour of the two similar compounds. But how to 
avoid the error of ignoring factors which may provoke opposite behaviour? ToxDelta wants to 
address this issue. It carefully identifies the differences and the related toxicological meaning. 
The theoretical basis is closely related to the SA paradigm. Thus, ToxDelta complements the 
ToxRead software, which exploits all the SAs of the target compound. Beyond this global 
assessment, done by ToxRead, it is useful to apply ToxDelta for a closer look at the two 
substances (i.e. the target and the reference compounds), in particular, when they may have 
opposite toxicological properties. Indeed, it should be reminded that ToxRead predicts the 
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toxicological property of the target compound, and thus the predicted value of the target 
compound may be the opposite of the experimental value of the similar compound.  
Table 1: The two case studies: Case study 1) target molecule: Diazepam, source molecule: Flunitrazepam; Case 
study 2) target molecule: cholestan-6-one, 3-bromo-, cyclic 1,2-ethanediyl mercaptole, S,S,S',S'-tetraoxide, (3-beta,5-
alpha)-, source molecule: mepitiostane and the results of ToxDelta: Maximum common substructure and dissimilar 
fragments. 
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Case study 1: Benzodiazepine derivatives  
Source molecule 1: Flunitrazepam 
Systematic name: 1,3-dihydro-5-(o-fluorophenyl)-1-methyl-7nitro-2H-1,4-benzodiazepin-2-one 
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SMILES: c12C(=NCC(=O)N(c1ccc(c2)[N+](=O)[O-])C)c1c(cccc1)F 
Experimental activity: Mutagenic in Ames test [45] 
CAS number: 1622-62-4 
Target molecule 1: Diazepam  
Systematic name: 1-methyl-5-phenyl-7-chloro-1,3-dihydro-2H1,4-benzodiazepin-2-one 
SMILES: O=C1N(c3ccc(cc3(C(=NC1)c2ccccc2))Cl)C 
Experimental activity: Non-mutagenic in Ames test [45] 
CAS number: 439-14-5 
 
ToxDelta identifies “1-methyl-5-phenyl-2,3-dihydro1H-1,4-benzodiazepin-2-one” as MCS 
shared by these two chemicals (Table 1). ToxDelta also extracts three fragments of 
dissimilarities: the nitro group, the fluorine and chlorine atoms, each linked to an aromatic 
carbon. Diazepam lacks the first two fragments, which are present in Flunitrazepam. The 
nitroaromatic moiety matches two ToxRead SAs for mutagenicity both referring to the generic 
nitroaromatic ring; the Benigni–Bossa alert does not include chemicals with orthodistribution 
and with a sulphonic group on the nitroaromatic ring. This leads to a slight difference in the 
accuracies of these fragments, which are respectively 85% and 87%. ToxDelta identifies also 
the fluorine and chlorine atoms linked to aromatic carbons as dissimilarity fragments between 
the two molecules. These moieties do not match any rule for Ames mutagenicity included in the 
ToxRead “libraries” of SAs [3,4]. As a conclusion, ToxDelta immediately reports as a key 
difference the presence of the nitroaromatic fragment, which is at the basis of the different 
mutagenicity value of the two substances.  
Case Study 2: Androstane derivatives 
Source molecule 2: cholestan-6-one, 3-bromo-, cyclic 1,2-ethanediyl mercaptole, S,S,S',S'-
tetraoxide, (3-beta,5-alpha)- 
Systematic name: Cholestan-6-one, 3-bromo-, cyclic 1,2-ethanediyl mercaptole, S,S,S',S'-
tetraoxide, (3-beta,5-alpha)- 
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SMILES:  O=S5(=O)(CCS(=O)(=O)C35(CC1C4CCC(C(C) 
CCCC(C)C)C4(C)(CCC1C2(C)(CCC(CC23)Br))) 
CAS number: 133331-34-7 
Experimental activity: Mutagenic in Ames test [45] 
Target molecule 2: mepitiostane 
Systematic name: 5-alpha-Androstane, 2-alpha,3-alpha-epithio-17beta-(1-
methoxycyclopentyloxy)- 
SMILES: O(C)C6(OC2CCC3C4CCC1CC5C(CC1(C) 
C4(CCC23(C)))S5)(CCCC6) 
CAS number: 21362-69-6 
Experimental activity: Non-mutagenic in Ames test [45] 
ToxDelta identifies the androstane tetracyclic system as MCS shared by these two chemicals 
and extracts five fragments of dissimilarity (Table 1). Three of these are aliphatic rings: the 
thiirane, 1,1-dimethoxycyclopentane, and 1,3-Dithiolane 1,1,3,3-tetraoxide rings and two are 
aliphatic chains: the 2-methylheptyl group and a bromine atom, both linked to an aliphatic 
carbon ring. The cyclic moieties and the alkyl carbon chain do not match any rule potentially 
responsible for mutagenic/non-mutagenic activity listed in the ToxRead software. Conversely, 
the bromine atom linked to an aliphatic carbon ring corresponds to two ToxRead SAs both 
referring to bromo-/haloethyl moieties with different levels of specificity and a prevalence of 
mutagenic activity of 71% and 67%, respectively. These rules, which are present in the source 
molecule but not in the target chemical, give a first indication of different toxicological profiles 
for these chemicals.  
Evaluating the two case studies, it is important to notice that sometimes the identified dissimilar 
fragment is not an entire SA. In many cases the fragment of dissimilarity is a fraction of the 
whole rule (an already existing rule in the rule set) and the rest of the SA appears in the MCS. 
This issue is completely solved by the ToxRead software. In fact, the dissimilarities examination 
of ToxDelta takes place after the visualization of the results of ToxRead, when the user has 
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already observed all the existing SAs that are matched with the target molecule and are in 
common between the target molecule and a set of structurally similar molecules. 
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Discussion and Conclusion 
ToxDelta is a new tool for read-across concept not aimed at substituting other tools, but to 
complement them. It has been designed to match certain features of ToxRead, but it can also be 
used alone. It is important to underline that ToxDelta addresses differences between two 
molecules, and per se it does not address the overall toxic property of the molecule, while this 
aim may be accomplished by other tools, like ToxRead, covering the assessment of the target 
molecule. The main advantage of ToxDelta to the other read-across programs is its focus on 
dissimilarities in addition to the similarities and the resembling properties between structurally 
similar compounds. It exploits the adverse effects that these dissimilar fragments may trigger in 
the biological activities or properties of the chemical substances. 
ToxDelta provides a further insight by analysing the modulations of the effects which are 
expected in relation to the presence of the additional fragments in one of the two molecules 
under evaluation. Compared to other tools for read-across, ToxDelta is more “local”, and this 
fact makes it an ideal tool to evaluate the effect of the metabolites and the impurities related to a 
compound having at hand the experimental values for the parent compound. Two important 
fields in which this issue can be applied are impurities in pharmaceutics and pesticides. The 
Food and Drug Administration (FDA) has provided a guideline for industry about the 
mutagenicity of the pharmaceutical impurities [46] that describes a practical framework for 
identification and control of the identified mutagenic impurities in order to limit potential 
carcinogenic risk. Another appropriate field of application for this tool is in pesticides 
assessment. The European Food Safety Authority (EFSA) has addressed the possible use of in 
silico methods for the evaluation of the effects of metabolites of pesticides [47]. ToxDelta may 
represent an ideal tool for pesticides, biocides and pharmaceutical compounds; because in these 
cases the experimental property values of the parent compound is requested by the relative 
regulations and ToxDelta can provide this information. Thus, ToxDelta may be particularly 
useful in those cases where data for the parent compound are available, and the user is interested 
not in the absolute effect of the related compound, but the possible increase of effect in an 
impurity product. For instance, if the toxicity level of the impurities is similar to the parent 
compound, this fact does not affect the way the substance with the impurity should be handled 
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and regulated. Conversely, if the impurity represents an increased hazard, this may be a serious 
issue. To overcome this kind of problems, local tools that deal with measuring the relative 
increase or decrease of the effects are probably more accurate than absolute de novo predictions. 
ToxDelta aims to address an important issue associated with read-across. Although the use of 
read-across approaches is widespread, the acceptance of the dossiers using read-across is not 
straightforward. Detailed documentation has to be provided by the expert. One of the main 
sources of scepticism on the assessment of read-across is that there are two (or more) substances 
under consideration, the target compound, lacking of data, and the reference compound, which 
is assumed to represent the properties of the target compound. So far the existing software for 
read-across have focused on the assessment of similarity between the target and the source 
compounds, with the idea that the higher the similarity is, the higher is the likelihood that the 
properties of the two compounds will be similar. However, authorities often argue that even 
minor modifications of the chemical structure may provoke a dramatic change in the property 
value. To complement the existing software addressing similarity, we focused our attention on 
the differences between two compounds, introducing ToxDelta. 
It is noticeable that unlike other read-across programs, the SAs within ToxRead and ToxDelta 
do not exclusively contain active fragments, but also inactive fragments. This advantage allows 
exploring positive and negative modulations of the effect, and recognizing whether any relevant 
impact is expected. These SAs are associated to statistical characterizations, based on the 
number of chemicals containing the fragment, and on the prevalence of one of the categories: 
toxic or non-toxic. As a result, the user has both, the evidence that a certain fragment is 
associated to a certain effect and the statistics related to the prevalence of active or inactive 
compounds containing that SA. ToxRead provides all the data available on mutagenicity and 
BCF endpoints, and enables the user to access the available knowledge in a read-across 
approach. This software with its genuine graphical user interface organizes different groups of 
similar molecules and allows the user to move in different levels of reasoning. ToxDelta nicely 
complements ToxRead, offering additional focus on all the fragments which may affect the 
toxicity. 
 206 
 
Currently, a beta version of ToxDelta is freely available on the VEGA platform 
(https://www.vegahub.eu/) and the toxicity endpoint for which this tool can be used is 
mutagenicity. Other endpoints will be added to the software in the next future. 
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